Formation-of-ATP-by-chemiosmotic-coupling |
16 |
1.29e-10 |
4.72e-09 |
1.31000 |
-0.933000 |
-9.19e-01 |
1.02e-10 |
1.89e-10 |
Complex-I-biogenesis |
54 |
1.62e-33 |
2.07e-31 |
1.30000 |
-0.930000 |
-9.04e-01 |
2.28e-32 |
1.25e-30 |
Citric-acid-cycle-(TCA-cycle) |
22 |
2.51e-13 |
1.53e-11 |
1.26000 |
-0.894000 |
-8.89e-01 |
3.71e-13 |
5.02e-13 |
Cristae-formation |
29 |
4.27e-17 |
3.22e-15 |
1.25000 |
-0.905000 |
-8.61e-01 |
3.21e-17 |
9.79e-16 |
Respiratory-electron-transport |
100 |
4.63e-57 |
1.97e-54 |
1.25000 |
-0.904000 |
-8.59e-01 |
2.80e-55 |
4.76e-50 |
Branched-chain-amino-acid-catabolism |
19 |
5.85e-11 |
2.49e-09 |
1.22000 |
-0.859000 |
-8.71e-01 |
9.04e-11 |
4.89e-11 |
Respiratory-electron-transport,-ATP-synthesis-by-chemiosmotic-coupling,-and-heat-production-by-uncoupling-proteins. |
120 |
4.61e-65 |
2.95e-62 |
1.22000 |
-0.883000 |
-8.36e-01 |
5.28e-63 |
1.12e-56 |
Mitochondrial-Fatty-Acid-Beta-Oxidation |
31 |
5.13e-17 |
3.65e-15 |
1.21000 |
-0.858000 |
-8.50e-01 |
1.25e-16 |
2.49e-16 |
The-citric-acid-(TCA)-cycle-and-respiratory-electron-transport |
167 |
1.25e-82 |
1.60e-79 |
1.17000 |
-0.835000 |
-8.13e-01 |
5.14e-78 |
5.46e-74 |
rRNA-processing-in-the-mitochondrion |
22 |
1.56e-11 |
7.41e-10 |
1.16000 |
-0.783000 |
-8.54e-01 |
2.00e-10 |
3.93e-12 |
tRNA-processing-in-the-mitochondrion |
18 |
3.43e-09 |
1.18e-07 |
1.13000 |
-0.750000 |
-8.42e-01 |
3.52e-08 |
6.26e-10 |
Mitochondrial-translation-elongation |
88 |
2.90e-41 |
6.18e-39 |
1.12000 |
-0.827000 |
-7.58e-01 |
3.38e-41 |
8.11e-35 |
Mitochondrial-translation |
94 |
6.95e-44 |
1.78e-41 |
1.12000 |
-0.825000 |
-7.58e-01 |
1.11e-43 |
4.24e-37 |
Mitochondrial-translation-termination |
88 |
4.51e-41 |
8.23e-39 |
1.12000 |
-0.825000 |
-7.56e-01 |
5.15e-41 |
1.18e-34 |
Mitochondrial-translation-initiation |
88 |
1.35e-40 |
2.16e-38 |
1.11000 |
-0.821000 |
-7.50e-01 |
1.25e-40 |
4.30e-34 |
Mitochondrial-iron-sulfur-cluster-biogenesis |
10 |
6.99e-05 |
9.35e-04 |
1.07000 |
-0.741000 |
-7.75e-01 |
4.95e-05 |
2.19e-05 |
Glyoxylate-metabolism-and-glycine-degradation |
25 |
7.78e-11 |
3.12e-09 |
1.06000 |
-0.751000 |
-7.48e-01 |
7.74e-11 |
9.53e-11 |
Pyruvate-metabolism-and-Citric-Acid-(TCA)-cycle |
51 |
4.48e-21 |
4.10e-19 |
1.05000 |
-0.725000 |
-7.60e-01 |
3.15e-19 |
5.37e-21 |
Collagen-chain-trimerization |
33 |
1.12e-13 |
7.15e-12 |
1.04000 |
0.737000 |
7.40e-01 |
2.34e-13 |
1.79e-13 |
Mitochondrial-tRNA-aminoacylation |
19 |
3.66e-08 |
1.06e-06 |
1.04000 |
-0.756000 |
-7.12e-01 |
1.14e-08 |
7.59e-08 |
Mitochondrial-protein-import |
57 |
8.67e-23 |
8.53e-21 |
1.03000 |
-0.762000 |
-6.86e-01 |
2.29e-23 |
2.95e-19 |
Metabolism-of-cofactors |
18 |
6.03e-07 |
1.40e-05 |
0.97900 |
-0.703000 |
-6.81e-01 |
2.41e-07 |
5.56e-07 |
Keratan-sulfate-degradation |
10 |
6.99e-04 |
5.96e-03 |
0.93200 |
0.680000 |
6.38e-01 |
1.95e-04 |
4.80e-04 |
CS/DS-degradation |
11 |
3.22e-04 |
3.17e-03 |
0.92800 |
0.620000 |
6.91e-01 |
3.74e-04 |
7.28e-05 |
Collagen-biosynthesis-and-modifying-enzymes |
56 |
1.44e-17 |
1.15e-15 |
0.91400 |
0.637000 |
6.55e-01 |
1.59e-16 |
2.10e-17 |
Regulation-of-pyruvate-dehydrogenase-(PDH)-complex |
15 |
2.55e-05 |
4.24e-04 |
0.91400 |
-0.615000 |
-6.76e-01 |
3.77e-05 |
5.76e-06 |
Crosslinking-of-collagen-fibrils |
10 |
8.72e-04 |
7.29e-03 |
0.88700 |
0.685000 |
5.63e-01 |
1.75e-04 |
2.06e-03 |
ECM-proteoglycans |
43 |
3.42e-13 |
1.90e-11 |
0.88600 |
0.661000 |
5.90e-01 |
6.20e-14 |
2.23e-11 |
tRNA-Aminoacylation |
26 |
4.87e-08 |
1.35e-06 |
0.87000 |
-0.652000 |
-5.76e-01 |
8.49e-09 |
3.70e-07 |
Chondroitin-sulfate-biosynthesis |
16 |
4.32e-05 |
6.35e-04 |
0.87000 |
0.625000 |
6.05e-01 |
1.52e-05 |
2.75e-05 |
Triglyceride-catabolism |
15 |
9.29e-06 |
1.75e-04 |
0.86800 |
-0.503000 |
-7.08e-01 |
7.41e-04 |
2.07e-06 |
Heme-biosynthesis |
12 |
5.39e-04 |
4.76e-03 |
0.86800 |
-0.601000 |
-6.27e-01 |
3.12e-04 |
1.70e-04 |
Elastic-fibre-formation |
38 |
7.80e-11 |
3.12e-09 |
0.86000 |
0.608000 |
6.08e-01 |
8.52e-11 |
8.68e-11 |
Pyruvate-metabolism |
27 |
5.41e-08 |
1.47e-06 |
0.85300 |
-0.567000 |
-6.37e-01 |
3.40e-07 |
9.95e-09 |
Defects-in-cobalamin-(B12)-metabolism |
12 |
1.10e-03 |
8.65e-03 |
0.82300 |
-0.562000 |
-6.02e-01 |
7.53e-04 |
3.04e-04 |
Mitochondrial-biogenesis |
88 |
1.70e-19 |
1.45e-17 |
0.76900 |
-0.530000 |
-5.57e-01 |
7.78e-18 |
1.67e-19 |
Collagen-formation |
75 |
1.22e-16 |
8.24e-15 |
0.76900 |
0.546000 |
5.42e-01 |
3.06e-16 |
4.96e-16 |
Assembly-of-collagen-fibrils-and-other-multimeric-structures |
46 |
8.17e-11 |
3.17e-09 |
0.76900 |
0.576000 |
5.09e-01 |
1.34e-11 |
2.38e-09 |
Carnitine-metabolism |
12 |
1.61e-03 |
1.21e-02 |
0.76400 |
-0.476000 |
-5.98e-01 |
4.31e-03 |
3.37e-04 |
Syndecan-interactions |
20 |
7.01e-05 |
9.35e-04 |
0.75900 |
0.544000 |
5.29e-01 |
2.50e-05 |
4.16e-05 |
Molecules-associated-with-elastic-fibres |
28 |
1.45e-06 |
2.98e-05 |
0.75800 |
0.516000 |
5.54e-01 |
2.25e-06 |
3.82e-07 |
MET-activates-PTK2-signaling |
17 |
1.25e-04 |
1.50e-03 |
0.74900 |
0.593000 |
4.58e-01 |
2.33e-05 |
1.08e-03 |
Protein-localization |
142 |
7.41e-29 |
7.90e-27 |
0.74200 |
-0.512000 |
-5.37e-01 |
6.06e-26 |
2.04e-28 |
Prolactin-receptor-signaling |
11 |
5.73e-03 |
3.32e-02 |
0.73100 |
-0.472000 |
-5.59e-01 |
6.73e-03 |
1.34e-03 |
Peroxisomal-protein-import |
53 |
2.97e-12 |
1.52e-10 |
0.72900 |
-0.446000 |
-5.77e-01 |
1.95e-08 |
3.55e-13 |
Mitochondrial-calcium-ion-transport |
21 |
1.53e-04 |
1.76e-03 |
0.71000 |
-0.495000 |
-5.09e-01 |
8.64e-05 |
5.32e-05 |
Chondroitin-sulfate/dermatan-sulfate-metabolism |
42 |
1.03e-08 |
3.30e-07 |
0.70700 |
0.540000 |
4.56e-01 |
1.42e-09 |
3.11e-07 |
p130Cas-linkage-to-MAPK-signaling-for-integrins |
14 |
1.95e-03 |
1.38e-02 |
0.70400 |
0.545000 |
4.46e-01 |
4.11e-04 |
3.88e-03 |
Defects-in-vitamin-and-cofactor-metabolism |
20 |
1.95e-04 |
2.08e-03 |
0.69900 |
-0.452000 |
-5.33e-01 |
4.61e-04 |
3.72e-05 |
Laminin-interactions |
22 |
5.04e-05 |
7.24e-04 |
0.69800 |
0.548000 |
4.33e-01 |
8.72e-06 |
4.33e-04 |
Sulfur-amino-acid-metabolism |
20 |
3.47e-04 |
3.35e-03 |
0.69100 |
-0.475000 |
-5.02e-01 |
2.39e-04 |
1.00e-04 |
Peroxisomal-lipid-metabolism |
22 |
3.71e-05 |
5.65e-04 |
0.68700 |
-0.409000 |
-5.52e-01 |
9.02e-04 |
7.27e-06 |
Triglyceride-metabolism |
22 |
6.65e-05 |
9.17e-04 |
0.68400 |
-0.420000 |
-5.39e-01 |
6.50e-04 |
1.19e-05 |
Extracellular-matrix-organization |
228 |
1.35e-38 |
1.92e-36 |
0.67700 |
0.499000 |
4.58e-01 |
1.41e-38 |
1.08e-32 |
TNF-receptor-superfamily-(TNFSF)-members-mediating-non-canonical-NF-kB-pathway |
11 |
1.67e-02 |
7.30e-02 |
0.66500 |
0.491000 |
4.48e-01 |
4.83e-03 |
1.01e-02 |
Class-I-peroxisomal-membrane-protein-import |
19 |
1.70e-04 |
1.90e-03 |
0.66000 |
-0.377000 |
-5.42e-01 |
4.41e-03 |
4.30e-05 |
Cobalamin-(Cbl,-vitamin-B12)-transport-and-metabolism |
13 |
8.93e-03 |
4.73e-02 |
0.65900 |
-0.450000 |
-4.81e-01 |
4.98e-03 |
2.66e-03 |
Defective-B3GALT6-causes-EDSP2-and-SEMDJL1 |
16 |
2.19e-03 |
1.51e-02 |
0.64400 |
0.505000 |
4.00e-01 |
4.69e-04 |
5.66e-03 |
Gluconeogenesis |
26 |
9.45e-05 |
1.18e-03 |
0.64000 |
-0.417000 |
-4.86e-01 |
2.36e-04 |
1.78e-05 |
Hyaluronan-uptake-and-degradation |
11 |
2.47e-02 |
9.95e-02 |
0.63400 |
0.431000 |
4.64e-01 |
1.32e-02 |
7.70e-03 |
Diseases-associated-with-glycosaminoglycan-metabolism |
34 |
7.91e-06 |
1.51e-04 |
0.62800 |
0.479000 |
4.06e-01 |
1.31e-06 |
4.26e-05 |
Transcriptional-activation-of-mitochondrial-biogenesis |
51 |
3.86e-08 |
1.10e-06 |
0.62800 |
-0.418000 |
-4.68e-01 |
2.43e-07 |
7.23e-09 |
Mucopolysaccharidoses |
11 |
1.94e-02 |
8.18e-02 |
0.62400 |
0.489000 |
3.88e-01 |
4.99e-03 |
2.60e-02 |
Pink/Parkin-Mediated-Mitophagy |
20 |
1.23e-03 |
9.40e-03 |
0.61600 |
-0.473000 |
-3.94e-01 |
2.54e-04 |
2.26e-03 |
Non-integrin-membrane-ECM-interactions |
41 |
1.74e-06 |
3.49e-05 |
0.61500 |
0.461000 |
4.06e-01 |
3.18e-07 |
6.74e-06 |
TNFs-bind-their-physiological-receptors |
12 |
6.81e-03 |
3.84e-02 |
0.60900 |
0.334000 |
5.09e-01 |
4.52e-02 |
2.25e-03 |
The-canonical-retinoid-cycle-in-rods-(twilight-vision) |
12 |
4.09e-04 |
3.79e-03 |
0.60900 |
0.245000 |
5.57e-01 |
1.41e-01 |
8.31e-04 |
Aflatoxin-activation-and-detoxification |
10 |
3.02e-02 |
1.14e-01 |
0.60700 |
-0.369000 |
-4.82e-01 |
4.34e-02 |
8.32e-03 |
Integrin-cell-surface-interactions |
53 |
1.23e-07 |
3.14e-06 |
0.60200 |
0.430000 |
4.21e-01 |
5.95e-08 |
1.12e-07 |
Collagen-degradation |
26 |
1.57e-04 |
1.78e-03 |
0.60000 |
0.473000 |
3.68e-01 |
2.93e-05 |
1.17e-03 |
Activation-of-SMO |
15 |
6.16e-03 |
3.52e-02 |
0.59700 |
0.362000 |
4.74e-01 |
1.52e-02 |
1.47e-03 |
Translation |
241 |
4.00e-31 |
4.66e-29 |
0.59500 |
-0.415000 |
-4.26e-01 |
1.35e-28 |
4.55e-30 |
GRB2:SOS-provides-linkage-to-MAPK-signaling-for-Integrins |
14 |
9.96e-03 |
5.17e-02 |
0.58800 |
0.467000 |
3.57e-01 |
2.47e-03 |
2.06e-02 |
MET-promotes-cell-motility |
27 |
4.01e-05 |
5.96e-04 |
0.58800 |
0.488000 |
3.29e-01 |
1.16e-05 |
3.08e-03 |
Defective-B3GAT3-causes-JDSSDHD |
16 |
5.53e-03 |
3.25e-02 |
0.58600 |
0.464000 |
3.57e-01 |
1.30e-03 |
1.34e-02 |
Mitophagy |
27 |
4.58e-04 |
4.17e-03 |
0.58200 |
-0.429000 |
-3.94e-01 |
1.16e-04 |
3.92e-04 |
Processing-of-SMDT1 |
15 |
1.32e-02 |
6.27e-02 |
0.58100 |
-0.385000 |
-4.35e-01 |
9.78e-03 |
3.54e-03 |
Negative-regulation-of-TCF-dependent-signaling-by-WNT-ligand-antagonists |
10 |
6.05e-02 |
1.88e-01 |
0.57100 |
0.430000 |
3.76e-01 |
1.85e-02 |
3.96e-02 |
Defective-B4GALT7-causes-EDS,-progeroid-type |
16 |
5.72e-03 |
3.32e-02 |
0.57100 |
0.460000 |
3.38e-01 |
1.44e-03 |
1.94e-02 |
Unwinding-of-DNA |
12 |
1.08e-02 |
5.44e-02 |
0.55600 |
0.289000 |
4.75e-01 |
8.30e-02 |
4.40e-03 |
Glycosaminoglycan-metabolism |
99 |
1.18e-12 |
6.29e-11 |
0.55100 |
0.431000 |
3.43e-01 |
1.26e-13 |
3.57e-09 |
Heparan-sulfate/heparin-(HS-GAG)-metabolism |
42 |
1.75e-07 |
4.23e-06 |
0.55100 |
0.471000 |
2.87e-01 |
1.31e-07 |
1.31e-03 |
Metabolism-of-porphyrins |
19 |
5.53e-03 |
3.25e-02 |
0.55100 |
-0.348000 |
-4.27e-01 |
8.69e-03 |
1.26e-03 |
mTORC1-mediated-signalling |
20 |
5.39e-03 |
3.22e-02 |
0.55000 |
-0.361000 |
-4.15e-01 |
5.17e-03 |
1.30e-03 |
A-tetrasaccharide-linker-sequence-is-required-for-GAG-synthesis |
21 |
1.81e-03 |
1.31e-02 |
0.55000 |
0.444000 |
3.24e-01 |
4.28e-04 |
1.01e-02 |
O-glycosylation-of-TSR-domain-containing-proteins |
33 |
1.99e-04 |
2.10e-03 |
0.54400 |
0.414000 |
3.52e-01 |
3.79e-05 |
4.70e-04 |
Hyaluronan-metabolism |
15 |
1.41e-02 |
6.49e-02 |
0.54300 |
0.327000 |
4.33e-01 |
2.84e-02 |
3.66e-03 |
Biotin-transport-and-metabolism |
11 |
4.41e-02 |
1.53e-01 |
0.53900 |
-0.322000 |
-4.32e-01 |
6.47e-02 |
1.30e-02 |
Defective-B3GALTL-causes-Peters-plus-syndrome-(PpS) |
32 |
4.00e-04 |
3.74e-03 |
0.53500 |
0.401000 |
3.55e-01 |
8.77e-05 |
5.08e-04 |
Degradation-of-the-extracellular-matrix |
74 |
5.69e-11 |
2.49e-09 |
0.53100 |
0.445000 |
2.89e-01 |
3.56e-11 |
1.80e-05 |
HS-GAG-degradation |
18 |
4.70e-04 |
4.23e-03 |
0.52600 |
0.471000 |
2.34e-01 |
5.46e-04 |
8.52e-02 |
Regulation-of-Insulin-like-Growth-Factor-(IGF)-transport-and-uptake-by-Insulin-like-Growth-Factor-Binding-Proteins-(IGFBPs) |
84 |
4.05e-09 |
1.36e-07 |
0.52100 |
0.389000 |
3.47e-01 |
7.59e-10 |
3.74e-08 |
Receptor-Mediated-Mitophagy |
11 |
6.92e-02 |
2.04e-01 |
0.51900 |
-0.328000 |
-4.02e-01 |
5.94e-02 |
2.08e-02 |
Post-translational-protein-phosphorylation |
77 |
2.65e-08 |
7.88e-07 |
0.51800 |
0.385000 |
3.48e-01 |
5.49e-09 |
1.34e-07 |
Activation-of-Matrix-Metalloproteinases |
17 |
1.06e-02 |
5.40e-02 |
0.51300 |
0.417000 |
2.98e-01 |
2.91e-03 |
3.33e-02 |
Glutamate-Neurotransmitter-Release-Cycle |
18 |
7.24e-03 |
4.01e-02 |
0.51100 |
0.292000 |
4.20e-01 |
3.19e-02 |
2.05e-03 |
NOTCH2-intracellular-domain-regulates-transcription |
10 |
8.33e-02 |
2.32e-01 |
0.50700 |
0.305000 |
4.05e-01 |
9.46e-02 |
2.65e-02 |
Caspase-mediated-cleavage-of-cytoskeletal-proteins |
12 |
6.93e-02 |
2.04e-01 |
0.50100 |
0.385000 |
3.22e-01 |
2.10e-02 |
5.38e-02 |
Keratan-sulfate/keratin-metabolism |
27 |
3.04e-03 |
1.95e-02 |
0.50000 |
0.376000 |
3.29e-01 |
7.15e-04 |
3.07e-03 |
The-NLRP3-inflammasome |
14 |
5.13e-02 |
1.70e-01 |
0.49700 |
0.328000 |
3.74e-01 |
3.35e-02 |
1.55e-02 |
WNT5A-dependent-internalization-of-FZD2,-FZD5-and-ROR2 |
13 |
5.29e-03 |
3.18e-02 |
0.49200 |
0.446000 |
2.06e-01 |
5.33e-03 |
1.98e-01 |
Kinesins |
35 |
8.36e-04 |
7.04e-03 |
0.48800 |
0.364000 |
3.25e-01 |
1.92e-04 |
8.91e-04 |
Signaling-by-Hippo |
20 |
1.54e-02 |
6.89e-02 |
0.48400 |
0.373000 |
3.09e-01 |
3.88e-03 |
1.67e-02 |
Glycogen-breakdown-(glycogenolysis) |
14 |
6.48e-02 |
1.95e-01 |
0.48400 |
-0.352000 |
-3.32e-01 |
2.24e-02 |
3.17e-02 |
Signaling-by-BMP |
18 |
3.07e-02 |
1.16e-01 |
0.48000 |
0.325000 |
3.53e-01 |
1.69e-02 |
9.49e-03 |
Defective-EXT1-causes-exostoses-1,-TRPS2-and-CHDS |
12 |
1.31e-02 |
6.22e-02 |
0.47700 |
0.430000 |
2.08e-01 |
9.98e-03 |
2.12e-01 |
Defective-EXT2-causes-exostoses-2 |
12 |
1.31e-02 |
6.22e-02 |
0.47700 |
0.430000 |
2.08e-01 |
9.98e-03 |
2.12e-01 |
HS-GAG-biosynthesis |
23 |
1.16e-04 |
1.41e-03 |
0.47500 |
0.434000 |
1.92e-01 |
3.13e-04 |
1.12e-01 |
TP53-Regulates-Metabolic-Genes |
85 |
1.59e-07 |
3.92e-06 |
0.47200 |
-0.335000 |
-3.33e-01 |
9.34e-08 |
1.13e-07 |
Keratan-sulfate-biosynthesis |
22 |
1.62e-02 |
7.16e-02 |
0.47100 |
0.349000 |
3.15e-01 |
4.55e-03 |
1.05e-02 |
Inflammasomes |
18 |
3.15e-02 |
1.18e-01 |
0.47000 |
0.306000 |
3.57e-01 |
2.47e-02 |
8.75e-03 |
Signaling-by-Retinoic-Acid |
32 |
1.88e-03 |
1.35e-02 |
0.47000 |
-0.300000 |
-3.62e-01 |
3.36e-03 |
3.98e-04 |
AKT-phosphorylates-targets-in-the-nucleus |
10 |
1.58e-01 |
3.48e-01 |
0.46900 |
-0.320000 |
-3.44e-01 |
7.99e-02 |
5.99e-02 |
EPHB-mediated-forward-signaling |
32 |
2.71e-03 |
1.77e-02 |
0.46900 |
0.346000 |
3.16e-01 |
7.13e-04 |
1.97e-03 |
Synthesis-of-PA |
27 |
8.76e-03 |
4.70e-02 |
0.46000 |
-0.331000 |
-3.19e-01 |
2.91e-03 |
4.10e-03 |
Fatty-acid-metabolism |
131 |
2.54e-11 |
1.16e-09 |
0.46000 |
-0.294000 |
-3.53e-01 |
6.46e-09 |
2.95e-12 |
Glycogen-metabolism |
25 |
1.24e-02 |
5.97e-02 |
0.45900 |
-0.333000 |
-3.16e-01 |
3.93e-03 |
6.21e-03 |
Voltage-gated-Potassium-channels |
22 |
1.44e-02 |
6.58e-02 |
0.45900 |
-0.359000 |
-2.87e-01 |
3.61e-03 |
2.00e-02 |
EPHA-mediated-growth-cone-collapse |
14 |
1.40e-02 |
6.47e-02 |
0.45900 |
0.213000 |
4.06e-01 |
1.67e-01 |
8.54e-03 |
Nucleobase-biosynthesis |
13 |
1.07e-01 |
2.68e-01 |
0.44800 |
-0.336000 |
-2.97e-01 |
3.58e-02 |
6.41e-02 |
p75NTR-signals-via-NF-kB |
16 |
6.76e-02 |
2.02e-01 |
0.44200 |
0.290000 |
3.33e-01 |
4.43e-02 |
2.10e-02 |
RHO-GTPases-Activate-ROCKs |
18 |
1.49e-02 |
6.71e-02 |
0.43800 |
0.228000 |
3.74e-01 |
9.39e-02 |
6.03e-03 |
NCAM1-interactions |
30 |
8.78e-03 |
4.70e-02 |
0.43700 |
0.308000 |
3.10e-01 |
3.50e-03 |
3.34e-03 |
Receptor-type-tyrosine-protein-phosphatases |
15 |
5.56e-02 |
1.81e-01 |
0.43600 |
0.354000 |
2.54e-01 |
1.76e-02 |
8.89e-02 |
Intraflagellar-transport |
36 |
1.85e-03 |
1.33e-02 |
0.43500 |
0.342000 |
2.69e-01 |
3.92e-04 |
5.28e-03 |
Signaling-by-PDGF |
48 |
6.72e-04 |
5.77e-03 |
0.42600 |
0.313000 |
2.89e-01 |
1.75e-04 |
5.29e-04 |
Integrin-signaling |
26 |
1.29e-02 |
6.17e-02 |
0.42500 |
0.334000 |
2.62e-01 |
3.20e-03 |
2.06e-02 |
ATF6-(ATF6-alpha)-activates-chaperone-genes |
10 |
1.74e-01 |
3.69e-01 |
0.42300 |
-0.339000 |
-2.53e-01 |
6.31e-02 |
1.66e-01 |
Pyrimidine-salvage |
10 |
4.71e-02 |
1.59e-01 |
0.42300 |
0.174000 |
3.85e-01 |
3.42e-01 |
3.50e-02 |
Amine-ligand-binding-receptors |
12 |
5.12e-02 |
1.70e-01 |
0.41800 |
-0.368000 |
-1.97e-01 |
2.72e-02 |
2.37e-01 |
JNK-(c-Jun-kinases)-phosphorylation-and--activation-mediated-by-activated-human-TAK1 |
17 |
8.52e-02 |
2.34e-01 |
0.41800 |
-0.300000 |
-2.91e-01 |
3.21e-02 |
3.81e-02 |
O-linked-glycosylation |
74 |
6.33e-07 |
1.45e-05 |
0.41200 |
0.346000 |
2.24e-01 |
2.66e-07 |
8.88e-04 |
Purine-ribonucleoside-monophosphate-biosynthesis |
10 |
1.30e-01 |
3.13e-01 |
0.41100 |
-0.350000 |
-2.16e-01 |
5.52e-02 |
2.38e-01 |
O-linked-glycosylation-of-mucins |
32 |
1.25e-05 |
2.29e-04 |
0.41100 |
0.386000 |
1.41e-01 |
1.55e-04 |
1.69e-01 |
Vitamin-B5-(pantothenate)-metabolism |
15 |
1.27e-01 |
3.08e-01 |
0.40800 |
-0.288000 |
-2.88e-01 |
5.34e-02 |
5.33e-02 |
Sema4D-in-semaphorin-signaling |
23 |
2.28e-02 |
9.29e-02 |
0.40700 |
0.240000 |
3.28e-01 |
4.64e-02 |
6.42e-03 |
TP53-Regulates-Transcription-of-Genes-Involved-in-G1-Cell-Cycle-Arrest |
13 |
1.46e-01 |
3.33e-01 |
0.40600 |
0.314000 |
2.56e-01 |
4.96e-02 |
1.10e-01 |
Josephin-domain-DUBs |
10 |
2.22e-01 |
4.21e-01 |
0.40500 |
-0.317000 |
-2.53e-01 |
8.27e-02 |
1.66e-01 |
FOXO-mediated-transcription-of-cell-death-genes |
14 |
2.48e-02 |
9.96e-02 |
0.40500 |
-0.366000 |
-1.75e-01 |
1.79e-02 |
2.57e-01 |
Elevation-of-cytosolic-Ca2+-levels |
11 |
7.10e-02 |
2.07e-01 |
0.40500 |
0.187000 |
3.59e-01 |
2.84e-01 |
3.92e-02 |
FCGR-activation |
11 |
2.24e-01 |
4.21e-01 |
0.40300 |
0.273000 |
2.96e-01 |
1.16e-01 |
8.93e-02 |
mTOR-signalling |
37 |
4.57e-03 |
2.78e-02 |
0.40300 |
-0.254000 |
-3.12e-01 |
7.41e-03 |
1.03e-03 |
PI-3K-cascade:FGFR3 |
12 |
1.72e-01 |
3.66e-01 |
0.40200 |
-0.253000 |
-3.13e-01 |
1.29e-01 |
6.06e-02 |
Cell-extracellular-matrix-interactions |
16 |
3.67e-02 |
1.34e-01 |
0.40200 |
0.203000 |
3.47e-01 |
1.60e-01 |
1.64e-02 |
cGMP-effects |
12 |
9.11e-02 |
2.41e-01 |
0.40000 |
0.205000 |
3.43e-01 |
2.19e-01 |
3.96e-02 |
Processing-of-Intronless-Pre-mRNAs |
18 |
9.33e-02 |
2.44e-01 |
0.39900 |
-0.286000 |
-2.77e-01 |
3.54e-02 |
4.19e-02 |
Caspase-activation-via-extrinsic-apoptotic-signalling-pathway |
22 |
4.06e-02 |
1.46e-01 |
0.39700 |
0.312000 |
2.46e-01 |
1.14e-02 |
4.57e-02 |
Gap-junction-trafficking |
13 |
1.78e-01 |
3.72e-01 |
0.39600 |
0.294000 |
2.64e-01 |
6.62e-02 |
9.90e-02 |
Presynaptic-depolarization-and-calcium-channel-opening |
10 |
2.06e-03 |
1.45e-02 |
0.39600 |
0.022500 |
3.95e-01 |
9.02e-01 |
3.06e-02 |
DARPP-32-events |
22 |
7.90e-03 |
4.31e-02 |
0.39500 |
-0.187000 |
-3.48e-01 |
1.29e-01 |
4.75e-03 |
Termination-of-O-glycan-biosynthesis |
10 |
1.12e-03 |
8.70e-03 |
0.39100 |
0.391000 |
-5.26e-03 |
3.24e-02 |
9.77e-01 |
Regulation-of-Apoptosis |
49 |
1.45e-05 |
2.61e-04 |
0.39000 |
-0.347000 |
-1.77e-01 |
2.60e-05 |
3.17e-02 |
Signal-transduction-by-L1 |
21 |
1.19e-02 |
5.83e-02 |
0.38800 |
0.341000 |
1.85e-01 |
6.77e-03 |
1.42e-01 |
Diseases-associated-with-the-TLR-signaling-cascade |
22 |
6.01e-02 |
1.87e-01 |
0.38800 |
0.259000 |
2.89e-01 |
3.53e-02 |
1.90e-02 |
Diseases-of-Immune-System |
22 |
6.01e-02 |
1.87e-01 |
0.38800 |
0.259000 |
2.89e-01 |
3.53e-02 |
1.90e-02 |
Post-chaperonin-tubulin-folding-pathway |
18 |
1.05e-01 |
2.65e-01 |
0.38500 |
0.259000 |
2.85e-01 |
5.69e-02 |
3.62e-02 |
Diseases-associated-with-O-glycosylation-of-proteins |
46 |
3.63e-03 |
2.28e-02 |
0.38400 |
0.276000 |
2.68e-01 |
1.23e-03 |
1.70e-03 |
Synthesis-of-PE |
11 |
1.74e-01 |
3.69e-01 |
0.38400 |
-0.318000 |
-2.16e-01 |
6.81e-02 |
2.16e-01 |
NF-kB-is-activated-and-signals-survival |
13 |
1.93e-01 |
3.90e-01 |
0.38100 |
0.247000 |
2.90e-01 |
1.23e-01 |
7.05e-02 |
Platelet-Aggregation-(Plug-Formation) |
29 |
3.11e-02 |
1.17e-01 |
0.38000 |
0.266000 |
2.71e-01 |
1.30e-02 |
1.15e-02 |
TNFR1-induced-proapoptotic-signaling |
12 |
2.28e-01 |
4.26e-01 |
0.38000 |
0.285000 |
2.51e-01 |
8.79e-02 |
1.32e-01 |
Gap-junction-trafficking-and-regulation |
15 |
1.59e-01 |
3.49e-01 |
0.37700 |
0.285000 |
2.47e-01 |
5.62e-02 |
9.82e-02 |
Vif-mediated-degradation-of-APOBEC3G |
48 |
3.71e-05 |
5.65e-04 |
0.37600 |
-0.335000 |
-1.70e-01 |
5.91e-05 |
4.14e-02 |
FRS-mediated-FGFR3-signaling |
14 |
1.75e-01 |
3.69e-01 |
0.37600 |
-0.241000 |
-2.88e-01 |
1.18e-01 |
6.21e-02 |
p75NTR-recruits-signalling-complexes |
13 |
2.17e-01 |
4.16e-01 |
0.37300 |
0.251000 |
2.76e-01 |
1.17e-01 |
8.46e-02 |
Signaling-by-high-kinase-activity-BRAF-mutants |
31 |
2.73e-02 |
1.07e-01 |
0.37300 |
0.272000 |
2.55e-01 |
8.73e-03 |
1.40e-02 |
G-protein-activation |
16 |
7.03e-02 |
2.06e-01 |
0.37000 |
0.316000 |
1.94e-01 |
2.89e-02 |
1.80e-01 |
Biosynthesis-of-DHA-derived-SPMs |
11 |
2.81e-01 |
4.86e-01 |
0.36900 |
-0.247000 |
-2.74e-01 |
1.57e-01 |
1.15e-01 |
RORA-activates-gene-expression |
18 |
1.96e-02 |
8.24e-02 |
0.36600 |
-0.157000 |
-3.31e-01 |
2.50e-01 |
1.50e-02 |
PI-3K-cascade:FGFR4 |
12 |
1.46e-01 |
3.34e-01 |
0.36600 |
-0.192000 |
-3.11e-01 |
2.49e-01 |
6.22e-02 |
SHC1-events-in-EGFR-signaling |
12 |
1.77e-01 |
3.72e-01 |
0.36500 |
0.303000 |
2.05e-01 |
6.96e-02 |
2.20e-01 |
MicroRNA-(miRNA)-biogenesis |
23 |
6.45e-02 |
1.95e-01 |
0.36500 |
-0.282000 |
-2.32e-01 |
1.92e-02 |
5.44e-02 |
Synthesis-of-bile-acids-and-bile-salts-via-7alpha-hydroxycholesterol |
12 |
2.08e-01 |
4.08e-01 |
0.36500 |
-0.216000 |
-2.93e-01 |
1.94e-01 |
7.86e-02 |
Role-of-LAT2/NTAL/LAB-on-calcium-mobilization |
14 |
1.70e-01 |
3.63e-01 |
0.36400 |
0.221000 |
2.90e-01 |
1.53e-01 |
6.05e-02 |
RUNX2-regulates-bone-development |
27 |
4.40e-02 |
1.53e-01 |
0.36300 |
0.277000 |
2.34e-01 |
1.26e-02 |
3.51e-02 |
Interferon-alpha/beta-signaling |
40 |
1.39e-08 |
4.33e-07 |
0.36300 |
0.047900 |
3.60e-01 |
6.01e-01 |
8.18e-05 |
Activation-of-RAC1 |
12 |
1.16e-01 |
2.87e-01 |
0.36300 |
0.317000 |
1.76e-01 |
5.70e-02 |
2.92e-01 |
COPI-dependent-Golgi-to-ER-retrograde-traffic |
74 |
1.18e-06 |
2.61e-05 |
0.36200 |
0.319000 |
1.71e-01 |
2.15e-06 |
1.09e-02 |
Regulation-of-FOXO-transcriptional-activity-by-acetylation |
10 |
3.26e-01 |
5.28e-01 |
0.35900 |
-0.234000 |
-2.73e-01 |
2.00e-01 |
1.36e-01 |
Glycerophospholipid-biosynthesis |
102 |
1.98e-05 |
3.42e-04 |
0.35900 |
-0.253000 |
-2.55e-01 |
1.02e-05 |
8.93e-06 |
alpha-linolenic-(omega3)-and-linoleic-(omega6)-acid-metabolism |
10 |
3.33e-01 |
5.31e-01 |
0.35900 |
-0.238000 |
-2.69e-01 |
1.93e-01 |
1.41e-01 |
alpha-linolenic-acid-(ALA)-metabolism |
10 |
3.33e-01 |
5.31e-01 |
0.35900 |
-0.238000 |
-2.69e-01 |
1.93e-01 |
1.41e-01 |
Vpu-mediated-degradation-of-CD4 |
48 |
5.10e-05 |
7.25e-04 |
0.35800 |
-0.323000 |
-1.54e-01 |
1.09e-04 |
6.44e-02 |
N-glycan-antennae-elongation-in-the-medial/trans-Golgi |
20 |
2.41e-04 |
2.49e-03 |
0.35500 |
0.351000 |
5.31e-02 |
6.62e-03 |
6.81e-01 |
Chk1/Chk2(Cds1)-mediated-inactivation-of-Cyclin-B:Cdk1-complex |
12 |
2.76e-01 |
4.83e-01 |
0.35100 |
0.228000 |
2.67e-01 |
1.72e-01 |
1.10e-01 |
Regulation-of-actin-dynamics-for-phagocytic-cup-formation |
59 |
2.59e-03 |
1.70e-02 |
0.35000 |
0.246000 |
2.49e-01 |
1.10e-03 |
9.59e-04 |
Nephrin-family-interactions |
18 |
2.82e-02 |
1.09e-01 |
0.34800 |
0.148000 |
3.15e-01 |
2.77e-01 |
2.08e-02 |
Regulation-of-ornithine-decarboxylase-(ODC) |
46 |
3.97e-05 |
5.96e-04 |
0.34700 |
-0.320000 |
-1.35e-01 |
1.73e-04 |
1.13e-01 |
Metabolism-of-amino-acids-and-derivatives |
256 |
1.02e-11 |
5.03e-10 |
0.34700 |
-0.241000 |
-2.51e-01 |
3.75e-11 |
5.47e-12 |
activated-TAK1-mediates-p38-MAPK-activation |
18 |
1.52e-01 |
3.39e-01 |
0.34600 |
-0.264000 |
-2.23e-01 |
5.28e-02 |
1.01e-01 |
Retrograde-neurotrophin-signalling |
12 |
2.29e-01 |
4.27e-01 |
0.34500 |
0.282000 |
1.99e-01 |
9.07e-02 |
2.32e-01 |
Acyl-chain-remodelling-of-PC |
18 |
9.31e-02 |
2.44e-01 |
0.34500 |
-0.288000 |
-1.90e-01 |
3.47e-02 |
1.63e-01 |
FRS-mediated-FGFR4-signaling |
14 |
1.60e-01 |
3.51e-01 |
0.34300 |
-0.190000 |
-2.86e-01 |
2.19e-01 |
6.36e-02 |
Activation-of-the-AP-1-family-of-transcription-factors |
10 |
1.35e-01 |
3.18e-01 |
0.34300 |
-0.142000 |
-3.13e-01 |
4.37e-01 |
8.70e-02 |
Regulation-of-activated-PAK-2p34-by-proteasome-mediated-degradation |
46 |
6.86e-05 |
9.33e-04 |
0.34300 |
-0.315000 |
-1.37e-01 |
2.24e-04 |
1.08e-01 |
mRNA-decay-by-5'-to-3'-exoribonuclease |
15 |
2.12e-01 |
4.12e-01 |
0.34100 |
-0.218000 |
-2.63e-01 |
1.44e-01 |
7.81e-02 |
Sema4D-induced-cell-migration-and-growth-cone-collapse |
19 |
7.95e-02 |
2.26e-01 |
0.34000 |
0.183000 |
2.86e-01 |
1.67e-01 |
3.07e-02 |
MET-activates-RAP1-and-RAC1 |
11 |
8.34e-02 |
2.32e-01 |
0.34000 |
0.316000 |
1.24e-01 |
6.94e-02 |
4.76e-01 |
Interleukin-10-signaling |
23 |
3.81e-02 |
1.39e-01 |
0.34000 |
0.291000 |
1.76e-01 |
1.59e-02 |
1.45e-01 |
Ubiquitin-Mediated-Degradation-of-Phosphorylated-Cdc25A |
48 |
2.72e-05 |
4.30e-04 |
0.33900 |
-0.315000 |
-1.27e-01 |
1.64e-04 |
1.29e-01 |
p53-Independent-DNA-Damage-Response |
48 |
2.72e-05 |
4.30e-04 |
0.33900 |
-0.315000 |
-1.27e-01 |
1.64e-04 |
1.29e-01 |
p53-Independent-G1/S-DNA-damage-checkpoint |
48 |
2.72e-05 |
4.30e-04 |
0.33900 |
-0.315000 |
-1.27e-01 |
1.64e-04 |
1.29e-01 |
Diseases-of-glycosylation |
113 |
1.33e-06 |
2.82e-05 |
0.33900 |
0.278000 |
1.93e-01 |
3.33e-07 |
3.94e-04 |
Retinoid-metabolism-and-transport |
29 |
6.43e-02 |
1.95e-01 |
0.33800 |
0.239000 |
2.39e-01 |
2.60e-02 |
2.57e-02 |
Synthesis-of-glycosylphosphatidylinositol-(GPI) |
17 |
1.99e-01 |
3.95e-01 |
0.33800 |
-0.245000 |
-2.32e-01 |
8.03e-02 |
9.74e-02 |
CRMPs-in-Sema3A-signaling |
15 |
2.09e-01 |
4.08e-01 |
0.33600 |
0.208000 |
2.64e-01 |
1.62e-01 |
7.69e-02 |
Signaling-by-FGFR3-in-disease |
16 |
1.44e-01 |
3.31e-01 |
0.33500 |
-0.189000 |
-2.77e-01 |
1.92e-01 |
5.47e-02 |
Signaling-by-FGFR3-point-mutants-in-cancer |
16 |
1.44e-01 |
3.31e-01 |
0.33500 |
-0.189000 |
-2.77e-01 |
1.92e-01 |
5.47e-02 |
Apoptotic-cleavage-of-cellular-proteins |
34 |
1.50e-02 |
6.72e-02 |
0.33500 |
0.279000 |
1.86e-01 |
4.86e-03 |
6.05e-02 |
RUNX2-regulates-osteoblast-differentiation |
21 |
9.40e-02 |
2.45e-01 |
0.33500 |
0.271000 |
1.97e-01 |
3.14e-02 |
1.19e-01 |
Signaling-by-Activin |
11 |
1.25e-02 |
6.00e-02 |
0.33500 |
0.333000 |
3.84e-02 |
5.60e-02 |
8.25e-01 |
SCF-beta-TrCP-mediated-degradation-of-Emi1 |
51 |
8.26e-05 |
1.06e-03 |
0.33500 |
-0.303000 |
-1.42e-01 |
1.81e-04 |
8.02e-02 |
Regulation-of-RUNX1-Expression-and-Activity |
17 |
1.89e-01 |
3.87e-01 |
0.33400 |
0.216000 |
2.55e-01 |
1.23e-01 |
6.87e-02 |
ABC-family-proteins-mediated-transport |
89 |
1.75e-05 |
3.10e-04 |
0.33400 |
-0.279000 |
-1.85e-01 |
5.62e-06 |
2.63e-03 |
Signaling-by-MET |
60 |
2.20e-04 |
2.31e-03 |
0.33400 |
0.287000 |
1.70e-01 |
1.19e-04 |
2.28e-02 |
Degradation-of-DVL |
52 |
2.99e-04 |
2.99e-03 |
0.33300 |
-0.293000 |
-1.58e-01 |
2.56e-04 |
4.90e-02 |
Glucose-metabolism |
79 |
1.57e-04 |
1.78e-03 |
0.33300 |
-0.195000 |
-2.70e-01 |
2.73e-03 |
3.44e-05 |
Fcgamma-receptor-(FCGR)-dependent-phagocytosis |
82 |
3.49e-04 |
3.35e-03 |
0.33200 |
0.213000 |
2.55e-01 |
8.87e-04 |
6.69e-05 |
Degradation-of-GLI1-by-the-proteasome |
55 |
1.82e-04 |
1.99e-03 |
0.33100 |
-0.292000 |
-1.55e-01 |
1.78e-04 |
4.67e-02 |
Activation-of-IRF3/IRF7-mediated-by-TBK1/IKK-epsilon |
15 |
1.78e-01 |
3.72e-01 |
0.33000 |
0.188000 |
2.72e-01 |
2.07e-01 |
6.86e-02 |
Acyl-chain-remodelling-of-PE |
17 |
1.71e-01 |
3.66e-01 |
0.32800 |
-0.262000 |
-1.98e-01 |
6.15e-02 |
1.57e-01 |
SMAD2/SMAD3:SMAD4-heterotrimer-regulates-transcription |
31 |
1.02e-02 |
5.21e-02 |
0.32400 |
0.285000 |
1.53e-01 |
6.02e-03 |
1.40e-01 |
Interleukin-15-signaling |
14 |
1.20e-01 |
2.94e-01 |
0.32300 |
-0.150000 |
-2.86e-01 |
3.30e-01 |
6.39e-02 |
Oxygen-dependent-proline-hydroxylation-of-Hypoxia-inducible-Factor-Alpha |
60 |
4.60e-04 |
4.17e-03 |
0.32300 |
-0.276000 |
-1.67e-01 |
2.17e-04 |
2.57e-02 |
ABC-transporter-disorders |
66 |
7.84e-05 |
1.01e-03 |
0.32200 |
-0.283000 |
-1.55e-01 |
7.23e-05 |
2.99e-02 |
Activated-NTRK2-signals-through-FRS2-and-FRS3 |
10 |
1.04e-01 |
2.64e-01 |
0.32100 |
-0.103000 |
-3.04e-01 |
5.72e-01 |
9.64e-02 |
Defective-CFTR-causes-cystic-fibrosis |
55 |
4.89e-04 |
4.38e-03 |
0.32000 |
-0.280000 |
-1.56e-01 |
3.33e-04 |
4.53e-02 |
CDT1-association-with-the-CDC6:ORC:origin-complex |
55 |
2.89e-05 |
4.51e-04 |
0.32000 |
-0.296000 |
-1.23e-01 |
1.49e-04 |
1.16e-01 |
Glycosphingolipid-metabolism |
34 |
1.75e-02 |
7.52e-02 |
0.32000 |
0.270000 |
1.71e-01 |
6.41e-03 |
8.38e-02 |
Energy-dependent-regulation-of-mTOR-by-LKB1-AMPK |
29 |
5.68e-02 |
1.83e-01 |
0.31900 |
-0.191000 |
-2.56e-01 |
7.52e-02 |
1.73e-02 |
IRAK4-deficiency-(TLR2/4) |
10 |
4.08e-01 |
5.96e-01 |
0.31900 |
0.205000 |
2.44e-01 |
2.62e-01 |
1.81e-01 |
MyD88-deficiency-(TLR2/4) |
10 |
4.08e-01 |
5.96e-01 |
0.31900 |
0.205000 |
2.44e-01 |
2.62e-01 |
1.81e-01 |
Negative-regulation-of-NOTCH4-signaling |
51 |
1.22e-04 |
1.47e-03 |
0.31800 |
-0.291000 |
-1.28e-01 |
3.29e-04 |
1.14e-01 |
FBXL7-down-regulates-AURKA-during-mitotic-entry-and-in-early-mitosis |
51 |
1.71e-04 |
1.90e-03 |
0.31800 |
-0.289000 |
-1.32e-01 |
3.60e-04 |
1.04e-01 |
Hh-mutants-that-don't-undergo-autocatalytic-processing-are-degraded-by-ERAD |
51 |
4.47e-04 |
4.11e-03 |
0.31700 |
-0.283000 |
-1.43e-01 |
4.82e-04 |
7.68e-02 |
Interconversion-of-nucleotide-di--and-triphosphates |
24 |
1.35e-01 |
3.18e-01 |
0.31700 |
-0.218000 |
-2.29e-01 |
6.41e-02 |
5.17e-02 |
Activation-of-gene-expression-by-SREBF-(SREBP) |
42 |
1.14e-02 |
5.66e-02 |
0.31600 |
-0.178000 |
-2.61e-01 |
4.60e-02 |
3.47e-03 |
Autodegradation-of-the-E3-ubiquitin-ligase-COP1 |
47 |
7.41e-05 |
9.77e-04 |
0.31500 |
-0.295000 |
-1.10e-01 |
4.69e-04 |
1.92e-01 |
Processing-of-Capped-Intronless-Pre-mRNA |
26 |
9.33e-02 |
2.44e-01 |
0.31400 |
-0.194000 |
-2.47e-01 |
8.67e-02 |
2.95e-02 |
Adenylate-cyclase-inhibitory-pathway |
12 |
3.43e-01 |
5.38e-01 |
0.31300 |
0.196000 |
2.44e-01 |
2.39e-01 |
1.43e-01 |
Metabolism-of-fat-soluble-vitamins |
33 |
5.83e-02 |
1.84e-01 |
0.31200 |
0.240000 |
1.99e-01 |
1.72e-02 |
4.77e-02 |
EPH-Ephrin-signaling |
82 |
2.92e-04 |
2.94e-03 |
0.31200 |
0.254000 |
1.80e-01 |
6.99e-05 |
4.81e-03 |
Selective-autophagy |
50 |
1.73e-02 |
7.49e-02 |
0.31100 |
-0.229000 |
-2.11e-01 |
5.14e-03 |
9.95e-03 |
GRB2-events-in-EGFR-signaling |
11 |
3.00e-01 |
5.09e-01 |
0.31100 |
0.261000 |
1.70e-01 |
1.35e-01 |
3.30e-01 |
Interleukin-4-and-Interleukin-13-signaling |
76 |
5.17e-05 |
7.26e-04 |
0.31000 |
0.271000 |
1.51e-01 |
4.48e-05 |
2.30e-02 |
GAB1-signalosome |
15 |
1.37e-01 |
3.22e-01 |
0.31000 |
0.272000 |
1.49e-01 |
6.87e-02 |
3.18e-01 |
TP53-Regulates-Transcription-of-Caspase-Activators-and-Caspases |
10 |
3.26e-01 |
5.28e-01 |
0.30900 |
0.262000 |
1.65e-01 |
1.52e-01 |
3.66e-01 |
Regulation-of-TLR-by-endogenous-ligand |
12 |
6.30e-02 |
1.94e-01 |
0.30900 |
0.088600 |
2.96e-01 |
5.95e-01 |
7.61e-02 |
AUF1-(hnRNP-D0)-binds-and-destabilizes-mRNA |
50 |
9.96e-05 |
1.22e-03 |
0.30800 |
-0.286000 |
-1.13e-01 |
4.63e-04 |
1.68e-01 |
Deadenylation-of-mRNA |
20 |
1.64e-01 |
3.56e-01 |
0.30700 |
-0.186000 |
-2.45e-01 |
1.50e-01 |
5.82e-02 |
Resolution-of-D-loop-Structures-through-Holliday-Junction-Intermediates |
30 |
5.58e-02 |
1.81e-01 |
0.30500 |
0.176000 |
2.50e-01 |
9.54e-02 |
1.80e-02 |
RHO-GTPases-activate-CIT |
18 |
1.39e-01 |
3.26e-01 |
0.30500 |
0.162000 |
2.58e-01 |
2.34e-01 |
5.78e-02 |
DNA-strand-elongation |
31 |
8.91e-03 |
4.73e-02 |
0.30500 |
0.130000 |
2.76e-01 |
2.12e-01 |
7.85e-03 |
Resolution-of-D-Loop-Structures |
31 |
6.30e-02 |
1.94e-01 |
0.30500 |
0.184000 |
2.43e-01 |
7.70e-02 |
1.92e-02 |
Metabolism-of-Angiotensinogen-to-Angiotensins |
11 |
3.70e-01 |
5.64e-01 |
0.30500 |
0.244000 |
1.82e-01 |
1.61e-01 |
2.96e-01 |
Amino-acid-transport-across-the-plasma-membrane |
21 |
1.96e-01 |
3.93e-01 |
0.30500 |
0.223000 |
2.08e-01 |
7.74e-02 |
9.95e-02 |
Chemokine-receptors-bind-chemokines |
20 |
2.50e-03 |
1.65e-02 |
0.30300 |
0.299000 |
4.74e-02 |
2.05e-02 |
7.14e-01 |
Resolution-of-D-loop-Structures-through-Synthesis-Dependent-Strand-Annealing-(SDSA) |
25 |
6.78e-02 |
2.02e-01 |
0.30300 |
0.161000 |
2.56e-01 |
1.64e-01 |
2.67e-02 |
Golgi-to-ER-retrograde-transport |
105 |
1.65e-06 |
3.35e-05 |
0.30200 |
0.266000 |
1.44e-01 |
2.62e-06 |
1.07e-02 |
Loss-of-function-of-MECP2-in-Rett-syndrome |
12 |
7.47e-02 |
2.16e-01 |
0.30100 |
-0.088300 |
-2.88e-01 |
5.96e-01 |
8.39e-02 |
Pervasive-developmental-disorders |
12 |
7.47e-02 |
2.16e-01 |
0.30100 |
-0.088300 |
-2.88e-01 |
5.96e-01 |
8.39e-02 |
GLI3-is-processed-to-GLI3R-by-the-proteasome |
55 |
9.59e-04 |
7.81e-03 |
0.30000 |
-0.264000 |
-1.43e-01 |
7.06e-04 |
6.74e-02 |
Metabolism |
1613 |
5.51e-49 |
1.76e-46 |
0.30000 |
-0.200000 |
-2.24e-01 |
1.76e-39 |
2.43e-49 |
MAP2K-and-MAPK-activation |
35 |
7.62e-02 |
2.19e-01 |
0.29800 |
0.212000 |
2.10e-01 |
3.02e-02 |
3.16e-02 |
HSF1-activation |
23 |
5.89e-02 |
1.85e-01 |
0.29600 |
-0.261000 |
-1.41e-01 |
3.05e-02 |
2.42e-01 |
Response-to-elevated-platelet-cytosolic-Ca2+ |
113 |
1.45e-04 |
1.69e-03 |
0.29600 |
0.229000 |
1.88e-01 |
2.63e-05 |
5.63e-04 |
Formation-of-Incision-Complex-in-GG-NER |
43 |
6.52e-03 |
3.71e-02 |
0.29600 |
-0.145000 |
-2.58e-01 |
9.92e-02 |
3.44e-03 |
RHO-GTPases-Activate-WASPs-and-WAVEs |
36 |
6.99e-02 |
2.05e-01 |
0.29600 |
0.219000 |
1.99e-01 |
2.29e-02 |
3.90e-02 |
Degradation-of-GLI2-by-the-proteasome |
55 |
1.02e-03 |
8.12e-03 |
0.29600 |
-0.261000 |
-1.39e-01 |
8.06e-04 |
7.55e-02 |
Platelet-degranulation |
108 |
9.24e-05 |
1.17e-03 |
0.29600 |
0.238000 |
1.75e-01 |
1.91e-05 |
1.69e-03 |
Methylation |
12 |
4.12e-01 |
5.98e-01 |
0.29600 |
-0.219000 |
-1.98e-01 |
1.88e-01 |
2.35e-01 |
Semaphorin-interactions |
61 |
1.09e-02 |
5.51e-02 |
0.29600 |
0.197000 |
2.20e-01 |
7.77e-03 |
2.94e-03 |
Downstream-signaling-of-activated-FGFR3 |
19 |
1.41e-01 |
3.28e-01 |
0.29500 |
-0.156000 |
-2.50e-01 |
2.39e-01 |
5.93e-02 |
tRNA-processing |
116 |
2.53e-04 |
2.59e-03 |
0.29500 |
-0.208000 |
-2.08e-01 |
1.08e-04 |
1.08e-04 |
mRNA-Capping |
29 |
1.24e-01 |
3.00e-01 |
0.29400 |
-0.214000 |
-2.02e-01 |
4.64e-02 |
5.97e-02 |
Role-of-phospholipids-in-phagocytosis |
24 |
1.61e-01 |
3.52e-01 |
0.29400 |
0.189000 |
2.25e-01 |
1.09e-01 |
5.63e-02 |
mRNA-3'-end-processing |
54 |
2.11e-02 |
8.77e-02 |
0.29400 |
-0.212000 |
-2.03e-01 |
6.95e-03 |
1.01e-02 |
RHO-GTPases-activate-PAKs |
20 |
8.52e-02 |
2.34e-01 |
0.29300 |
0.137000 |
2.59e-01 |
2.88e-01 |
4.52e-02 |
Hh-mutants-abrogate-ligand-secretion |
53 |
3.99e-04 |
3.74e-03 |
0.29200 |
-0.267000 |
-1.19e-01 |
7.77e-04 |
1.34e-01 |
Signaling-by-Leptin |
10 |
2.32e-01 |
4.31e-01 |
0.29200 |
-0.120000 |
-2.66e-01 |
5.11e-01 |
1.45e-01 |
Stabilization-of-p53 |
51 |
7.50e-05 |
9.79e-04 |
0.29100 |
-0.276000 |
-9.40e-02 |
6.62e-04 |
2.46e-01 |
Cellular-response-to-hypoxia |
68 |
8.97e-04 |
7.40e-03 |
0.29000 |
-0.248000 |
-1.50e-01 |
4.10e-04 |
3.31e-02 |
Formation-of-apoptosome |
10 |
4.97e-01 |
6.64e-01 |
0.28900 |
-0.199000 |
-2.11e-01 |
2.77e-01 |
2.49e-01 |
Regulation-of-the-apoptosome-activity |
10 |
4.97e-01 |
6.64e-01 |
0.28900 |
-0.199000 |
-2.11e-01 |
2.77e-01 |
2.49e-01 |
Potassium-Channels |
56 |
2.20e-03 |
1.51e-02 |
0.28900 |
-0.251000 |
-1.44e-01 |
1.17e-03 |
6.24e-02 |
Signaling-by-FGFR2-IIIa-TM |
19 |
2.48e-01 |
4.46e-01 |
0.28900 |
-0.221000 |
-1.87e-01 |
9.55e-02 |
1.59e-01 |
Cross-presentation-of-soluble-exogenous-antigens-(endosomes) |
44 |
5.19e-04 |
4.61e-03 |
0.28900 |
-0.271000 |
-1.00e-01 |
1.86e-03 |
2.50e-01 |
TRAF3-dependent-IRF-activation-pathway |
12 |
1.23e-02 |
5.94e-02 |
0.28800 |
-0.002980 |
2.88e-01 |
9.86e-01 |
8.43e-02 |
Ubiquitin-dependent-degradation-of-Cyclin-D |
48 |
1.72e-04 |
1.90e-03 |
0.28800 |
-0.272000 |
-9.36e-02 |
1.11e-03 |
2.62e-01 |
Signaling-by-FGFR4-in-disease |
10 |
1.72e-01 |
3.66e-01 |
0.28800 |
-0.096200 |
-2.71e-01 |
5.98e-01 |
1.38e-01 |
EGFR-downregulation |
27 |
1.21e-01 |
2.96e-01 |
0.28700 |
0.228000 |
1.75e-01 |
4.05e-02 |
1.16e-01 |
Zinc-transporters |
12 |
2.63e-01 |
4.65e-01 |
0.28600 |
0.250000 |
1.39e-01 |
1.34e-01 |
4.05e-01 |
Signaling-by-NODAL |
11 |
6.48e-02 |
1.95e-01 |
0.28600 |
-0.054200 |
-2.81e-01 |
7.56e-01 |
1.07e-01 |
PPARA-activates-gene-expression |
109 |
1.93e-04 |
2.08e-03 |
0.28600 |
-0.172000 |
-2.28e-01 |
1.94e-03 |
3.85e-05 |
mRNA-Splicing---Minor-Pathway |
51 |
1.65e-02 |
7.25e-02 |
0.28600 |
-0.230000 |
-1.69e-01 |
4.47e-03 |
3.65e-02 |
Regulation-of-glycolysis-by-fructose-2,6-bisphosphate-metabolism |
10 |
2.21e-01 |
4.21e-01 |
0.28500 |
-0.110000 |
-2.64e-01 |
5.48e-01 |
1.49e-01 |
Synaptic-adhesion-like-molecules |
15 |
1.73e-03 |
1.27e-02 |
0.28500 |
0.283000 |
-3.47e-02 |
5.76e-02 |
8.16e-01 |
RNA-Pol-II-CTD-phosphorylation-and-interaction-with-CE |
27 |
1.55e-01 |
3.45e-01 |
0.28500 |
-0.213000 |
-1.90e-01 |
5.60e-02 |
8.76e-02 |
RNA-Pol-II-CTD-phosphorylation-and-interaction-with-CE-during-HIV-infection |
27 |
1.55e-01 |
3.45e-01 |
0.28500 |
-0.213000 |
-1.90e-01 |
5.60e-02 |
8.76e-02 |
RIP-mediated-NFkB-activation-via-ZBP1 |
17 |
3.13e-01 |
5.18e-01 |
0.28500 |
0.210000 |
1.93e-01 |
1.34e-01 |
1.69e-01 |
Regulation-of-PTEN-stability-and-activity |
65 |
3.58e-04 |
3.39e-03 |
0.28300 |
-0.253000 |
-1.27e-01 |
4.21e-04 |
7.71e-02 |
Glycogen-storage-diseases |
13 |
3.33e-01 |
5.31e-01 |
0.28300 |
-0.233000 |
-1.61e-01 |
1.46e-01 |
3.16e-01 |
SEMA3A-Plexin-repulsion-signaling-by-inhibiting-Integrin-adhesion |
14 |
3.83e-01 |
5.74e-01 |
0.28300 |
0.187000 |
2.12e-01 |
2.26e-01 |
1.69e-01 |
ADP-signalling-through-P2Y-purinoceptor-12 |
15 |
1.40e-01 |
3.27e-01 |
0.28200 |
0.256000 |
1.20e-01 |
8.66e-02 |
4.22e-01 |
Regulation-of-lipid-metabolism-by-PPARalpha |
111 |
1.88e-04 |
2.04e-03 |
0.28200 |
-0.168000 |
-2.26e-01 |
2.28e-03 |
3.88e-05 |
STING-mediated-induction-of-host-immune-responses |
14 |
2.96e-02 |
1.13e-01 |
0.28200 |
0.047900 |
2.77e-01 |
7.56e-01 |
7.23e-02 |
NIK-->noncanonical-NF-kB-signaling |
55 |
5.97e-04 |
5.19e-03 |
0.28000 |
-0.256000 |
-1.15e-01 |
1.03e-03 |
1.41e-01 |
Biosynthesis-of-specialized-proresolving-mediators-(SPMs) |
13 |
3.74e-01 |
5.67e-01 |
0.28000 |
-0.169000 |
-2.24e-01 |
2.91e-01 |
1.63e-01 |
Prostacyclin-signalling-through-prostacyclin-receptor |
13 |
1.66e-01 |
3.60e-01 |
0.27900 |
0.256000 |
1.12e-01 |
1.10e-01 |
4.85e-01 |
Transcriptional-activity-of-SMAD2/SMAD3:SMAD4-heterotrimer |
43 |
1.40e-03 |
1.06e-02 |
0.27900 |
0.260000 |
1.02e-01 |
3.18e-03 |
2.50e-01 |
Nucleotide-like-(purinergic)-receptors |
12 |
3.12e-01 |
5.18e-01 |
0.27900 |
-0.239000 |
-1.43e-01 |
1.51e-01 |
3.91e-01 |
RHO-GTPases-activate-KTN1 |
10 |
3.52e-01 |
5.46e-01 |
0.27800 |
0.243000 |
1.35e-01 |
1.84e-01 |
4.59e-01 |
mRNA-Splicing---Major-Pathway |
172 |
1.87e-05 |
3.27e-04 |
0.27700 |
-0.191000 |
-2.01e-01 |
1.53e-05 |
5.88e-06 |
Insulin-processing |
21 |
2.55e-01 |
4.56e-01 |
0.27700 |
0.184000 |
2.06e-01 |
1.44e-01 |
1.02e-01 |
Degradation-of-AXIN |
51 |
2.92e-04 |
2.94e-03 |
0.27600 |
-0.259000 |
-9.33e-02 |
1.36e-03 |
2.49e-01 |
Downstream-signaling-of-activated-FGFR4 |
19 |
9.61e-02 |
2.48e-01 |
0.27500 |
-0.118000 |
-2.49e-01 |
3.74e-01 |
6.05e-02 |
SUMOylation-of-intracellular-receptors |
27 |
8.86e-02 |
2.38e-01 |
0.27400 |
-0.144000 |
-2.33e-01 |
1.94e-01 |
3.62e-02 |
ABC-transporters-in-lipid-homeostasis |
14 |
4.07e-01 |
5.94e-01 |
0.27400 |
-0.181000 |
-2.06e-01 |
2.41e-01 |
1.83e-01 |
BMAL1:CLOCK,NPAS2-activates-circadian-gene-expression |
25 |
2.45e-02 |
9.87e-02 |
0.27300 |
-0.097700 |
-2.55e-01 |
3.98e-01 |
2.75e-02 |
TGF-beta-receptor-signaling-in-EMT-(epithelial-to-mesenchymal-transition) |
15 |
1.67e-01 |
3.60e-01 |
0.27200 |
0.246000 |
1.17e-01 |
9.96e-02 |
4.31e-01 |
Senescence-Associated-Secretory-Phenotype-(SASP) |
45 |
5.00e-03 |
3.03e-02 |
0.27200 |
0.245000 |
1.18e-01 |
4.48e-03 |
1.71e-01 |
Synthesis-of-PIPs-at-the-plasma-membrane |
51 |
3.76e-03 |
2.34e-02 |
0.27200 |
0.242000 |
1.24e-01 |
2.84e-03 |
1.25e-01 |
Interleukin-37-signaling |
18 |
3.33e-01 |
5.31e-01 |
0.27200 |
0.190000 |
1.94e-01 |
1.62e-01 |
1.55e-01 |
CREB1-phosphorylation-through-the-activation-of-Adenylate-Cyclase |
10 |
2.40e-01 |
4.38e-01 |
0.27200 |
-0.100000 |
-2.52e-01 |
5.84e-01 |
1.67e-01 |
Phosphorylation-of-the-APC/C |
18 |
6.87e-02 |
2.04e-01 |
0.27100 |
0.254000 |
9.61e-02 |
6.22e-02 |
4.80e-01 |
RNA-Polymerase-II-Transcription-Termination |
62 |
2.21e-02 |
9.10e-02 |
0.27100 |
-0.183000 |
-2.00e-01 |
1.26e-02 |
6.62e-03 |
NCAM-signaling-for-neurite-out-growth |
50 |
4.15e-02 |
1.48e-01 |
0.26900 |
0.174000 |
2.06e-01 |
3.39e-02 |
1.18e-02 |
Common-Pathway-of-Fibrin-Clot-Formation |
10 |
2.26e-01 |
4.23e-01 |
0.26900 |
0.093400 |
2.52e-01 |
6.09e-01 |
1.67e-01 |
IRF3-mediated-induction-of-type-I-IFN |
11 |
1.78e-01 |
3.72e-01 |
0.26900 |
0.088100 |
2.54e-01 |
6.13e-01 |
1.45e-01 |
mRNA-Splicing |
180 |
2.48e-05 |
4.17e-04 |
0.26800 |
-0.190000 |
-1.89e-01 |
1.16e-05 |
1.20e-05 |
Condensation-of-Prometaphase-Chromosomes |
11 |
4.96e-01 |
6.64e-01 |
0.26800 |
0.172000 |
2.06e-01 |
3.24e-01 |
2.37e-01 |
PIWI-interacting-RNA-(piRNA)-biogenesis |
16 |
8.26e-02 |
2.31e-01 |
0.26800 |
-0.253000 |
-8.77e-02 |
7.96e-02 |
5.44e-01 |
GPVI-mediated-activation-cascade |
29 |
1.45e-01 |
3.32e-01 |
0.26800 |
0.211000 |
1.65e-01 |
4.96e-02 |
1.24e-01 |
G-beta:gamma-signalling-through-CDC42 |
14 |
1.55e-01 |
3.44e-01 |
0.26800 |
0.247000 |
1.02e-01 |
1.09e-01 |
5.08e-01 |
FGFR2-mutant-receptor-activation |
24 |
2.08e-01 |
4.08e-01 |
0.26700 |
-0.209000 |
-1.66e-01 |
7.66e-02 |
1.59e-01 |
ZBP1(DAI)-mediated-induction-of-type-I-IFNs |
20 |
2.81e-01 |
4.86e-01 |
0.26700 |
0.206000 |
1.70e-01 |
1.11e-01 |
1.89e-01 |
HIV-Transcription-Initiation |
45 |
5.87e-02 |
1.84e-01 |
0.26700 |
-0.170000 |
-2.05e-01 |
4.84e-02 |
1.73e-02 |
RNA-Polymerase-II-HIV-Promoter-Escape |
45 |
5.87e-02 |
1.84e-01 |
0.26700 |
-0.170000 |
-2.05e-01 |
4.84e-02 |
1.73e-02 |
RNA-Polymerase-II-Promoter-Escape |
45 |
5.87e-02 |
1.84e-01 |
0.26700 |
-0.170000 |
-2.05e-01 |
4.84e-02 |
1.73e-02 |
RNA-Polymerase-II-Transcription-Initiation |
45 |
5.87e-02 |
1.84e-01 |
0.26700 |
-0.170000 |
-2.05e-01 |
4.84e-02 |
1.73e-02 |
RNA-Polymerase-II-Transcription-Initiation-And-Promoter-Clearance |
45 |
5.87e-02 |
1.84e-01 |
0.26700 |
-0.170000 |
-2.05e-01 |
4.84e-02 |
1.73e-02 |
RNA-Polymerase-II-Transcription-Pre-Initiation-And-Promoter-Opening |
45 |
5.87e-02 |
1.84e-01 |
0.26700 |
-0.170000 |
-2.05e-01 |
4.84e-02 |
1.73e-02 |
Deposition-of-new-CENPA-containing-nucleosomes-at-the-centromere |
19 |
2.36e-01 |
4.35e-01 |
0.26600 |
0.220000 |
1.49e-01 |
9.73e-02 |
2.61e-01 |
Nucleosome-assembly |
19 |
2.36e-01 |
4.35e-01 |
0.26600 |
0.220000 |
1.49e-01 |
9.73e-02 |
2.61e-01 |
Response-of-EIF2AK1-(HRI)-to-heme-deficiency |
15 |
3.55e-01 |
5.49e-01 |
0.26500 |
0.157000 |
2.13e-01 |
2.91e-01 |
1.53e-01 |
Signaling-by-FGFR2-in-disease |
34 |
1.33e-01 |
3.16e-01 |
0.26400 |
-0.176000 |
-1.97e-01 |
7.60e-02 |
4.67e-02 |
Recycling-pathway-of-L1 |
25 |
4.37e-02 |
1.52e-01 |
0.26400 |
0.242000 |
1.04e-01 |
3.60e-02 |
3.70e-01 |
Mismatch-repair-(MMR)-directed-by-MSH2:MSH3-(MutSbeta) |
11 |
2.98e-01 |
5.06e-01 |
0.26300 |
-0.237000 |
-1.15e-01 |
1.74e-01 |
5.10e-01 |
Glycogen-synthesis |
14 |
4.06e-01 |
5.94e-01 |
0.26100 |
-0.207000 |
-1.59e-01 |
1.80e-01 |
3.02e-01 |
Dectin-1-mediated-noncanonical-NF-kB-signaling |
56 |
1.08e-03 |
8.56e-03 |
0.26100 |
-0.240000 |
-1.03e-01 |
1.94e-03 |
1.84e-01 |
Synthesis-of-IP2,-IP,-and-Ins-in-the-cytosol |
13 |
3.09e-01 |
5.14e-01 |
0.26100 |
0.227000 |
1.28e-01 |
1.57e-01 |
4.23e-01 |
HSF1-dependent-transactivation |
30 |
1.43e-01 |
3.30e-01 |
0.25900 |
-0.207000 |
-1.55e-01 |
4.96e-02 |
1.41e-01 |
Leading-Strand-Synthesis |
13 |
3.20e-01 |
5.22e-01 |
0.25900 |
0.129000 |
2.24e-01 |
4.21e-01 |
1.61e-01 |
Polymerase-switching |
13 |
3.20e-01 |
5.22e-01 |
0.25900 |
0.129000 |
2.24e-01 |
4.21e-01 |
1.61e-01 |
Polymerase-switching-on-the-C-strand-of-the-telomere |
13 |
3.20e-01 |
5.22e-01 |
0.25900 |
0.129000 |
2.24e-01 |
4.21e-01 |
1.61e-01 |
Synthesis-of-PIPs-at-the-late-endosome-membrane |
11 |
1.44e-01 |
3.31e-01 |
0.25800 |
-0.064800 |
-2.50e-01 |
7.10e-01 |
1.51e-01 |
PTK6-Regulates-RHO-GTPases,-RAS-GTPase-and-MAP-kinases |
14 |
4.21e-01 |
6.06e-01 |
0.25800 |
0.203000 |
1.59e-01 |
1.89e-01 |
3.04e-01 |
FCERI-mediated-NF-kB-activation |
73 |
1.92e-03 |
1.38e-02 |
0.25700 |
-0.223000 |
-1.29e-01 |
1.01e-03 |
5.75e-02 |
Nuclear-Receptor-transcription-pathway |
43 |
8.62e-02 |
2.35e-01 |
0.25700 |
-0.167000 |
-1.94e-01 |
5.76e-02 |
2.74e-02 |
Negative-regulation-of-NMDA-receptor-mediated-neuronal-transmission |
14 |
1.30e-01 |
3.13e-01 |
0.25600 |
0.243000 |
8.14e-02 |
1.16e-01 |
5.98e-01 |
Transport-of-Mature-mRNA-Derived-from-an-Intronless-Transcript |
40 |
9.46e-02 |
2.46e-01 |
0.25500 |
-0.160000 |
-1.98e-01 |
8.10e-02 |
2.99e-02 |
Sphingolipid-metabolism |
67 |
6.93e-03 |
3.89e-02 |
0.25400 |
0.214000 |
1.37e-01 |
2.45e-03 |
5.24e-02 |
Antimicrobial-peptides |
13 |
3.99e-02 |
1.44e-01 |
0.25400 |
0.254000 |
1.88e-02 |
1.14e-01 |
9.07e-01 |
Attenuation-phase |
21 |
1.48e-01 |
3.35e-01 |
0.25400 |
-0.224000 |
-1.20e-01 |
7.62e-02 |
3.41e-01 |
Amino-acids-regulate-mTORC1 |
48 |
6.92e-02 |
2.04e-01 |
0.25300 |
-0.165000 |
-1.92e-01 |
4.87e-02 |
2.12e-02 |
WNT-ligand-biogenesis-and-trafficking |
16 |
3.95e-01 |
5.86e-01 |
0.25200 |
0.157000 |
1.97e-01 |
2.77e-01 |
1.73e-01 |
TP53-Regulates-Transcription-of-Genes-Involved-in-Cytochrome-C-Release |
16 |
4.02e-01 |
5.93e-01 |
0.25200 |
0.195000 |
1.59e-01 |
1.77e-01 |
2.71e-01 |
Interferon-gamma-signaling |
58 |
7.00e-03 |
3.91e-02 |
0.25000 |
0.121000 |
2.19e-01 |
1.12e-01 |
3.95e-03 |
Metabolism-of-water-soluble-vitamins-and-cofactors |
103 |
3.97e-03 |
2.46e-02 |
0.25000 |
-0.163000 |
-1.89e-01 |
4.25e-03 |
9.27e-04 |
Downregulation-of-SMAD2/3:SMAD4-transcriptional-activity |
23 |
6.01e-03 |
3.47e-02 |
0.25000 |
0.248000 |
2.80e-02 |
3.95e-02 |
8.17e-01 |
Transport-of-Mature-mRNAs-Derived-from-Intronless-Transcripts |
41 |
1.00e-01 |
2.56e-01 |
0.25000 |
-0.157000 |
-1.94e-01 |
8.14e-02 |
3.19e-02 |
Negative-regulation-of-MET-activity |
19 |
3.27e-01 |
5.28e-01 |
0.24800 |
0.198000 |
1.50e-01 |
1.36e-01 |
2.59e-01 |
Cilium-Assembly |
176 |
4.78e-05 |
6.95e-04 |
0.24700 |
0.195000 |
1.52e-01 |
8.38e-06 |
5.08e-04 |
Glutathione-conjugation |
25 |
2.24e-01 |
4.21e-01 |
0.24700 |
-0.199000 |
-1.47e-01 |
8.57e-02 |
2.04e-01 |
Activation-of-the-pre-replicative-complex |
32 |
5.28e-03 |
3.18e-02 |
0.24700 |
0.059900 |
2.39e-01 |
5.58e-01 |
1.91e-02 |
Keratinization |
22 |
8.05e-02 |
2.28e-01 |
0.24600 |
0.228000 |
9.30e-02 |
6.40e-02 |
4.50e-01 |
Processing-of-Capped-Intron-Containing-Pre-mRNA |
230 |
1.11e-05 |
2.06e-04 |
0.24600 |
-0.172000 |
-1.77e-01 |
7.62e-06 |
4.18e-06 |
Regulation-of-RUNX2-expression-and-activity |
66 |
1.43e-04 |
1.68e-03 |
0.24600 |
-0.233000 |
-7.79e-02 |
1.08e-03 |
2.74e-01 |
Glucagon-type-ligand-receptors |
15 |
8.96e-02 |
2.39e-01 |
0.24500 |
0.238000 |
6.05e-02 |
1.11e-01 |
6.85e-01 |
Intra-Golgi-and-retrograde-Golgi-to-ER-traffic |
168 |
7.64e-10 |
2.71e-08 |
0.24500 |
0.230000 |
8.31e-02 |
2.68e-07 |
6.36e-02 |
Constitutive-Signaling-by-Overexpressed-ERBB2 |
10 |
6.07e-01 |
7.36e-01 |
0.24400 |
0.178000 |
1.67e-01 |
3.29e-01 |
3.61e-01 |
Caspase-activation-via-Death-Receptors-in-the-presence-of-ligand |
13 |
5.23e-01 |
6.86e-01 |
0.24400 |
0.179000 |
1.66e-01 |
2.64e-01 |
3.01e-01 |
Deadenylation-dependent-mRNA-decay |
50 |
8.39e-02 |
2.32e-01 |
0.24400 |
-0.166000 |
-1.78e-01 |
4.23e-02 |
2.93e-02 |
Regulation-of-FZD-by-ubiquitination |
15 |
1.87e-01 |
3.83e-01 |
0.24200 |
-0.090100 |
-2.24e-01 |
5.46e-01 |
1.33e-01 |
PI-3K-cascade:FGFR2 |
14 |
2.23e-01 |
4.21e-01 |
0.24100 |
-0.093400 |
-2.23e-01 |
5.45e-01 |
1.49e-01 |
RHO-GTPase-Effectors |
220 |
2.69e-05 |
4.30e-04 |
0.24100 |
0.165000 |
1.75e-01 |
2.50e-05 |
7.61e-06 |
Ion-homeostasis |
39 |
8.51e-02 |
2.34e-01 |
0.24100 |
-0.200000 |
-1.34e-01 |
3.07e-02 |
1.47e-01 |
Sema3A-PAK-dependent-Axon-repulsion |
15 |
4.81e-01 |
6.55e-01 |
0.24100 |
0.163000 |
1.77e-01 |
2.74e-01 |
2.35e-01 |
VEGFR2-mediated-vascular-permeability |
25 |
2.79e-01 |
4.84e-01 |
0.24000 |
-0.185000 |
-1.54e-01 |
1.10e-01 |
1.83e-01 |
Transport-of-Mature-Transcript-to-Cytoplasm |
78 |
2.42e-02 |
9.79e-02 |
0.24000 |
-0.164000 |
-1.75e-01 |
1.23e-02 |
7.74e-03 |
Interleukin-receptor-SHC-signaling |
21 |
3.38e-01 |
5.36e-01 |
0.23900 |
0.186000 |
1.51e-01 |
1.41e-01 |
2.30e-01 |
Synthesis-of-PC |
24 |
3.13e-01 |
5.18e-01 |
0.23900 |
-0.178000 |
-1.60e-01 |
1.32e-01 |
1.75e-01 |
Acyl-chain-remodelling-of-PG |
10 |
4.21e-01 |
6.06e-01 |
0.23900 |
-0.213000 |
-1.08e-01 |
2.43e-01 |
5.55e-01 |
Sialic-acid-metabolism |
26 |
3.27e-03 |
2.07e-02 |
0.23900 |
0.238000 |
1.68e-02 |
3.55e-02 |
8.82e-01 |
Carboxyterminal-post-translational-modifications-of-tubulin |
26 |
1.02e-01 |
2.59e-01 |
0.23900 |
0.106000 |
2.14e-01 |
3.49e-01 |
5.93e-02 |
MET-receptor-recycling |
10 |
5.78e-01 |
7.22e-01 |
0.23700 |
0.190000 |
1.42e-01 |
2.98e-01 |
4.36e-01 |
Regulation-of-signaling-by-CBL |
18 |
3.42e-01 |
5.38e-01 |
0.23700 |
0.134000 |
1.95e-01 |
3.23e-01 |
1.51e-01 |
Hedgehog-ligand-biogenesis |
56 |
2.45e-03 |
1.64e-02 |
0.23700 |
-0.220000 |
-8.77e-02 |
4.49e-03 |
2.56e-01 |
IL-6-type-cytokine-receptor-ligand-interactions |
12 |
4.41e-01 |
6.26e-01 |
0.23600 |
0.123000 |
2.02e-01 |
4.60e-01 |
2.26e-01 |
Glycolysis |
63 |
1.43e-02 |
6.57e-02 |
0.23600 |
-0.124000 |
-2.01e-01 |
8.98e-02 |
5.71e-03 |
FRS-mediated-FGFR2-signaling |
16 |
2.45e-01 |
4.43e-01 |
0.23600 |
-0.103000 |
-2.12e-01 |
4.74e-01 |
1.42e-01 |
Pre-NOTCH-Transcription-and-Translation |
32 |
2.10e-01 |
4.11e-01 |
0.23600 |
0.180000 |
1.52e-01 |
7.80e-02 |
1.37e-01 |
APC/C:Cdc20-mediated-degradation-of-Securin |
62 |
6.76e-03 |
3.83e-02 |
0.23600 |
-0.209000 |
-1.09e-01 |
4.50e-03 |
1.37e-01 |
Unblocking-of-NMDA-receptors,-glutamate-binding-and-activation |
13 |
1.68e-01 |
3.62e-01 |
0.23500 |
0.226000 |
6.51e-02 |
1.58e-01 |
6.84e-01 |
SUMOylation-of-DNA-methylation-proteins |
16 |
1.68e-01 |
3.62e-01 |
0.23500 |
0.220000 |
8.30e-02 |
1.28e-01 |
5.66e-01 |
DAP12-signaling |
23 |
3.42e-01 |
5.38e-01 |
0.23400 |
0.175000 |
1.56e-01 |
1.47e-01 |
1.94e-01 |
FGFR2-alternative-splicing |
24 |
3.02e-01 |
5.10e-01 |
0.23400 |
-0.182000 |
-1.46e-01 |
1.22e-01 |
2.15e-01 |
WNT5A-dependent-internalization-of-FZD4 |
15 |
1.48e-01 |
3.35e-01 |
0.23200 |
0.222000 |
6.89e-02 |
1.37e-01 |
6.44e-01 |
SUMOylation-of-immune-response-proteins |
11 |
6.12e-01 |
7.38e-01 |
0.23200 |
0.165000 |
1.63e-01 |
3.43e-01 |
3.49e-01 |
SHC-mediated-cascade:FGFR3 |
12 |
5.79e-01 |
7.22e-01 |
0.23200 |
-0.155000 |
-1.72e-01 |
3.51e-01 |
3.01e-01 |
Macroautophagy |
99 |
4.33e-03 |
2.67e-02 |
0.23200 |
-0.134000 |
-1.89e-01 |
2.17e-02 |
1.16e-03 |
ATF6-(ATF6-alpha)-activates-chaperones |
12 |
5.41e-01 |
6.94e-01 |
0.23100 |
-0.184000 |
-1.40e-01 |
2.69e-01 |
4.02e-01 |
Trafficking-and-processing-of-endosomal-TLR |
11 |
3.36e-01 |
5.35e-01 |
0.23000 |
0.213000 |
8.73e-02 |
2.22e-01 |
6.16e-01 |
Neurotransmitter-release-cycle |
33 |
5.07e-02 |
1.69e-01 |
0.23000 |
0.094400 |
2.10e-01 |
3.48e-01 |
3.73e-02 |
RUNX1-regulates-transcription-of-genes-involved-in-differentiation-of-HSCs |
64 |
3.53e-04 |
3.37e-03 |
0.23000 |
-0.219000 |
-6.80e-02 |
2.40e-03 |
3.47e-01 |
Polo-like-kinase-mediated-events |
14 |
5.44e-01 |
6.96e-01 |
0.22900 |
0.162000 |
1.63e-01 |
2.95e-01 |
2.92e-01 |
YAP1--and-WWTR1-(TAZ)-stimulated-gene-expression |
14 |
5.03e-01 |
6.69e-01 |
0.22900 |
0.181000 |
1.41e-01 |
2.42e-01 |
3.62e-01 |
Endosomal-Sorting-Complex-Required-For-Transport-(ESCRT) |
30 |
7.64e-03 |
4.20e-02 |
0.22900 |
0.225000 |
4.12e-02 |
3.28e-02 |
6.96e-01 |
TICAM1-dependent-activation-of-IRF3/IRF7 |
12 |
4.04e-01 |
5.94e-01 |
0.22900 |
0.107000 |
2.02e-01 |
5.22e-01 |
2.25e-01 |
Effects-of-PIP2-hydrolysis |
23 |
4.49e-02 |
1.54e-01 |
0.22800 |
-0.220000 |
-5.90e-02 |
6.73e-02 |
6.24e-01 |
Signaling-by-EGFR |
45 |
3.35e-02 |
1.24e-01 |
0.22800 |
0.202000 |
1.06e-01 |
1.91e-02 |
2.20e-01 |
Gastrin-CREB-signalling-pathway-via-PKC-and-MAPK |
16 |
2.50e-01 |
4.48e-01 |
0.22800 |
0.207000 |
9.55e-02 |
1.52e-01 |
5.08e-01 |
RNA-Polymerase-I-Promoter-Escape |
32 |
1.95e-01 |
3.91e-01 |
0.22800 |
-0.183000 |
-1.35e-01 |
7.27e-02 |
1.86e-01 |
Assembly-and-cell-surface-presentation-of-NMDA-receptors |
16 |
4.85e-01 |
6.58e-01 |
0.22700 |
0.173000 |
1.47e-01 |
2.30e-01 |
3.09e-01 |
Long-term-potentiation |
16 |
6.49e-02 |
1.95e-01 |
0.22700 |
0.224000 |
3.34e-02 |
1.21e-01 |
8.17e-01 |
Regulation-of-KIT-signaling |
15 |
1.14e-01 |
2.83e-01 |
0.22600 |
0.050200 |
2.21e-01 |
7.37e-01 |
1.39e-01 |
Uptake-and-actions-of-bacterial-toxins |
23 |
3.53e-01 |
5.47e-01 |
0.22600 |
0.144000 |
1.74e-01 |
2.30e-01 |
1.49e-01 |
Synthesis-of-active-ubiquitin:-roles-of-E1-and-E2-enzymes |
29 |
3.25e-03 |
2.07e-02 |
0.22500 |
-0.014700 |
-2.25e-01 |
8.91e-01 |
3.62e-02 |
Formation-of-the-Early-Elongation-Complex |
33 |
1.86e-01 |
3.81e-01 |
0.22500 |
-0.183000 |
-1.32e-01 |
6.97e-02 |
1.90e-01 |
Formation-of-the-HIV-1-Early-Elongation-Complex |
33 |
1.86e-01 |
3.81e-01 |
0.22500 |
-0.183000 |
-1.32e-01 |
6.97e-02 |
1.90e-01 |
Class-B/2-(Secretin-family-receptors) |
46 |
8.16e-02 |
2.30e-01 |
0.22400 |
0.186000 |
1.25e-01 |
2.92e-02 |
1.42e-01 |
Tie2-Signaling |
17 |
4.92e-01 |
6.61e-01 |
0.22400 |
-0.162000 |
-1.54e-01 |
2.47e-01 |
2.70e-01 |
Visual-phototransduction |
54 |
7.82e-02 |
2.24e-01 |
0.22300 |
0.136000 |
1.77e-01 |
8.44e-02 |
2.43e-02 |
N-Glycan-antennae-elongation |
13 |
1.99e-01 |
3.95e-01 |
0.22300 |
0.215000 |
6.13e-02 |
1.80e-01 |
7.02e-01 |
PI-3K-cascade:FGFR1 |
11 |
1.94e-01 |
3.91e-01 |
0.22300 |
-0.043400 |
-2.18e-01 |
8.03e-01 |
2.10e-01 |
PECAM1-interactions |
11 |
4.50e-01 |
6.31e-01 |
0.22300 |
0.103000 |
1.97e-01 |
5.55e-01 |
2.57e-01 |
Signaling-by-TGF-beta-family-members |
88 |
1.19e-03 |
9.19e-03 |
0.22200 |
0.199000 |
9.81e-02 |
1.25e-03 |
1.12e-01 |
Blood-group-systems-biosynthesis |
11 |
2.78e-01 |
4.84e-01 |
0.22200 |
0.212000 |
6.57e-02 |
2.23e-01 |
7.06e-01 |
RNA-Polymerase-I-Transcription-Termination |
30 |
1.75e-01 |
3.69e-01 |
0.22100 |
-0.188000 |
-1.17e-01 |
7.53e-02 |
2.69e-01 |
Metabolism-of-polyamines |
53 |
1.43e-03 |
1.08e-02 |
0.22100 |
-0.213000 |
-5.86e-02 |
7.45e-03 |
4.61e-01 |
InlB-mediated-entry-of-Listeria-monocytogenes-into-host-cell |
13 |
5.76e-01 |
7.20e-01 |
0.22000 |
0.168000 |
1.43e-01 |
2.95e-01 |
3.73e-01 |
Autodegradation-of-Cdh1-by-Cdh1:APC/C |
60 |
1.41e-02 |
6.49e-02 |
0.22000 |
-0.195000 |
-1.02e-01 |
8.87e-03 |
1.74e-01 |
SHC1-events-in-ERBB2-signaling |
21 |
2.91e-01 |
4.99e-01 |
0.21900 |
0.187000 |
1.14e-01 |
1.37e-01 |
3.65e-01 |
Signaling-by-Rho-GTPases |
340 |
1.22e-06 |
2.65e-05 |
0.21900 |
0.146000 |
1.64e-01 |
3.89e-06 |
2.40e-07 |
Synthesis-of-bile-acids-and-bile-salts |
22 |
3.38e-01 |
5.36e-01 |
0.21900 |
-0.127000 |
-1.79e-01 |
3.03e-01 |
1.46e-01 |
p53-Dependent-G1-DNA-Damage-Response |
59 |
9.94e-04 |
8.00e-03 |
0.21900 |
-0.210000 |
-6.14e-02 |
5.29e-03 |
4.15e-01 |
p53-Dependent-G1/S-DNA-damage-checkpoint |
59 |
9.94e-04 |
8.00e-03 |
0.21900 |
-0.210000 |
-6.14e-02 |
5.29e-03 |
4.15e-01 |
Apoptotic-execution-phase |
41 |
3.03e-02 |
1.15e-01 |
0.21900 |
0.201000 |
8.66e-02 |
2.63e-02 |
3.38e-01 |
Dectin-2-family |
11 |
5.72e-01 |
7.18e-01 |
0.21800 |
0.180000 |
1.24e-01 |
3.01e-01 |
4.78e-01 |
Paradoxical-activation-of-RAF-signaling-by-kinase-inactive-BRAF |
39 |
1.81e-01 |
3.75e-01 |
0.21800 |
0.171000 |
1.36e-01 |
6.45e-02 |
1.43e-01 |
Signaling-by-RAS-mutants |
39 |
1.81e-01 |
3.75e-01 |
0.21800 |
0.171000 |
1.36e-01 |
6.45e-02 |
1.43e-01 |
Signaling-by-moderate-kinase-activity-BRAF-mutants |
39 |
1.81e-01 |
3.75e-01 |
0.21800 |
0.171000 |
1.36e-01 |
6.45e-02 |
1.43e-01 |
Signaling-downstream-of-RAS-mutants |
39 |
1.81e-01 |
3.75e-01 |
0.21800 |
0.171000 |
1.36e-01 |
6.45e-02 |
1.43e-01 |
SCF(Skp2)-mediated-degradation-of-p27/p21 |
57 |
2.76e-03 |
1.79e-02 |
0.21800 |
-0.206000 |
-7.12e-02 |
7.12e-03 |
3.53e-01 |
RHO-GTPases-Activate-Formins |
110 |
1.35e-02 |
6.33e-02 |
0.21800 |
0.154000 |
1.55e-01 |
5.44e-03 |
5.08e-03 |
SLBP-Dependent-Processing-of-Replication-Dependent-Histone-Pre-mRNAs |
10 |
2.15e-01 |
4.14e-01 |
0.21800 |
-0.034900 |
-2.15e-01 |
8.48e-01 |
2.39e-01 |
Activation-of-HOX-genes-during-differentiation |
51 |
1.10e-01 |
2.75e-01 |
0.21800 |
-0.136000 |
-1.70e-01 |
9.26e-02 |
3.58e-02 |
Activation-of-anterior-HOX-genes-in-hindbrain-development-during-early-embryogenesis |
51 |
1.10e-01 |
2.75e-01 |
0.21800 |
-0.136000 |
-1.70e-01 |
9.26e-02 |
3.58e-02 |
Regulation-of-IFNA-signaling |
12 |
1.49e-01 |
3.35e-01 |
0.21800 |
0.031300 |
2.15e-01 |
8.51e-01 |
1.96e-01 |
Metabolism-of-vitamins-and-cofactors |
153 |
2.20e-03 |
1.51e-02 |
0.21800 |
-0.145000 |
-1.63e-01 |
2.06e-03 |
5.27e-04 |
FOXO-mediated-transcription-of-cell-cycle-genes |
14 |
2.24e-02 |
9.20e-02 |
0.21700 |
0.043700 |
-2.13e-01 |
7.77e-01 |
1.68e-01 |
Constitutive-Signaling-by-Aberrant-PI3K-in-Cancer |
54 |
1.22e-01 |
2.96e-01 |
0.21600 |
0.158000 |
1.48e-01 |
4.47e-02 |
6.08e-02 |
Protein-protein-interactions-at-synapses |
61 |
1.93e-02 |
8.18e-02 |
0.21600 |
0.190000 |
1.03e-01 |
1.05e-02 |
1.64e-01 |
DAP12-interactions |
25 |
3.80e-01 |
5.73e-01 |
0.21600 |
0.149000 |
1.56e-01 |
1.97e-01 |
1.77e-01 |
FRS-mediated-FGFR1-signaling |
13 |
2.38e-01 |
4.37e-01 |
0.21600 |
-0.063300 |
-2.06e-01 |
6.93e-01 |
1.98e-01 |
NRAGE-signals-death-through-JNK |
55 |
6.32e-02 |
1.94e-01 |
0.21600 |
0.121000 |
1.79e-01 |
1.22e-01 |
2.20e-02 |
Scavenging-by-Class-A-Receptors |
16 |
5.42e-01 |
6.95e-01 |
0.21500 |
0.154000 |
1.50e-01 |
2.86e-01 |
3.00e-01 |
Platelet-activation,-signaling-and-aggregation |
214 |
2.24e-04 |
2.33e-03 |
0.21500 |
0.162000 |
1.41e-01 |
4.52e-05 |
3.93e-04 |
Smooth-Muscle-Contraction |
31 |
9.21e-03 |
4.83e-02 |
0.21300 |
0.031400 |
2.11e-01 |
7.62e-01 |
4.21e-02 |
Formation-of-TC-NER-Pre-Incision-Complex |
53 |
1.30e-01 |
3.13e-01 |
0.21200 |
-0.140000 |
-1.59e-01 |
7.75e-02 |
4.48e-02 |
Asymmetric-localization-of-PCP-proteins |
60 |
1.78e-02 |
7.65e-02 |
0.21000 |
-0.188000 |
-9.46e-02 |
1.19e-02 |
2.05e-01 |
Signaling-by-NOTCH4 |
78 |
4.53e-03 |
2.78e-02 |
0.21000 |
-0.189000 |
-9.23e-02 |
3.95e-03 |
1.59e-01 |
Cellular-response-to-heat-stress |
91 |
3.22e-02 |
1.20e-01 |
0.21000 |
-0.158000 |
-1.37e-01 |
9.07e-03 |
2.36e-02 |
Signal-amplification |
23 |
1.60e-01 |
3.51e-01 |
0.21000 |
0.193000 |
8.21e-02 |
1.09e-01 |
4.95e-01 |
Cell-Cell-communication |
83 |
4.50e-02 |
1.54e-01 |
0.20900 |
0.138000 |
1.57e-01 |
3.01e-02 |
1.33e-02 |
Mitotic-Telophase/Cytokinesis |
13 |
1.62e-01 |
3.53e-01 |
0.20900 |
0.206000 |
3.40e-02 |
1.99e-01 |
8.32e-01 |
HDR-through-MMEJ-(alt-NHEJ) |
10 |
5.97e-01 |
7.33e-01 |
0.20900 |
-0.111000 |
-1.77e-01 |
5.45e-01 |
3.33e-01 |
L1CAM-interactions |
82 |
1.16e-02 |
5.72e-02 |
0.20800 |
0.179000 |
1.06e-01 |
5.12e-03 |
9.69e-02 |
Resolution-of-Sister-Chromatid-Cohesion |
95 |
1.20e-02 |
5.83e-02 |
0.20700 |
0.172000 |
1.16e-01 |
3.79e-03 |
5.18e-02 |
EML4-and-NUDC-in-mitotic-spindle-formation |
87 |
2.89e-02 |
1.11e-01 |
0.20700 |
0.165000 |
1.25e-01 |
7.97e-03 |
4.37e-02 |
Gene-Silencing-by-RNA |
63 |
1.05e-01 |
2.65e-01 |
0.20600 |
-0.152000 |
-1.39e-01 |
3.66e-02 |
5.65e-02 |
RHO-GTPases-activate-PKNs |
31 |
3.20e-01 |
5.22e-01 |
0.20600 |
0.135000 |
1.56e-01 |
1.94e-01 |
1.33e-01 |
Cyclin-A/B1/B2-associated-events-during-G2/M-transition |
23 |
4.22e-01 |
6.06e-01 |
0.20600 |
0.132000 |
1.58e-01 |
2.73e-01 |
1.90e-01 |
Lysosome-Vesicle-Biogenesis |
28 |
3.72e-01 |
5.64e-01 |
0.20600 |
0.140000 |
1.50e-01 |
1.99e-01 |
1.68e-01 |
Activation-of-PPARGC1A-(PGC-1alpha)-by-phosphorylation |
10 |
4.76e-01 |
6.53e-01 |
0.20500 |
-0.082500 |
-1.88e-01 |
6.51e-01 |
3.03e-01 |
G1/S-Specific-Transcription |
27 |
3.83e-01 |
5.74e-01 |
0.20500 |
0.152000 |
1.38e-01 |
1.72e-01 |
2.15e-01 |
Signaling-by-BRAF-and-RAF-fusions |
57 |
4.13e-02 |
1.48e-01 |
0.20500 |
0.179000 |
1.01e-01 |
1.98e-02 |
1.87e-01 |
G1/S-DNA-Damage-Checkpoints |
61 |
1.77e-03 |
1.29e-02 |
0.20500 |
-0.197000 |
-5.66e-02 |
7.84e-03 |
4.45e-01 |
ERBB2-Activates-PTK6-Signaling |
12 |
5.47e-01 |
6.97e-01 |
0.20500 |
0.174000 |
1.08e-01 |
2.97e-01 |
5.19e-01 |
Downstream-signaling-of-activated-FGFR2 |
21 |
1.21e-01 |
2.95e-01 |
0.20400 |
-0.058900 |
-1.96e-01 |
6.41e-01 |
1.20e-01 |
Downstream-TCR-signaling |
77 |
5.45e-03 |
3.23e-02 |
0.20400 |
-0.185000 |
-8.74e-02 |
5.10e-03 |
1.85e-01 |
Orc1-removal-from-chromatin |
66 |
9.92e-05 |
1.22e-03 |
0.20300 |
-0.201000 |
-2.76e-02 |
4.76e-03 |
6.98e-01 |
Thrombin-signalling-through-proteinase-activated-receptors-(PARs) |
22 |
1.85e-01 |
3.81e-01 |
0.20200 |
0.187000 |
7.70e-02 |
1.29e-01 |
5.32e-01 |
Golgi-Cisternae-Pericentriolar-Stack-Reorganization |
13 |
4.24e-02 |
1.50e-01 |
0.20200 |
0.197000 |
-4.70e-02 |
2.20e-01 |
7.69e-01 |
Bile-acid-and-bile-salt-metabolism |
25 |
4.11e-01 |
5.97e-01 |
0.20200 |
-0.131000 |
-1.54e-01 |
2.58e-01 |
1.83e-01 |
PTEN-Regulation |
135 |
1.10e-02 |
5.52e-02 |
0.20200 |
-0.142000 |
-1.43e-01 |
4.35e-03 |
4.22e-03 |
Pentose-phosphate-pathway |
12 |
1.75e-01 |
3.69e-01 |
0.20100 |
0.200000 |
2.22e-02 |
2.30e-01 |
8.94e-01 |
Norepinephrine-Neurotransmitter-Release-Cycle |
12 |
6.18e-01 |
7.41e-01 |
0.20100 |
0.119000 |
1.62e-01 |
4.77e-01 |
3.31e-01 |
Synthesis,-secretion,-and-deacylation-of-Ghrelin |
11 |
1.98e-01 |
3.95e-01 |
0.20000 |
0.199000 |
1.97e-02 |
2.52e-01 |
9.10e-01 |
Regulation-of-HSF1-mediated-heat-shock-response |
76 |
7.47e-02 |
2.16e-01 |
0.19900 |
-0.150000 |
-1.31e-01 |
2.34e-02 |
4.88e-02 |
Formation-of-Fibrin-Clot-(Clotting-Cascade) |
18 |
3.45e-01 |
5.40e-01 |
0.19900 |
0.090700 |
1.77e-01 |
5.06e-01 |
1.93e-01 |
Regulation-of-RAS-by-GAPs |
63 |
1.17e-03 |
9.04e-03 |
0.19800 |
-0.193000 |
-4.70e-02 |
8.17e-03 |
5.19e-01 |
Regulation-of-localization-of-FOXO-transcription-factors |
12 |
6.03e-01 |
7.34e-01 |
0.19800 |
-0.112000 |
-1.64e-01 |
5.03e-01 |
3.26e-01 |
Regulation-of-mRNA-stability-by-proteins-that-bind-AU-rich-elements |
83 |
3.05e-03 |
1.95e-02 |
0.19800 |
-0.182000 |
-7.82e-02 |
4.26e-03 |
2.19e-01 |
Competing-endogenous-RNAs-(ceRNAs)-regulate-PTEN-translation |
10 |
6.88e-01 |
7.91e-01 |
0.19800 |
-0.119000 |
-1.57e-01 |
5.14e-01 |
3.89e-01 |
MAPK-targets/-Nuclear-events-mediated-by-MAP-kinases |
30 |
3.27e-02 |
1.22e-01 |
0.19700 |
-0.040400 |
-1.93e-01 |
7.02e-01 |
6.76e-02 |
Interleukin-12-family-signaling |
37 |
2.80e-02 |
1.09e-01 |
0.19700 |
0.189000 |
5.37e-02 |
4.65e-02 |
5.72e-01 |
Nucleotide-binding-domain,-leucine-rich-repeat-containing-receptor-(NLR)-signaling-pathways |
45 |
2.29e-01 |
4.27e-01 |
0.19600 |
0.131000 |
1.47e-01 |
1.30e-01 |
8.89e-02 |
Autophagy |
110 |
8.95e-03 |
4.73e-02 |
0.19600 |
-0.108000 |
-1.64e-01 |
5.14e-02 |
2.97e-03 |
Transcriptional-Regulation-by-MECP2 |
46 |
6.42e-02 |
1.95e-01 |
0.19600 |
-0.086900 |
-1.76e-01 |
3.08e-01 |
3.90e-02 |
Processive-synthesis-on-the-lagging-strand |
14 |
1.07e-01 |
2.68e-01 |
0.19600 |
0.005410 |
1.96e-01 |
9.72e-01 |
2.04e-01 |
Activation-of-NF-kappaB-in-B-cells |
62 |
1.68e-03 |
1.25e-02 |
0.19600 |
-0.190000 |
-4.75e-02 |
9.72e-03 |
5.18e-01 |
Listeria-monocytogenes-entry-into-host-cells |
16 |
5.88e-01 |
7.27e-01 |
0.19500 |
0.148000 |
1.27e-01 |
3.04e-01 |
3.79e-01 |
SHC-mediated-cascade:FGFR4 |
12 |
5.38e-01 |
6.93e-01 |
0.19500 |
-0.095000 |
-1.70e-01 |
5.69e-01 |
3.07e-01 |
RAF-independent-MAPK1/3-activation |
21 |
4.55e-01 |
6.34e-01 |
0.19400 |
0.157000 |
1.15e-01 |
2.13e-01 |
3.63e-01 |
Transcription-of-E2F-targets-under-negative-control-by-p107-(RBL1)-and-p130-(RBL2)-in-complex-with-HDAC1 |
15 |
3.04e-01 |
5.11e-01 |
0.19400 |
0.183000 |
6.56e-02 |
2.21e-01 |
6.60e-01 |
Regulation-of-PTEN-mRNA-translation |
11 |
6.04e-01 |
7.34e-01 |
0.19400 |
-0.101000 |
-1.66e-01 |
5.61e-01 |
3.42e-01 |
Signaling-by-TGF-beta-Receptor-Complex |
71 |
2.37e-03 |
1.60e-02 |
0.19400 |
0.184000 |
6.02e-02 |
7.28e-03 |
3.81e-01 |
Regulation-of-MECP2-expression-and-activity |
28 |
2.05e-01 |
4.04e-01 |
0.19400 |
-0.087500 |
-1.73e-01 |
4.23e-01 |
1.14e-01 |
VLDLR-internalisation-and-degradation |
11 |
4.65e-02 |
1.57e-01 |
0.19400 |
0.098700 |
-1.66e-01 |
5.71e-01 |
3.39e-01 |
IRAK2-mediated-activation-of-TAK1-complex-upon-TLR7/8-or-9-stimulation |
14 |
4.98e-01 |
6.64e-01 |
0.19400 |
0.168000 |
9.53e-02 |
2.75e-01 |
5.37e-01 |
TRAF6-mediated-induction-of-TAK1-complex-within-TLR4-complex |
14 |
4.98e-01 |
6.64e-01 |
0.19400 |
0.168000 |
9.53e-02 |
2.75e-01 |
5.37e-01 |
RAF-activation |
29 |
3.94e-01 |
5.85e-01 |
0.19300 |
-0.126000 |
-1.46e-01 |
2.40e-01 |
1.74e-01 |
SHC1-events-in-ERBB4-signaling |
13 |
4.48e-01 |
6.31e-01 |
0.19300 |
0.175000 |
8.09e-02 |
2.75e-01 |
6.13e-01 |
Host-Interactions-of-HIV-factors |
114 |
2.21e-02 |
9.10e-02 |
0.19200 |
-0.150000 |
-1.20e-01 |
5.75e-03 |
2.65e-02 |
CDK-mediated-phosphorylation-and-removal-of-Cdc6 |
66 |
1.82e-02 |
7.77e-02 |
0.19200 |
-0.174000 |
-8.07e-02 |
1.47e-02 |
2.57e-01 |
Olfactory-Signaling-Pathway |
16 |
2.43e-01 |
4.41e-01 |
0.19200 |
0.055100 |
1.83e-01 |
7.03e-01 |
2.04e-01 |
Peptide-hormone-metabolism |
51 |
2.32e-02 |
9.42e-02 |
0.19100 |
0.179000 |
6.78e-02 |
2.71e-02 |
4.03e-01 |
Trafficking-of-GluR2-containing-AMPA-receptors |
15 |
5.09e-01 |
6.73e-01 |
0.19100 |
0.099100 |
1.64e-01 |
5.06e-01 |
2.72e-01 |
Establishment-of-Sister-Chromatid-Cohesion |
10 |
7.85e-02 |
2.24e-01 |
0.19100 |
0.175000 |
-7.72e-02 |
3.38e-01 |
6.73e-01 |
Interleukin-20-family-signaling |
14 |
6.13e-01 |
7.38e-01 |
0.19100 |
-0.116000 |
-1.52e-01 |
4.53e-01 |
3.24e-01 |
CD28-dependent-Vav1-pathway |
11 |
7.13e-01 |
8.08e-01 |
0.19100 |
0.129000 |
1.41e-01 |
4.58e-01 |
4.18e-01 |
RA-biosynthesis-pathway |
13 |
6.14e-01 |
7.38e-01 |
0.19100 |
-0.110000 |
-1.56e-01 |
4.91e-01 |
3.30e-01 |
Metabolism-of-lipids |
575 |
1.26e-10 |
4.72e-09 |
0.19100 |
-0.104000 |
-1.60e-01 |
2.19e-05 |
7.10e-11 |
Abortive-elongation-of-HIV-1-transcript-in-the-absence-of-Tat |
23 |
8.90e-02 |
2.38e-01 |
0.19100 |
-0.187000 |
-4.06e-02 |
1.22e-01 |
7.36e-01 |
Factors-involved-in-megakaryocyte-development-and-platelet-production |
104 |
2.57e-02 |
1.02e-01 |
0.19100 |
0.153000 |
1.14e-01 |
7.14e-03 |
4.51e-02 |
Viral-Messenger-RNA-Synthesis |
43 |
2.73e-01 |
4.80e-01 |
0.19000 |
-0.139000 |
-1.30e-01 |
1.15e-01 |
1.40e-01 |
Amplification--of-signal-from-unattached--kinetochores-via-a-MAD2--inhibitory-signal |
83 |
6.61e-02 |
1.98e-01 |
0.19000 |
0.148000 |
1.19e-01 |
1.98e-02 |
6.06e-02 |
Amplification-of-signal-from-the-kinetochores |
83 |
6.61e-02 |
1.98e-01 |
0.19000 |
0.148000 |
1.19e-01 |
1.98e-02 |
6.06e-02 |
RNA-Polymerase-I-Transcription-Initiation |
46 |
2.53e-01 |
4.52e-01 |
0.19000 |
-0.135000 |
-1.34e-01 |
1.14e-01 |
1.15e-01 |
Transport-of-Mature-mRNA-derived-from-an-Intron-Containing-Transcript |
70 |
1.17e-01 |
2.87e-01 |
0.19000 |
-0.126000 |
-1.42e-01 |
6.80e-02 |
3.99e-02 |
p75-NTR-receptor-mediated-signalling |
90 |
5.70e-02 |
1.83e-01 |
0.19000 |
0.122000 |
1.46e-01 |
4.64e-02 |
1.68e-02 |
Tight-junction-interactions |
11 |
4.50e-02 |
1.54e-01 |
0.19000 |
0.146000 |
-1.21e-01 |
4.01e-01 |
4.87e-01 |
Depolymerisation-of-the-Nuclear-Lamina |
15 |
5.72e-01 |
7.17e-01 |
0.18900 |
0.155000 |
1.08e-01 |
2.99e-01 |
4.68e-01 |
Neddylation |
210 |
2.19e-03 |
1.51e-02 |
0.18900 |
-0.135000 |
-1.32e-01 |
7.60e-04 |
1.01e-03 |
Regulation-of-cholesterol-biosynthesis-by-SREBP-(SREBF) |
53 |
3.44e-02 |
1.27e-01 |
0.18900 |
-0.074600 |
-1.73e-01 |
3.48e-01 |
2.93e-02 |
MHC-class-II-antigen-presentation |
82 |
1.72e-02 |
7.47e-02 |
0.18900 |
0.166000 |
8.99e-02 |
9.51e-03 |
1.60e-01 |
Neurexins-and-neuroligins |
38 |
2.58e-01 |
4.59e-01 |
0.18700 |
0.152000 |
1.08e-01 |
1.05e-01 |
2.48e-01 |
Hemostasis |
440 |
2.40e-06 |
4.72e-05 |
0.18700 |
0.142000 |
1.21e-01 |
3.95e-07 |
1.39e-05 |
Oncogenic-MAPK-signaling |
64 |
5.60e-02 |
1.81e-01 |
0.18600 |
0.161000 |
9.32e-02 |
2.56e-02 |
1.98e-01 |
Assembly-of-the-pre-replicative-complex |
64 |
6.67e-05 |
9.17e-04 |
0.18600 |
-0.186000 |
-3.35e-04 |
9.99e-03 |
9.96e-01 |
Nuclear-Events-(kinase-and-transcription-factor-activation) |
24 |
9.35e-02 |
2.44e-01 |
0.18600 |
-0.040700 |
-1.82e-01 |
7.30e-01 |
1.23e-01 |
Rho-GTPase-cycle |
130 |
1.17e-02 |
5.73e-02 |
0.18600 |
0.110000 |
1.50e-01 |
3.09e-02 |
3.12e-03 |
Degradation-of-beta-catenin-by-the-destruction-complex |
81 |
2.28e-02 |
9.29e-02 |
0.18600 |
-0.163000 |
-9.06e-02 |
1.15e-02 |
1.59e-01 |
Growth-hormone-receptor-signaling |
20 |
4.45e-01 |
6.30e-01 |
0.18600 |
-0.157000 |
-9.92e-02 |
2.24e-01 |
4.43e-01 |
Immunoregulatory-interactions-between-a-Lymphoid-and-a-non-Lymphoid-cell |
40 |
3.14e-01 |
5.19e-01 |
0.18600 |
0.137000 |
1.26e-01 |
1.35e-01 |
1.69e-01 |
Sphingolipid-de-novo-biosynthesis |
33 |
2.78e-01 |
4.84e-01 |
0.18600 |
0.155000 |
1.01e-01 |
1.22e-01 |
3.14e-01 |
Striated-Muscle-Contraction |
27 |
1.92e-01 |
3.90e-01 |
0.18500 |
0.073400 |
1.70e-01 |
5.09e-01 |
1.27e-01 |
Surfactant-metabolism |
15 |
6.41e-01 |
7.51e-01 |
0.18400 |
0.140000 |
1.19e-01 |
3.47e-01 |
4.25e-01 |
Condensation-of-Prophase-Chromosomes |
14 |
6.37e-01 |
7.51e-01 |
0.18400 |
0.112000 |
1.46e-01 |
4.69e-01 |
3.44e-01 |
Pre-NOTCH-Processing-in-Golgi |
16 |
1.52e-01 |
3.39e-01 |
0.18400 |
-0.022600 |
-1.82e-01 |
8.75e-01 |
2.07e-01 |
ERBB2-Regulates-Cell-Motility |
14 |
4.14e-01 |
6.00e-01 |
0.18300 |
0.170000 |
6.97e-02 |
2.72e-01 |
6.52e-01 |
Biological-oxidations |
111 |
4.52e-02 |
1.54e-01 |
0.18300 |
-0.134000 |
-1.25e-01 |
1.49e-02 |
2.29e-02 |
tRNA-processing-in-the-nucleus |
56 |
1.97e-01 |
3.94e-01 |
0.18300 |
-0.118000 |
-1.39e-01 |
1.26e-01 |
7.22e-02 |
Metabolism-of-nucleotides |
83 |
6.94e-02 |
2.04e-01 |
0.18300 |
-0.146000 |
-1.09e-01 |
2.16e-02 |
8.49e-02 |
APC/C:Cdh1-mediated-degradation-of-Cdc20-and-other-APC/C:Cdh1-targeted-proteins-in-late-mitosis/early-G1 |
67 |
2.07e-02 |
8.67e-02 |
0.18200 |
-0.167000 |
-7.39e-02 |
1.83e-02 |
2.96e-01 |
Mitotic-Spindle-Checkpoint |
98 |
2.73e-02 |
1.07e-01 |
0.18100 |
0.152000 |
9.91e-02 |
9.52e-03 |
9.05e-02 |
Transcriptional-regulation-by-small-RNAs |
46 |
2.84e-01 |
4.91e-01 |
0.18100 |
-0.123000 |
-1.33e-01 |
1.49e-01 |
1.20e-01 |
Phase-II---Conjugation-of-compounds |
52 |
2.49e-01 |
4.46e-01 |
0.18000 |
-0.125000 |
-1.29e-01 |
1.19e-01 |
1.07e-01 |
Signaling-by-Receptor-Tyrosine-Kinases |
390 |
1.34e-06 |
2.82e-05 |
0.17900 |
0.149000 |
9.92e-02 |
4.50e-07 |
8.10e-04 |
Metabolism-of-non-coding-RNA |
51 |
2.23e-01 |
4.21e-01 |
0.17900 |
-0.112000 |
-1.40e-01 |
1.68e-01 |
8.33e-02 |
snRNP-Assembly |
51 |
2.23e-01 |
4.21e-01 |
0.17900 |
-0.112000 |
-1.40e-01 |
1.68e-01 |
8.33e-02 |
The-role-of-GTSE1-in-G2/M-progression-after-G2-checkpoint |
55 |
1.73e-03 |
1.27e-02 |
0.17900 |
-0.178000 |
-1.90e-02 |
2.23e-02 |
8.08e-01 |
GRB2-events-in-ERBB2-signaling |
15 |
4.14e-01 |
6.00e-01 |
0.17900 |
0.165000 |
6.92e-02 |
2.69e-01 |
6.43e-01 |
Cytochrome-c-mediated-apoptotic-response |
12 |
5.46e-01 |
6.96e-01 |
0.17900 |
-0.078200 |
-1.61e-01 |
6.39e-01 |
3.35e-01 |
Metabolism-of-RNA |
619 |
1.46e-07 |
3.67e-06 |
0.17800 |
-0.129000 |
-1.23e-01 |
4.75e-08 |
2.26e-07 |
UCH-proteinases |
80 |
9.06e-04 |
7.42e-03 |
0.17800 |
-0.173000 |
-4.07e-02 |
7.49e-03 |
5.30e-01 |
TRAF6-mediated-IRF7-activation |
14 |
5.50e-02 |
1.79e-01 |
0.17800 |
-0.058900 |
1.68e-01 |
7.03e-01 |
2.77e-01 |
TRAF6-mediated-NF-kB-activation |
20 |
1.09e-01 |
2.72e-01 |
0.17800 |
0.021200 |
1.76e-01 |
8.70e-01 |
1.72e-01 |
Transcriptional-Regulation-by-E2F6 |
33 |
3.74e-01 |
5.67e-01 |
0.17700 |
0.141000 |
1.08e-01 |
1.62e-01 |
2.83e-01 |
DNA-Damage-Recognition-in-GG-NER |
38 |
3.07e-01 |
5.12e-01 |
0.17700 |
-0.143000 |
-1.05e-01 |
1.27e-01 |
2.62e-01 |
Aggrephagy |
18 |
5.16e-01 |
6.78e-01 |
0.17700 |
0.094700 |
1.50e-01 |
4.87e-01 |
2.71e-01 |
Regulated-proteolysis-of-p75NTR |
11 |
4.59e-01 |
6.38e-01 |
0.17700 |
0.168000 |
5.57e-02 |
3.34e-01 |
7.49e-01 |
Cleavage-of-the-damaged-purine |
10 |
7.23e-01 |
8.15e-01 |
0.17700 |
0.102000 |
1.45e-01 |
5.76e-01 |
4.27e-01 |
Depurination |
10 |
7.23e-01 |
8.15e-01 |
0.17700 |
0.102000 |
1.45e-01 |
5.76e-01 |
4.27e-01 |
Recognition-and-association-of-DNA-glycosylase-with-site-containing-an-affected-purine |
10 |
7.23e-01 |
8.15e-01 |
0.17700 |
0.102000 |
1.45e-01 |
5.76e-01 |
4.27e-01 |
Transcriptional-regulation-of-granulopoiesis |
28 |
4.74e-01 |
6.53e-01 |
0.17700 |
0.132000 |
1.18e-01 |
2.26e-01 |
2.81e-01 |
Regulation-of-RUNX3-expression-and-activity |
52 |
2.51e-03 |
1.65e-02 |
0.17700 |
-0.176000 |
-1.65e-02 |
2.83e-02 |
8.37e-01 |
Downstream-signaling-events-of-B-Cell-Receptor-(BCR) |
75 |
2.67e-02 |
1.05e-01 |
0.17700 |
-0.158000 |
-7.82e-02 |
1.78e-02 |
2.42e-01 |
Anchoring-of-the-basal-body-to-the-plasma-membrane |
96 |
2.26e-02 |
9.25e-02 |
0.17600 |
0.152000 |
8.92e-02 |
1.01e-02 |
1.31e-01 |
LDL-clearance |
16 |
2.73e-01 |
4.81e-01 |
0.17600 |
0.170000 |
4.44e-02 |
2.39e-01 |
7.58e-01 |
Influenza-Life-Cycle |
110 |
5.05e-02 |
1.68e-01 |
0.17500 |
-0.111000 |
-1.35e-01 |
4.37e-02 |
1.46e-02 |
Formation-of-tubulin-folding-intermediates-by-CCT/TriC |
20 |
8.88e-02 |
2.38e-01 |
0.17500 |
0.009930 |
1.75e-01 |
9.39e-01 |
1.76e-01 |
Cell-junction-organization |
57 |
1.67e-01 |
3.60e-01 |
0.17500 |
0.143000 |
1.01e-01 |
6.23e-02 |
1.88e-01 |
Formation-of-HIV-elongation-complex-in-the-absence-of-HIV-Tat |
43 |
3.06e-01 |
5.12e-01 |
0.17500 |
-0.136000 |
-1.10e-01 |
1.24e-01 |
2.13e-01 |
Meiotic-synapsis |
23 |
3.94e-01 |
5.85e-01 |
0.17400 |
0.152000 |
8.58e-02 |
2.08e-01 |
4.76e-01 |
Signaling-by-Non-Receptor-Tyrosine-Kinases |
52 |
8.64e-02 |
2.35e-01 |
0.17400 |
0.156000 |
7.72e-02 |
5.14e-02 |
3.36e-01 |
Signaling-by-PTK6 |
52 |
8.64e-02 |
2.35e-01 |
0.17400 |
0.156000 |
7.72e-02 |
5.14e-02 |
3.36e-01 |
Transport-of-the-SLBP-independent-Mature-mRNA |
34 |
3.24e-01 |
5.27e-01 |
0.17400 |
-0.096800 |
-1.45e-01 |
3.29e-01 |
1.44e-01 |
Regulation-of-PTEN-gene-transcription |
59 |
4.45e-03 |
2.74e-02 |
0.17400 |
-0.033100 |
-1.71e-01 |
6.61e-01 |
2.33e-02 |
Cargo-trafficking-to-the-periciliary-membrane |
46 |
2.86e-01 |
4.92e-01 |
0.17400 |
0.110000 |
1.35e-01 |
1.98e-01 |
1.14e-01 |
APC/C:Cdc20-mediated-degradation-of-Cyclin-B |
22 |
1.96e-01 |
3.93e-01 |
0.17400 |
0.167000 |
4.88e-02 |
1.76e-01 |
6.92e-01 |
Diseases-of-metabolism |
70 |
1.75e-01 |
3.69e-01 |
0.17400 |
-0.122000 |
-1.23e-01 |
7.74e-02 |
7.42e-02 |
Activation-of-the-mRNA-upon-binding-of-the-cap-binding-complex-and-eIFs,-and-subsequent-binding-to-43S |
47 |
5.43e-02 |
1.77e-01 |
0.17400 |
-0.060200 |
-1.63e-01 |
4.75e-01 |
5.35e-02 |
Cyclin-E-associated-events-during-G1/S-transition |
79 |
4.84e-02 |
1.62e-01 |
0.17400 |
-0.150000 |
-8.77e-02 |
2.15e-02 |
1.78e-01 |
Mismatch-repair-(MMR)-directed-by-MSH2:MSH6-(MutSalpha) |
11 |
3.15e-01 |
5.19e-01 |
0.17300 |
-0.172000 |
-2.13e-02 |
3.23e-01 |
9.03e-01 |
Mismatch-Repair |
12 |
5.70e-01 |
7.17e-01 |
0.17300 |
-0.155000 |
-7.62e-02 |
3.52e-01 |
6.48e-01 |
TP53-regulates-transcription-of-several-additional-cell-death-genes-whose-specific-roles-in-p53-dependent-apoptosis-remain-uncertain |
11 |
2.72e-01 |
4.80e-01 |
0.17300 |
0.009720 |
1.73e-01 |
9.55e-01 |
3.21e-01 |
Translation-initiation-complex-formation |
46 |
4.36e-02 |
1.52e-01 |
0.17300 |
-0.053200 |
-1.64e-01 |
5.32e-01 |
5.39e-02 |
Regulation-of-expression-of-SLITs-and-ROBOs |
125 |
4.35e-02 |
1.52e-01 |
0.17200 |
-0.129000 |
-1.15e-01 |
1.32e-02 |
2.68e-02 |
Regulation-of-TP53-Activity-through-Association-with-Co-factors |
11 |
5.55e-01 |
7.04e-01 |
0.17200 |
-0.158000 |
-6.78e-02 |
3.63e-01 |
6.97e-01 |
Synthesis-of-substrates-in-N-glycan-biosythesis |
56 |
3.48e-03 |
2.19e-02 |
0.17200 |
0.171000 |
2.30e-02 |
2.73e-02 |
7.66e-01 |
Influenza-Viral-RNA-Transcription-and-Replication |
102 |
7.67e-02 |
2.21e-01 |
0.17200 |
-0.113000 |
-1.29e-01 |
4.85e-02 |
2.43e-02 |
Inactivation-of-APC/C-via-direct-inhibition-of-the-APC/C-complex |
18 |
2.15e-01 |
4.14e-01 |
0.17100 |
0.168000 |
3.58e-02 |
2.18e-01 |
7.92e-01 |
Inhibition-of-the-proteolytic-activity-of-APC/C-required-for-the-onset-of-anaphase-by-mitotic-spindle-checkpoint-components |
18 |
2.15e-01 |
4.14e-01 |
0.17100 |
0.168000 |
3.58e-02 |
2.18e-01 |
7.92e-01 |
ER-Phagosome-pathway |
73 |
5.67e-04 |
4.97e-03 |
0.17000 |
-0.169000 |
-1.98e-02 |
1.25e-02 |
7.70e-01 |
Transport-of-the-SLBP-Dependant-Mature-mRNA |
35 |
3.38e-01 |
5.36e-01 |
0.17000 |
-0.096000 |
-1.41e-01 |
3.26e-01 |
1.50e-01 |
Interleukin-6-signaling |
10 |
2.78e-01 |
4.84e-01 |
0.17000 |
0.170000 |
-1.60e-03 |
3.51e-01 |
9.93e-01 |
Cdc20:Phospho-APC/C-mediated-degradation-of-Cyclin-A |
65 |
2.91e-02 |
1.12e-01 |
0.17000 |
-0.157000 |
-6.38e-02 |
2.85e-02 |
3.74e-01 |
BBSome-mediated-cargo-targeting-to-cilium |
21 |
4.56e-01 |
6.36e-01 |
0.16900 |
0.084400 |
1.47e-01 |
5.03e-01 |
2.45e-01 |
Cyclin-A:Cdk2-associated-events-at-S-phase-entry |
81 |
4.57e-02 |
1.56e-01 |
0.16900 |
-0.147000 |
-8.27e-02 |
2.21e-02 |
1.98e-01 |
G0-and-Early-G1 |
25 |
3.50e-01 |
5.46e-01 |
0.16900 |
0.150000 |
7.77e-02 |
1.94e-01 |
5.02e-01 |
ERK/MAPK-targets |
21 |
8.82e-02 |
2.37e-01 |
0.16900 |
-0.006700 |
-1.68e-01 |
9.58e-01 |
1.82e-01 |
Intra-Golgi-traffic |
41 |
5.73e-03 |
3.32e-02 |
0.16800 |
0.168000 |
-2.91e-03 |
6.30e-02 |
9.74e-01 |
Selenoamino-acid-metabolism |
76 |
1.69e-01 |
3.62e-01 |
0.16800 |
-0.115000 |
-1.22e-01 |
8.32e-02 |
6.57e-02 |
Mitotic-Prometaphase |
174 |
1.97e-03 |
1.39e-02 |
0.16800 |
0.145000 |
8.42e-02 |
1.00e-03 |
5.59e-02 |
Cell-death-signalling-via-NRAGE,-NRIF-and-NADE |
72 |
1.40e-01 |
3.27e-01 |
0.16700 |
0.099800 |
1.34e-01 |
1.44e-01 |
4.90e-02 |
Budding-and-maturation-of-HIV-virion |
25 |
8.35e-02 |
2.32e-01 |
0.16700 |
0.166000 |
1.91e-02 |
1.51e-01 |
8.69e-01 |
Transcription-of-the-HIV-genome |
66 |
2.08e-01 |
4.08e-01 |
0.16700 |
-0.110000 |
-1.26e-01 |
1.24e-01 |
7.78e-02 |
Selenocysteine-synthesis |
61 |
2.12e-01 |
4.13e-01 |
0.16600 |
-0.103000 |
-1.30e-01 |
1.63e-01 |
7.85e-02 |
Inwardly-rectifying-K+-channels |
20 |
5.61e-01 |
7.10e-01 |
0.16500 |
-0.136000 |
-9.39e-02 |
2.92e-01 |
4.67e-01 |
CDC6-association-with-the-ORC:origin-complex |
11 |
4.51e-01 |
6.31e-01 |
0.16500 |
0.040800 |
1.60e-01 |
8.15e-01 |
3.59e-01 |
trans-Golgi-Network-Vesicle-Budding |
64 |
1.57e-01 |
3.47e-01 |
0.16400 |
0.136000 |
9.26e-02 |
6.03e-02 |
2.00e-01 |
Diseases-associated-with-N-glycosylation-of-proteins |
16 |
4.19e-02 |
1.48e-01 |
0.16400 |
0.144000 |
-7.99e-02 |
3.20e-01 |
5.80e-01 |
Constitutive-Signaling-by-EGFRvIII |
14 |
3.59e-01 |
5.51e-01 |
0.16400 |
-0.039200 |
-1.59e-01 |
8.00e-01 |
3.02e-01 |
Signaling-by-EGFRvIII-in-Cancer |
14 |
3.59e-01 |
5.51e-01 |
0.16400 |
-0.039200 |
-1.59e-01 |
8.00e-01 |
3.02e-01 |
Signaling-by-NTRK3-(TRKC) |
17 |
6.43e-01 |
7.52e-01 |
0.16400 |
0.131000 |
9.83e-02 |
3.50e-01 |
4.83e-01 |
Conversion-from-APC/C:Cdc20-to-APC/C:Cdh1-in-late-anaphase |
18 |
9.60e-02 |
2.48e-01 |
0.16400 |
0.163000 |
-1.18e-02 |
2.31e-01 |
9.31e-01 |
Deregulated-CDK5-triggers-multiple-neurodegenerative-pathways-in-Alzheimer's-disease-models |
18 |
2.34e-01 |
4.32e-01 |
0.16400 |
0.161000 |
3.16e-02 |
2.38e-01 |
8.17e-01 |
Neurodegenerative-Diseases |
18 |
2.34e-01 |
4.32e-01 |
0.16400 |
0.161000 |
3.16e-02 |
2.38e-01 |
8.17e-01 |
Metabolism-of-steroid-hormones |
13 |
2.06e-01 |
4.05e-01 |
0.16300 |
0.163000 |
-5.00e-03 |
3.09e-01 |
9.75e-01 |
Eukaryotic-Translation-Elongation |
61 |
2.01e-01 |
3.98e-01 |
0.16300 |
-0.096400 |
-1.32e-01 |
1.93e-01 |
7.57e-02 |
Diseases-associated-with-glycosylation-precursor-biosynthesis |
18 |
7.77e-02 |
2.23e-01 |
0.16300 |
0.023800 |
-1.61e-01 |
8.61e-01 |
2.38e-01 |
FOXO-mediated-transcription-of-oxidative-stress,-metabolic-and-neuronal-genes |
23 |
9.53e-03 |
4.97e-02 |
0.16200 |
0.095500 |
-1.31e-01 |
4.28e-01 |
2.77e-01 |
Lewis-blood-group-biosynthesis |
10 |
6.27e-01 |
7.46e-01 |
0.16200 |
0.149000 |
6.42e-02 |
4.16e-01 |
7.25e-01 |
Disorders-of-transmembrane-transporters |
131 |
4.34e-02 |
1.52e-01 |
0.16200 |
-0.127000 |
-1.00e-01 |
1.23e-02 |
4.79e-02 |
Transcriptional-regulation-by-the-AP-2-(TFAP2)-family-of-transcription-factors |
24 |
5.65e-01 |
7.13e-01 |
0.16100 |
0.126000 |
1.01e-01 |
2.85e-01 |
3.92e-01 |
Pre-NOTCH-Expression-and-Processing |
47 |
1.91e-01 |
3.89e-01 |
0.16100 |
0.141000 |
7.84e-02 |
9.48e-02 |
3.53e-01 |
Regulation-of-gene-expression-in-late-stage-(branching-morphogenesis)-pancreatic-bud-precursor-cells |
12 |
7.64e-01 |
8.40e-01 |
0.16100 |
0.122000 |
1.06e-01 |
4.65e-01 |
5.26e-01 |
AURKA-Activation-by-TPX2 |
71 |
6.19e-02 |
1.92e-01 |
0.16100 |
0.144000 |
7.26e-02 |
3.63e-02 |
2.91e-01 |
RUNX3-regulates-NOTCH-signaling |
14 |
7.41e-01 |
8.26e-01 |
0.16100 |
0.113000 |
1.15e-01 |
4.66e-01 |
4.57e-01 |
Glutamate-and-glutamine-metabolism |
10 |
6.04e-01 |
7.34e-01 |
0.16000 |
-0.058300 |
-1.49e-01 |
7.50e-01 |
4.14e-01 |
Interactions-of-Vpr-with-host-cellular-proteins |
33 |
3.30e-01 |
5.31e-01 |
0.16000 |
-0.079400 |
-1.39e-01 |
4.30e-01 |
1.68e-01 |
HATs-acetylate-histones |
76 |
6.68e-02 |
2.00e-01 |
0.16000 |
-0.075900 |
-1.40e-01 |
2.53e-01 |
3.45e-02 |
Transport-of-Ribonucleoproteins-into-the-Host-Nucleus |
31 |
2.77e-01 |
4.83e-01 |
0.15900 |
-0.067700 |
-1.44e-01 |
5.14e-01 |
1.65e-01 |
Late-endosomal-microautophagy |
28 |
2.45e-01 |
4.43e-01 |
0.15900 |
0.148000 |
5.72e-02 |
1.74e-01 |
6.00e-01 |
Negative-regulation-of-FGFR3-signaling |
23 |
6.06e-01 |
7.35e-01 |
0.15900 |
-0.104000 |
-1.20e-01 |
3.88e-01 |
3.19e-01 |
Telomere-C-strand-(Lagging-Strand)-Synthesis |
23 |
3.02e-01 |
5.10e-01 |
0.15900 |
0.054800 |
1.49e-01 |
6.49e-01 |
2.16e-01 |
Constitutive-Signaling-by-Ligand-Responsive-EGFR-Cancer-Variants |
18 |
3.92e-01 |
5.84e-01 |
0.15900 |
-0.054600 |
-1.49e-01 |
6.88e-01 |
2.75e-01 |
Signaling-by-Ligand-Responsive-EGFR-Variants-in-Cancer |
18 |
3.92e-01 |
5.84e-01 |
0.15900 |
-0.054600 |
-1.49e-01 |
6.88e-01 |
2.75e-01 |
Activation-of-ATR-in-response-to-replication-stress |
36 |
6.44e-02 |
1.95e-01 |
0.15800 |
0.030100 |
1.56e-01 |
7.55e-01 |
1.06e-01 |
CLEC7A-(Dectin-1)-induces-NFAT-activation |
11 |
7.84e-01 |
8.49e-01 |
0.15800 |
-0.121000 |
-1.02e-01 |
4.86e-01 |
5.59e-01 |
Removal-of-the-Flap-Intermediate |
13 |
1.91e-01 |
3.89e-01 |
0.15800 |
-0.016100 |
1.58e-01 |
9.20e-01 |
3.25e-01 |
SUMOylation-of-SUMOylation-proteins |
34 |
2.45e-01 |
4.43e-01 |
0.15800 |
-0.066700 |
-1.43e-01 |
5.01e-01 |
1.48e-01 |
APC/C:Cdc20-mediated-degradation-of-mitotic-proteins |
68 |
3.28e-02 |
1.22e-01 |
0.15800 |
-0.148000 |
-5.59e-02 |
3.52e-02 |
4.25e-01 |
Viral-mRNA-Translation |
58 |
2.63e-01 |
4.65e-01 |
0.15800 |
-0.097700 |
-1.24e-01 |
1.99e-01 |
1.02e-01 |
COPI-independent-Golgi-to-ER-retrograde-traffic |
31 |
3.68e-01 |
5.62e-01 |
0.15800 |
0.136000 |
7.87e-02 |
1.89e-01 |
4.49e-01 |
PI-Metabolism |
78 |
1.61e-02 |
7.16e-02 |
0.15700 |
0.149000 |
5.23e-02 |
2.35e-02 |
4.25e-01 |
Interleukin-12-signaling |
31 |
3.71e-02 |
1.35e-01 |
0.15700 |
0.157000 |
1.18e-03 |
1.30e-01 |
9.91e-01 |
TRP-channels |
12 |
1.50e-01 |
3.37e-01 |
0.15700 |
-0.150000 |
4.78e-02 |
3.69e-01 |
7.74e-01 |
Activation-of-BAD-and-translocation-to-mitochondria |
15 |
5.86e-01 |
7.27e-01 |
0.15700 |
0.139000 |
7.33e-02 |
3.51e-01 |
6.23e-01 |
EPH-ephrin-mediated-repulsion-of-cells |
42 |
7.83e-02 |
2.24e-01 |
0.15600 |
0.150000 |
4.32e-02 |
9.18e-02 |
6.28e-01 |
APC:Cdc20-mediated-degradation-of-cell-cycle-proteins-prior-to-satisfation-of-the-cell-cycle-checkpoint |
66 |
3.61e-02 |
1.33e-01 |
0.15600 |
-0.147000 |
-5.41e-02 |
3.94e-02 |
4.47e-01 |
Phase-I---Functionalization-of-compounds |
54 |
2.75e-01 |
4.83e-01 |
0.15600 |
-0.126000 |
-9.27e-02 |
1.11e-01 |
2.39e-01 |
Rap1-signalling |
14 |
2.11e-01 |
4.11e-01 |
0.15600 |
0.004800 |
-1.56e-01 |
9.75e-01 |
3.13e-01 |
Protein-ubiquitination |
62 |
3.31e-04 |
3.24e-03 |
0.15600 |
0.022200 |
-1.54e-01 |
7.62e-01 |
3.60e-02 |
Global-Genome-Nucleotide-Excision-Repair-(GG-NER) |
83 |
1.71e-01 |
3.65e-01 |
0.15600 |
-0.099800 |
-1.19e-01 |
1.16e-01 |
6.02e-02 |
Homologous-DNA-Pairing-and-Strand-Exchange |
41 |
1.33e-01 |
3.16e-01 |
0.15600 |
0.054700 |
1.46e-01 |
5.45e-01 |
1.07e-01 |
Platelet-calcium-homeostasis |
20 |
4.87e-01 |
6.59e-01 |
0.15500 |
0.070700 |
1.38e-01 |
5.84e-01 |
2.85e-01 |
Ribosomal-scanning-and-start-codon-recognition |
47 |
6.35e-02 |
1.94e-01 |
0.15400 |
-0.042900 |
-1.48e-01 |
6.11e-01 |
7.90e-02 |
Extra-nuclear-estrogen-signaling |
62 |
1.56e-01 |
3.46e-01 |
0.15400 |
0.133000 |
7.83e-02 |
7.11e-02 |
2.87e-01 |
Regulation-of-APC/C-activators-between-G1/S-and-early-anaphase |
73 |
5.38e-02 |
1.77e-01 |
0.15400 |
-0.140000 |
-6.38e-02 |
3.86e-02 |
3.47e-01 |
Nitric-oxide-stimulates-guanylate-cyclase |
15 |
4.66e-01 |
6.46e-01 |
0.15400 |
0.050800 |
1.45e-01 |
7.34e-01 |
3.31e-01 |
Nonsense-Mediated-Decay-(NMD)-independent-of-the-Exon-Junction-Complex-(EJC) |
63 |
2.15e-01 |
4.14e-01 |
0.15300 |
-0.088000 |
-1.26e-01 |
2.28e-01 |
8.47e-02 |
PI5P,-PP2A-and-IER3-Regulate-PI3K/AKT-Signaling |
80 |
1.32e-01 |
3.15e-01 |
0.15300 |
0.127000 |
8.56e-02 |
4.99e-02 |
1.86e-01 |
Glutamate-binding,-activation-of-AMPA-receptors-and-synaptic-plasticity |
24 |
5.87e-01 |
7.27e-01 |
0.15300 |
0.092900 |
1.21e-01 |
4.31e-01 |
3.03e-01 |
Trafficking-of-AMPA-receptors |
24 |
5.87e-01 |
7.27e-01 |
0.15300 |
0.092900 |
1.21e-01 |
4.31e-01 |
3.03e-01 |
AMER1-mutants-destabilize-the-destruction-complex |
14 |
5.94e-01 |
7.29e-01 |
0.15300 |
0.138000 |
6.65e-02 |
3.72e-01 |
6.67e-01 |
APC-truncation-mutants-have-impaired-AXIN-binding |
14 |
5.94e-01 |
7.29e-01 |
0.15300 |
0.138000 |
6.65e-02 |
3.72e-01 |
6.67e-01 |
AXIN-missense-mutants-destabilize-the-destruction-complex |
14 |
5.94e-01 |
7.29e-01 |
0.15300 |
0.138000 |
6.65e-02 |
3.72e-01 |
6.67e-01 |
AXIN-mutants-destabilize-the-destruction-complex,-activating-WNT-signaling |
14 |
5.94e-01 |
7.29e-01 |
0.15300 |
0.138000 |
6.65e-02 |
3.72e-01 |
6.67e-01 |
Truncations-of-AMER1-destabilize-the-destruction-complex |
14 |
5.94e-01 |
7.29e-01 |
0.15300 |
0.138000 |
6.65e-02 |
3.72e-01 |
6.67e-01 |
truncated-APC-mutants-destabilize-the-destruction-complex |
14 |
5.94e-01 |
7.29e-01 |
0.15300 |
0.138000 |
6.65e-02 |
3.72e-01 |
6.67e-01 |
Interaction-between-L1-and-Ankyrins |
22 |
5.25e-01 |
6.87e-01 |
0.15300 |
-0.131000 |
-7.82e-02 |
2.86e-01 |
5.25e-01 |
Metabolism-of-nitric-oxide:-eNOS-activation-and-regulation |
14 |
8.36e-02 |
2.32e-01 |
0.15300 |
-0.128000 |
8.41e-02 |
4.08e-01 |
5.86e-01 |
Lagging-Strand-Synthesis |
19 |
2.60e-01 |
4.60e-01 |
0.15300 |
0.028600 |
1.50e-01 |
8.29e-01 |
2.58e-01 |
Assembly-of-active-LPL-and-LIPC-lipase-complexes |
11 |
6.37e-01 |
7.51e-01 |
0.15200 |
-0.061100 |
-1.40e-01 |
7.26e-01 |
4.22e-01 |
Formation-of-the-ternary-complex,-and-subsequently,-the-43S-complex |
41 |
4.83e-02 |
1.62e-01 |
0.15200 |
-0.025000 |
-1.50e-01 |
7.82e-01 |
9.71e-02 |
Interleukin-6-family-signaling |
18 |
7.03e-01 |
8.03e-01 |
0.15200 |
0.101000 |
1.13e-01 |
4.60e-01 |
4.05e-01 |
Translesion-Synthesis-by-POLH |
18 |
4.21e-01 |
6.06e-01 |
0.15200 |
-0.142000 |
-5.16e-02 |
2.95e-01 |
7.05e-01 |
HDMs-demethylate-histones |
21 |
3.16e-01 |
5.19e-01 |
0.15100 |
-0.043800 |
-1.45e-01 |
7.28e-01 |
2.51e-01 |
DDX58/IFIH1-mediated-induction-of-interferon-alpha/beta |
58 |
1.47e-01 |
3.35e-01 |
0.15100 |
0.070300 |
1.34e-01 |
3.55e-01 |
7.81e-02 |
E3-ubiquitin-ligases-ubiquitinate-target-proteins |
42 |
2.82e-02 |
1.09e-01 |
0.15100 |
-0.013200 |
-1.50e-01 |
8.82e-01 |
9.20e-02 |
Signaling-by-FGFR2 |
60 |
2.56e-01 |
4.56e-01 |
0.15100 |
-0.088500 |
-1.22e-01 |
2.36e-01 |
1.02e-01 |
Formation-of-HIV-1-elongation-complex-containing-HIV-1-Tat |
41 |
4.51e-01 |
6.31e-01 |
0.15000 |
-0.113000 |
-9.88e-02 |
2.09e-01 |
2.74e-01 |
HIV-Transcription-Elongation |
41 |
4.51e-01 |
6.31e-01 |
0.15000 |
-0.113000 |
-9.88e-02 |
2.09e-01 |
2.74e-01 |
Tat-mediated-elongation-of-the-HIV-1-transcript |
41 |
4.51e-01 |
6.31e-01 |
0.15000 |
-0.113000 |
-9.88e-02 |
2.09e-01 |
2.74e-01 |
NR1H3-&-NR1H2-regulate-gene-expression-linked-to-cholesterol-transport-and-efflux |
32 |
4.19e-01 |
6.05e-01 |
0.15000 |
-0.078900 |
-1.28e-01 |
4.40e-01 |
2.10e-01 |
Signaling-by-Type-1-Insulin-like-Growth-Factor-1-Receptor-(IGF1R) |
39 |
3.70e-01 |
5.64e-01 |
0.15000 |
0.126000 |
8.20e-02 |
1.73e-01 |
3.76e-01 |
TP53-Regulates-Transcription-of-Cell-Death-Genes |
34 |
5.30e-01 |
6.90e-01 |
0.15000 |
0.104000 |
1.08e-01 |
2.94e-01 |
2.75e-01 |
ER-Quality-Control-Compartment-(ERQC) |
20 |
6.90e-01 |
7.92e-01 |
0.15000 |
0.104000 |
1.07e-01 |
4.19e-01 |
4.07e-01 |
Signaling-by-FGFR3 |
33 |
3.17e-01 |
5.20e-01 |
0.14900 |
-0.065700 |
-1.34e-01 |
5.14e-01 |
1.83e-01 |
Constitutive-Signaling-by-AKT1-E17K-in-Cancer |
26 |
4.77e-01 |
6.53e-01 |
0.14900 |
-0.075500 |
-1.29e-01 |
5.05e-01 |
2.56e-01 |
Ovarian-tumor-domain-proteases |
36 |
2.22e-01 |
4.21e-01 |
0.14900 |
0.056100 |
1.38e-01 |
5.60e-01 |
1.52e-01 |
CLEC7A-(Dectin-1)-signaling |
92 |
2.57e-02 |
1.02e-01 |
0.14900 |
-0.137000 |
-5.85e-02 |
2.34e-02 |
3.33e-01 |
Metalloprotease-DUBs |
16 |
7.08e-01 |
8.05e-01 |
0.14900 |
0.088900 |
1.19e-01 |
5.38e-01 |
4.09e-01 |
Synthesis-of-PIPs-at-the-Golgi-membrane |
15 |
8.19e-02 |
2.30e-01 |
0.14900 |
0.080200 |
-1.25e-01 |
5.91e-01 |
4.02e-01 |
Death-Receptor-Signalling |
129 |
8.68e-02 |
2.36e-01 |
0.14900 |
0.097100 |
1.12e-01 |
5.71e-02 |
2.77e-02 |
Signaling-by-NOTCH2 |
30 |
5.66e-01 |
7.13e-01 |
0.14800 |
0.097400 |
1.12e-01 |
3.56e-01 |
2.88e-01 |
RNA-Polymerase-I-Promoter-Clearance |
50 |
3.92e-01 |
5.84e-01 |
0.14800 |
-0.098600 |
-1.11e-01 |
2.28e-01 |
1.75e-01 |
RNA-Polymerase-I-Transcription |
50 |
3.92e-01 |
5.84e-01 |
0.14800 |
-0.098600 |
-1.11e-01 |
2.28e-01 |
1.75e-01 |
Phospholipid-metabolism |
179 |
1.12e-02 |
5.59e-02 |
0.14800 |
-0.079900 |
-1.25e-01 |
6.56e-02 |
4.00e-03 |
Antigen-activates-B-Cell-Receptor-(BCR)-leading-to-generation-of-second-messengers |
29 |
1.48e-02 |
6.71e-02 |
0.14800 |
-0.051000 |
1.39e-01 |
6.34e-01 |
1.96e-01 |
LGI-ADAM-interactions |
10 |
3.36e-01 |
5.35e-01 |
0.14800 |
0.013400 |
-1.47e-01 |
9.41e-01 |
4.20e-01 |
Cap-dependent-Translation-Initiation |
86 |
9.02e-02 |
2.39e-01 |
0.14800 |
-0.074200 |
-1.28e-01 |
2.35e-01 |
4.10e-02 |
Eukaryotic-Translation-Initiation |
86 |
9.02e-02 |
2.39e-01 |
0.14800 |
-0.074200 |
-1.28e-01 |
2.35e-01 |
4.10e-02 |
C-type-lectin-receptors-(CLRs) |
114 |
5.20e-02 |
1.71e-01 |
0.14800 |
-0.125000 |
-7.76e-02 |
2.08e-02 |
1.53e-01 |
RAB-geranylgeranylation |
51 |
1.00e-03 |
8.01e-03 |
0.14800 |
0.142000 |
-4.10e-02 |
8.01e-02 |
6.13e-01 |
Synthesis-of-Prostaglandins-(PG)-and-Thromboxanes-(TX) |
13 |
1.40e-01 |
3.27e-01 |
0.14700 |
0.059600 |
-1.35e-01 |
7.10e-01 |
4.00e-01 |
Presynaptic-phase-of-homologous-DNA-pairing-and-strand-exchange |
38 |
1.91e-01 |
3.89e-01 |
0.14700 |
0.052400 |
1.38e-01 |
5.76e-01 |
1.42e-01 |
Post-translational-modification:-synthesis-of-GPI-anchored-proteins |
59 |
3.26e-01 |
5.28e-01 |
0.14700 |
-0.094700 |
-1.13e-01 |
2.09e-01 |
1.35e-01 |
Cytosolic-sulfonation-of-small-molecules |
12 |
2.42e-01 |
4.40e-01 |
0.14700 |
0.145000 |
-2.40e-02 |
3.85e-01 |
8.85e-01 |
Dopamine-Neurotransmitter-Release-Cycle |
17 |
4.02e-01 |
5.93e-01 |
0.14600 |
0.040000 |
1.41e-01 |
7.75e-01 |
3.15e-01 |
Aquaporin-mediated-transport |
34 |
1.77e-01 |
3.72e-01 |
0.14600 |
-0.042800 |
-1.40e-01 |
6.66e-01 |
1.58e-01 |
Cohesin-Loading-onto-Chromatin |
10 |
1.86e-01 |
3.81e-01 |
0.14600 |
0.098800 |
-1.08e-01 |
5.88e-01 |
5.55e-01 |
Amyloid-fiber-formation |
38 |
4.85e-01 |
6.58e-01 |
0.14600 |
0.093100 |
1.13e-01 |
3.21e-01 |
2.29e-01 |
Nuclear-signaling-by-ERBB4 |
28 |
4.87e-01 |
6.59e-01 |
0.14600 |
0.124000 |
7.65e-02 |
2.55e-01 |
4.84e-01 |
DNA-Replication-Pre-Initiation |
80 |
2.28e-05 |
3.89e-04 |
0.14600 |
-0.139000 |
4.26e-02 |
3.15e-02 |
5.10e-01 |
Protein-methylation |
13 |
7.45e-01 |
8.30e-01 |
0.14500 |
-0.120000 |
-8.20e-02 |
4.54e-01 |
6.09e-01 |
Nucleotide-salvage |
20 |
4.20e-01 |
6.06e-01 |
0.14500 |
0.050500 |
1.36e-01 |
6.96e-01 |
2.92e-01 |
TGF-beta-receptor-signaling-activates-SMADs |
32 |
2.37e-01 |
4.36e-01 |
0.14500 |
0.137000 |
4.79e-02 |
1.81e-01 |
6.39e-01 |
CD28-co-stimulation |
32 |
4.12e-01 |
5.99e-01 |
0.14500 |
0.071500 |
1.26e-01 |
4.84e-01 |
2.18e-01 |
Signal-Transduction |
1697 |
3.11e-13 |
1.81e-11 |
0.14400 |
0.113000 |
8.99e-02 |
3.26e-14 |
1.55e-09 |
Activation-of-APC/C-and-APC/C:Cdc20-mediated-degradation-of-mitotic-proteins |
69 |
4.15e-02 |
1.48e-01 |
0.14400 |
-0.136000 |
-4.52e-02 |
5.05e-02 |
5.16e-01 |
Influenza-Infection |
118 |
1.15e-01 |
2.85e-01 |
0.14300 |
-0.090800 |
-1.11e-01 |
8.89e-02 |
3.76e-02 |
Nonsense-Mediated-Decay-(NMD)-enhanced-by-the-Exon-Junction-Complex-(EJC) |
82 |
1.48e-01 |
3.35e-01 |
0.14300 |
-0.077700 |
-1.20e-01 |
2.24e-01 |
5.98e-02 |
Nonsense-Mediated-Decay-(NMD) |
82 |
1.48e-01 |
3.35e-01 |
0.14300 |
-0.077700 |
-1.20e-01 |
2.24e-01 |
5.98e-02 |
Biosynthesis-of-the-N-glycan-precursor-(dolichol-lipid-linked-oligosaccharide,-LLO)-and-transfer-to-a-nascent-protein |
69 |
6.68e-04 |
5.77e-03 |
0.14300 |
0.142000 |
-1.72e-02 |
4.15e-02 |
8.04e-01 |
Regulation-of-innate-immune-responses-to-cytosolic-DNA |
13 |
7.82e-01 |
8.49e-01 |
0.14300 |
0.088300 |
1.12e-01 |
5.81e-01 |
4.83e-01 |
Downregulation-of-ERBB2:ERBB3-signaling |
13 |
7.99e-01 |
8.59e-01 |
0.14200 |
-0.094800 |
-1.06e-01 |
5.54e-01 |
5.07e-01 |
L13a-mediated-translational-silencing-of-Ceruloplasmin-expression |
78 |
8.15e-02 |
2.30e-01 |
0.14200 |
-0.061500 |
-1.28e-01 |
3.48e-01 |
5.08e-02 |
Clathrin-mediated-endocytosis |
121 |
1.15e-02 |
5.70e-02 |
0.14100 |
0.131000 |
5.42e-02 |
1.32e-02 |
3.04e-01 |
Nucleotide-Excision-Repair |
109 |
1.64e-01 |
3.56e-01 |
0.14100 |
-0.103000 |
-9.68e-02 |
6.36e-02 |
8.12e-02 |
Signaling-by-SCF-KIT |
40 |
5.15e-01 |
6.78e-01 |
0.14100 |
0.103000 |
9.64e-02 |
2.60e-01 |
2.91e-01 |
Signaling-by-NTRK2-(TRKB) |
22 |
1.82e-01 |
3.77e-01 |
0.14100 |
-0.008870 |
-1.40e-01 |
9.43e-01 |
2.54e-01 |
Signaling-by-FGFR4 |
33 |
2.30e-01 |
4.27e-01 |
0.14000 |
-0.043700 |
-1.33e-01 |
6.64e-01 |
1.85e-01 |
Interleukin-3,-Interleukin-5-and-GM-CSF-signaling |
38 |
5.35e-01 |
6.92e-01 |
0.14000 |
0.095300 |
1.03e-01 |
3.09e-01 |
2.73e-01 |
Metabolism-of-folate-and-pterines |
16 |
1.48e-01 |
3.35e-01 |
0.14000 |
0.035500 |
-1.35e-01 |
8.06e-01 |
3.48e-01 |
Processive-synthesis-on-the-C-strand-of-the-telomere |
10 |
2.41e-01 |
4.40e-01 |
0.14000 |
-0.123000 |
6.59e-02 |
5.00e-01 |
7.18e-01 |
DNA-Double-Strand-Break-Response |
40 |
4.79e-01 |
6.53e-01 |
0.14000 |
-0.111000 |
-8.53e-02 |
2.26e-01 |
3.51e-01 |
APC-Cdc20-mediated-degradation-of-Nek2A |
23 |
2.98e-01 |
5.06e-01 |
0.14000 |
0.136000 |
3.37e-02 |
2.61e-01 |
7.80e-01 |
RNA-polymerase-II-transcribes-snRNA-genes |
70 |
3.09e-01 |
5.15e-01 |
0.13900 |
-0.091300 |
-1.05e-01 |
1.87e-01 |
1.27e-01 |
Negative-regulation-of-FGFR4-signaling |
23 |
5.80e-01 |
7.22e-01 |
0.13900 |
-0.072500 |
-1.19e-01 |
5.48e-01 |
3.23e-01 |
Transmission-across-Chemical-Synapses |
164 |
7.22e-02 |
2.10e-01 |
0.13900 |
0.102000 |
9.53e-02 |
2.51e-02 |
3.56e-02 |
Membrane-binding-and-targetting-of-GAG-proteins |
14 |
6.04e-01 |
7.34e-01 |
0.13900 |
0.128000 |
5.30e-02 |
4.05e-01 |
7.31e-01 |
Synthesis-And-Processing-Of-GAG,-GAGPOL-Polyproteins |
14 |
6.04e-01 |
7.34e-01 |
0.13900 |
0.128000 |
5.30e-02 |
4.05e-01 |
7.31e-01 |
Glucagon-signaling-in-metabolic-regulation |
24 |
2.45e-01 |
4.43e-01 |
0.13900 |
0.136000 |
2.60e-02 |
2.48e-01 |
8.26e-01 |
Cell-cell-junction-organization |
33 |
2.53e-02 |
1.01e-01 |
0.13800 |
0.135000 |
-2.99e-02 |
1.80e-01 |
7.66e-01 |
Nuclear-import-of-Rev-protein |
31 |
4.03e-01 |
5.93e-01 |
0.13800 |
-0.061500 |
-1.24e-01 |
5.54e-01 |
2.34e-01 |
Constitutive-Signaling-by-NOTCH1-HD-Domain-Mutants |
15 |
7.88e-01 |
8.52e-01 |
0.13800 |
-0.100000 |
-9.44e-02 |
5.00e-01 |
5.27e-01 |
Signaling-by-NOTCH1-HD-Domain-Mutants-in-Cancer |
15 |
7.88e-01 |
8.52e-01 |
0.13800 |
-0.100000 |
-9.44e-02 |
5.00e-01 |
5.27e-01 |
Synthesis-of-PIPs-at-the-early-endosome-membrane |
16 |
7.40e-01 |
8.26e-01 |
0.13800 |
0.111000 |
8.12e-02 |
4.42e-01 |
5.74e-01 |
Assembly-Of-The-HIV-Virion |
15 |
4.26e-01 |
6.09e-01 |
0.13700 |
0.135000 |
2.64e-02 |
3.67e-01 |
8.59e-01 |
GTP-hydrolysis-and-joining-of-the-60S-ribosomal-subunit |
80 |
8.19e-02 |
2.30e-01 |
0.13700 |
-0.057400 |
-1.24e-01 |
3.76e-01 |
5.45e-02 |
Peptide-ligand-binding-receptors |
57 |
5.45e-03 |
3.23e-02 |
0.13700 |
0.136000 |
-1.06e-02 |
7.50e-02 |
8.90e-01 |
HDR-through-Homologous-Recombination-(HRR) |
63 |
2.21e-01 |
4.21e-01 |
0.13700 |
0.068800 |
1.18e-01 |
3.46e-01 |
1.05e-01 |
Transcriptional-regulation-of-white-adipocyte-differentiation |
78 |
1.86e-01 |
3.81e-01 |
0.13600 |
-0.073100 |
-1.15e-01 |
2.65e-01 |
7.87e-02 |
Signalling-to-RAS |
17 |
7.58e-01 |
8.35e-01 |
0.13600 |
0.104000 |
8.80e-02 |
4.57e-01 |
5.30e-01 |
Post-NMDA-receptor-activation-events |
50 |
1.31e-03 |
9.94e-03 |
0.13600 |
0.122000 |
-6.09e-02 |
1.36e-01 |
4.56e-01 |
Alpha-protein-kinase-1-signaling-pathway |
11 |
3.48e-01 |
5.44e-01 |
0.13600 |
0.135000 |
-1.61e-02 |
4.37e-01 |
9.27e-01 |
RMTs-methylate-histone-arginines |
28 |
3.75e-01 |
5.67e-01 |
0.13600 |
-0.051100 |
-1.26e-01 |
6.40e-01 |
2.49e-01 |
Fc-epsilon-receptor-(FCERI)-signaling |
121 |
9.77e-02 |
2.51e-01 |
0.13600 |
-0.112000 |
-7.74e-02 |
3.44e-02 |
1.42e-01 |
Miscellaneous-transport-and-binding-events |
20 |
7.31e-01 |
8.21e-01 |
0.13600 |
-0.090300 |
-1.01e-01 |
4.84e-01 |
4.33e-01 |
Nef-mediates-down-modulation-of-cell-surface-receptors-by-recruiting-them-to-clathrin-adapters |
17 |
1.90e-01 |
3.89e-01 |
0.13500 |
0.134000 |
-1.89e-02 |
3.39e-01 |
8.93e-01 |
Regulation-of-TNFR1-signaling |
32 |
4.88e-01 |
6.60e-01 |
0.13500 |
0.070200 |
1.16e-01 |
4.92e-01 |
2.58e-01 |
Transport-of-inorganic-cations/anions-and-amino-acids/oligopeptides |
67 |
3.61e-01 |
5.54e-01 |
0.13500 |
0.099200 |
9.12e-02 |
1.61e-01 |
1.97e-01 |
Regulation-of-PLK1-Activity-at-G2/M-Transition |
86 |
5.72e-02 |
1.83e-01 |
0.13500 |
0.124000 |
5.19e-02 |
4.67e-02 |
4.06e-01 |
HIV-Infection |
209 |
4.52e-02 |
1.54e-01 |
0.13500 |
-0.094100 |
-9.62e-02 |
1.92e-02 |
1.68e-02 |
Transcriptional-Regulation-by-TP53 |
334 |
6.12e-03 |
3.51e-02 |
0.13500 |
-0.101000 |
-8.84e-02 |
1.50e-03 |
5.66e-03 |
VEGFA-VEGFR2-Pathway |
90 |
2.53e-01 |
4.52e-01 |
0.13400 |
0.088900 |
1.00e-01 |
1.45e-01 |
1.00e-01 |
Loss-of-Nlp-from-mitotic-centrosomes |
68 |
9.32e-02 |
2.44e-01 |
0.13400 |
0.125000 |
4.92e-02 |
7.55e-02 |
4.84e-01 |
Loss-of-proteins-required-for-interphase-microtubule-organization-from-the-centrosome |
68 |
9.32e-02 |
2.44e-01 |
0.13400 |
0.125000 |
4.92e-02 |
7.55e-02 |
4.84e-01 |
Cytosolic-iron-sulfur-cluster-assembly |
13 |
4.92e-01 |
6.61e-01 |
0.13300 |
-0.131000 |
-2.40e-02 |
4.15e-01 |
8.81e-01 |
Transcription-Coupled-Nucleotide-Excision-Repair-(TC-NER) |
77 |
3.23e-01 |
5.25e-01 |
0.13300 |
-0.097400 |
-9.01e-02 |
1.40e-01 |
1.72e-01 |
Rab-regulation-of-trafficking |
111 |
1.29e-01 |
3.10e-01 |
0.13300 |
-0.075200 |
-1.09e-01 |
1.72e-01 |
4.73e-02 |
Transcriptional-regulation-of-pluripotent-stem-cells |
15 |
1.42e-01 |
3.28e-01 |
0.13200 |
0.067300 |
-1.14e-01 |
6.52e-01 |
4.45e-01 |
Cardiac-conduction |
95 |
1.52e-01 |
3.39e-01 |
0.13200 |
-0.111000 |
-7.14e-02 |
6.17e-02 |
2.29e-01 |
Activation-of-NMDA-receptors-and-postsynaptic-events |
59 |
1.36e-02 |
6.36e-02 |
0.13200 |
0.132000 |
3.04e-03 |
7.97e-02 |
9.68e-01 |
eNOS-activation |
10 |
7.04e-01 |
8.03e-01 |
0.13200 |
-0.123000 |
-4.68e-02 |
4.99e-01 |
7.98e-01 |
Basigin-interactions |
19 |
7.45e-01 |
8.30e-01 |
0.13200 |
0.102000 |
8.42e-02 |
4.43e-01 |
5.26e-01 |
HDACs-deacetylate-histones |
31 |
1.63e-02 |
7.18e-02 |
0.13200 |
0.107000 |
-7.60e-02 |
3.01e-01 |
4.64e-01 |
G-beta:gamma-signalling-through-BTK |
12 |
3.51e-01 |
5.46e-01 |
0.13100 |
0.131000 |
-1.30e-02 |
4.33e-01 |
9.38e-01 |
PI3K-events-in-ERBB2-signaling |
15 |
3.39e-01 |
5.36e-01 |
0.13100 |
0.131000 |
3.04e-03 |
3.79e-01 |
9.84e-01 |
Signaling-by-ERBB2-in-Cancer |
24 |
3.20e-01 |
5.22e-01 |
0.13100 |
0.127000 |
3.01e-02 |
2.80e-01 |
7.99e-01 |
G-protein-mediated-events |
46 |
2.59e-01 |
4.59e-01 |
0.13100 |
0.053500 |
1.19e-01 |
5.30e-01 |
1.61e-01 |
Platelet-sensitization-by-LDL |
16 |
7.72e-01 |
8.44e-01 |
0.13100 |
-0.104000 |
-7.94e-02 |
4.73e-01 |
5.82e-01 |
ISG15-antiviral-mechanism |
67 |
3.90e-01 |
5.83e-01 |
0.13100 |
-0.092300 |
-9.24e-02 |
1.92e-01 |
1.91e-01 |
HDR-through-Single-Strand-Annealing-(SSA) |
36 |
1.57e-01 |
3.47e-01 |
0.13000 |
0.025000 |
1.28e-01 |
7.95e-01 |
1.84e-01 |
TNFR1-induced-NFkappaB-signaling-pathway |
25 |
7.05e-01 |
8.03e-01 |
0.13000 |
0.091300 |
9.27e-02 |
4.30e-01 |
4.23e-01 |
Ephrin-signaling |
19 |
2.15e-01 |
4.14e-01 |
0.13000 |
0.130000 |
-7.86e-03 |
3.27e-01 |
9.53e-01 |
Cell-surface-interactions-at-the-vascular-wall |
88 |
2.85e-01 |
4.91e-01 |
0.13000 |
0.086900 |
9.68e-02 |
1.59e-01 |
1.17e-01 |
Signaling-by-FGFR3-fusions-in-cancer |
10 |
7.34e-01 |
8.22e-01 |
0.13000 |
-0.050000 |
-1.20e-01 |
7.84e-01 |
5.13e-01 |
Gene-and-protein-expression-by-JAK-STAT-signaling-after-Interleukin-12-stimulation |
27 |
1.16e-01 |
2.87e-01 |
0.12900 |
0.129000 |
-8.29e-03 |
2.47e-01 |
9.41e-01 |
Interleukin-2-family-signaling |
32 |
6.40e-01 |
7.51e-01 |
0.12900 |
0.095100 |
8.69e-02 |
3.52e-01 |
3.95e-01 |
Eukaryotic-Translation-Termination |
62 |
3.44e-01 |
5.39e-01 |
0.12900 |
-0.073700 |
-1.06e-01 |
3.16e-01 |
1.51e-01 |
rRNA-processing |
178 |
9.01e-02 |
2.39e-01 |
0.12800 |
-0.089400 |
-9.21e-02 |
3.99e-02 |
3.44e-02 |
Thromboxane-signalling-through-TP-receptor |
15 |
3.81e-01 |
5.73e-01 |
0.12800 |
0.128000 |
8.11e-03 |
3.91e-01 |
9.57e-01 |
Cargo-concentration-in-the-ER |
26 |
7.20e-02 |
2.10e-01 |
0.12800 |
0.123000 |
-3.47e-02 |
2.78e-01 |
7.59e-01 |
Stimuli-sensing-channels |
55 |
4.47e-01 |
6.30e-01 |
0.12800 |
-0.080400 |
-9.90e-02 |
3.02e-01 |
2.04e-01 |
RUNX1-interacts-with-co-factors-whose-precise-effect-on-RUNX1-targets-is-not-known |
36 |
1.90e-02 |
8.07e-02 |
0.12700 |
0.118000 |
-4.79e-02 |
2.21e-01 |
6.19e-01 |
Switching-of-origins-to-a-post-replicative-state |
84 |
1.58e-02 |
7.03e-02 |
0.12700 |
-0.125000 |
-2.36e-02 |
4.79e-02 |
7.09e-01 |
VxPx-cargo-targeting-to-cilium |
18 |
7.52e-01 |
8.33e-01 |
0.12700 |
0.102000 |
7.59e-02 |
4.54e-01 |
5.77e-01 |
MAP-kinase-activation |
61 |
1.40e-01 |
3.27e-01 |
0.12700 |
-0.045500 |
-1.19e-01 |
5.39e-01 |
1.09e-01 |
IKK-complex-recruitment-mediated-by-RIP1 |
20 |
3.27e-01 |
5.29e-01 |
0.12700 |
0.126000 |
1.58e-02 |
3.31e-01 |
9.03e-01 |
NEP/NS2-Interacts-with-the-Cellular-Export-Machinery |
30 |
5.45e-01 |
6.96e-01 |
0.12700 |
-0.064500 |
-1.09e-01 |
5.41e-01 |
3.02e-01 |
G2/M-DNA-damage-checkpoint |
56 |
1.43e-01 |
3.31e-01 |
0.12600 |
0.041300 |
1.19e-01 |
5.93e-01 |
1.22e-01 |
CREB1-phosphorylation-through-NMDA-receptor-mediated-activation-of-RAS-signaling |
21 |
9.58e-02 |
2.48e-01 |
0.12600 |
0.115000 |
-5.26e-02 |
3.63e-01 |
6.77e-01 |
Plasma-lipoprotein-remodeling |
19 |
5.29e-01 |
6.90e-01 |
0.12600 |
-0.118000 |
-4.23e-02 |
3.71e-01 |
7.50e-01 |
Centrosome-maturation |
78 |
1.17e-01 |
2.87e-01 |
0.12600 |
0.115000 |
5.08e-02 |
7.93e-02 |
4.39e-01 |
Recruitment-of-mitotic-centrosome-proteins-and-complexes |
78 |
1.17e-01 |
2.87e-01 |
0.12600 |
0.115000 |
5.08e-02 |
7.93e-02 |
4.39e-01 |
Regulation-of-TP53-Expression-and-Degradation |
35 |
6.24e-01 |
7.45e-01 |
0.12500 |
-0.094300 |
-8.26e-02 |
3.34e-01 |
3.98e-01 |
Serotonin-Neurotransmitter-Release-Cycle |
13 |
7.33e-01 |
8.22e-01 |
0.12500 |
0.056100 |
1.12e-01 |
7.26e-01 |
4.85e-01 |
Plasma-lipoprotein-clearance |
27 |
6.85e-01 |
7.90e-01 |
0.12500 |
-0.078900 |
-9.67e-02 |
4.78e-01 |
3.85e-01 |
Interleukin-1-signaling |
90 |
2.77e-02 |
1.08e-01 |
0.12500 |
-0.120000 |
-3.26e-02 |
4.86e-02 |
5.93e-01 |
Signaling-by-the-B-Cell-Receptor-(BCR) |
103 |
2.88e-03 |
1.86e-02 |
0.12400 |
-0.124000 |
-1.17e-02 |
3.00e-02 |
8.37e-01 |
Complement-cascade |
26 |
6.68e-01 |
7.76e-01 |
0.12400 |
-0.072700 |
-1.01e-01 |
5.21e-01 |
3.74e-01 |
Chromosome-Maintenance |
52 |
5.16e-01 |
6.78e-01 |
0.12400 |
0.085800 |
8.94e-02 |
2.85e-01 |
2.65e-01 |
Nucleobase-catabolism |
29 |
5.14e-01 |
6.78e-01 |
0.12300 |
-0.110000 |
-5.55e-02 |
3.06e-01 |
6.05e-01 |
RAB-GEFs-exchange-GTP-for-GDP-on-RABs |
81 |
2.26e-01 |
4.23e-01 |
0.12300 |
-0.064200 |
-1.05e-01 |
3.18e-01 |
1.02e-01 |
Apoptotic-factor-mediated-response |
15 |
5.86e-01 |
7.27e-01 |
0.12300 |
-0.036200 |
-1.17e-01 |
8.08e-01 |
4.31e-01 |
Adrenaline,noradrenaline-inhibits-insulin-secretion |
21 |
6.55e-01 |
7.62e-01 |
0.12300 |
0.107000 |
6.02e-02 |
3.96e-01 |
6.33e-01 |
Transport-of-vitamins,-nucleosides,-and-related-molecules |
29 |
2.86e-01 |
4.92e-01 |
0.12300 |
0.120000 |
2.63e-02 |
2.65e-01 |
8.06e-01 |
Peptide-chain-elongation |
57 |
3.71e-01 |
5.64e-01 |
0.12300 |
-0.065700 |
-1.03e-01 |
3.91e-01 |
1.77e-01 |
TICAM1,TRAF6-dependent-induction-of-TAK1-complex |
11 |
3.06e-01 |
5.12e-01 |
0.12200 |
0.054700 |
-1.10e-01 |
7.53e-01 |
5.29e-01 |
Disassembly-of-the-destruction-complex-and-recruitment-of-AXIN-to-the-membrane |
27 |
8.77e-02 |
2.37e-01 |
0.12200 |
0.119000 |
-2.99e-02 |
2.86e-01 |
7.88e-01 |
Repression-of-WNT-target-genes |
14 |
8.34e-01 |
8.84e-01 |
0.12200 |
0.092800 |
7.92e-02 |
5.48e-01 |
6.08e-01 |
Activation-of-BH3-only-proteins |
28 |
5.99e-01 |
7.34e-01 |
0.12100 |
0.104000 |
6.20e-02 |
3.41e-01 |
5.70e-01 |
RNA-Polymerase-II-Pre-transcription-Events |
77 |
3.75e-01 |
5.67e-01 |
0.12100 |
-0.077900 |
-9.23e-02 |
2.38e-01 |
1.62e-01 |
Signaling-by-ROBO-receptors |
167 |
1.37e-01 |
3.22e-01 |
0.12000 |
-0.087000 |
-8.30e-02 |
5.28e-02 |
6.48e-02 |
FOXO-mediated-transcription |
54 |
2.01e-01 |
3.98e-01 |
0.12000 |
-0.041400 |
-1.13e-01 |
5.99e-01 |
1.52e-01 |
Circadian-Clock |
66 |
8.73e-02 |
2.37e-01 |
0.12000 |
-0.031300 |
-1.16e-01 |
6.60e-01 |
1.04e-01 |
Downstream-signaling-of-activated-FGFR1 |
20 |
1.98e-01 |
3.95e-01 |
0.12000 |
0.022200 |
-1.18e-01 |
8.64e-01 |
3.62e-01 |
Recruitment-and-ATM-mediated-phosphorylation-of-repair-and-signaling-proteins-at-DNA-double-strand-breaks |
39 |
5.64e-01 |
7.12e-01 |
0.12000 |
-0.097700 |
-6.91e-02 |
2.91e-01 |
4.55e-01 |
Signaling-by-FGFR-in-disease |
53 |
5.30e-01 |
6.90e-01 |
0.12000 |
-0.088000 |
-8.10e-02 |
2.68e-01 |
3.08e-01 |
Iron-uptake-and-transport |
49 |
8.15e-02 |
2.30e-01 |
0.12000 |
-0.013100 |
-1.19e-01 |
8.74e-01 |
1.50e-01 |
Golgi-Associated-Vesicle-Biogenesis |
50 |
3.01e-01 |
5.09e-01 |
0.11900 |
0.109000 |
4.97e-02 |
1.84e-01 |
5.43e-01 |
Dual-Incision-in-GG-NER |
40 |
5.44e-01 |
6.96e-01 |
0.11900 |
-0.066900 |
-9.85e-02 |
4.65e-01 |
2.81e-01 |
Deactivation-of-the-beta-catenin-transactivating-complex |
39 |
5.48e-01 |
6.97e-01 |
0.11900 |
-0.066200 |
-9.88e-02 |
4.74e-01 |
2.86e-01 |
HIV-elongation-arrest-and-recovery |
31 |
2.39e-01 |
4.37e-01 |
0.11900 |
-0.118000 |
-1.85e-02 |
2.58e-01 |
8.59e-01 |
Pausing-and-recovery-of-HIV-elongation |
31 |
2.39e-01 |
4.37e-01 |
0.11900 |
-0.118000 |
-1.85e-02 |
2.58e-01 |
8.59e-01 |
Downregulation-of-TGF-beta-receptor-signaling |
26 |
4.18e-01 |
6.04e-01 |
0.11900 |
0.114000 |
3.49e-02 |
3.16e-01 |
7.58e-01 |
NR1H2-and-NR1H3-mediated-signaling |
40 |
4.78e-01 |
6.53e-01 |
0.11900 |
-0.058900 |
-1.03e-01 |
5.19e-01 |
2.60e-01 |
XBP1(S)-activates-chaperone-genes |
48 |
2.87e-02 |
1.11e-01 |
0.11900 |
0.117000 |
-1.57e-02 |
1.59e-01 |
8.51e-01 |
IGF1R-signaling-cascade |
38 |
4.94e-01 |
6.62e-01 |
0.11800 |
0.103000 |
5.84e-02 |
2.72e-01 |
5.34e-01 |
Cytokine-Signaling-in-Immune-system |
610 |
7.31e-04 |
6.19e-03 |
0.11800 |
0.075700 |
9.06e-02 |
1.52e-03 |
1.46e-04 |
HDR-through-Homologous-Recombination-(HRR)-or-Single-Strand-Annealing-(SSA) |
89 |
1.27e-01 |
3.08e-01 |
0.11800 |
0.049100 |
1.07e-01 |
4.24e-01 |
8.14e-02 |
G-alpha-(s)-signalling-events |
81 |
3.96e-01 |
5.86e-01 |
0.11800 |
0.081800 |
8.46e-02 |
2.04e-01 |
1.88e-01 |
Reproduction |
52 |
4.55e-01 |
6.34e-01 |
0.11800 |
0.097800 |
6.52e-02 |
2.23e-01 |
4.16e-01 |
Metal-ion-SLC-transporters |
20 |
2.67e-01 |
4.71e-01 |
0.11800 |
0.117000 |
-7.22e-03 |
3.64e-01 |
9.55e-01 |
Vasopressin-regulates-renal-water-homeostasis-via-Aquaporins |
31 |
1.52e-01 |
3.39e-01 |
0.11700 |
0.001110 |
-1.17e-01 |
9.91e-01 |
2.58e-01 |
Phase-0---rapid-depolarisation |
30 |
7.05e-01 |
8.03e-01 |
0.11700 |
-0.087400 |
-7.83e-02 |
4.08e-01 |
4.58e-01 |
APC/C-mediated-degradation-of-cell-cycle-proteins |
79 |
1.31e-01 |
3.13e-01 |
0.11700 |
-0.108000 |
-4.44e-02 |
9.58e-02 |
4.95e-01 |
Regulation-of-mitotic-cell-cycle |
79 |
1.31e-01 |
3.13e-01 |
0.11700 |
-0.108000 |
-4.44e-02 |
9.58e-02 |
4.95e-01 |
Activation-of-kainate-receptors-upon-glutamate-binding |
22 |
3.66e-01 |
5.60e-01 |
0.11700 |
0.116000 |
1.71e-02 |
3.47e-01 |
8.90e-01 |
NOTCH4-Activation-and-Transmission-of-Signal-to-the-Nucleus |
10 |
5.28e-01 |
6.90e-01 |
0.11700 |
0.005500 |
-1.17e-01 |
9.76e-01 |
5.23e-01 |
Cytosolic-sensors-of-pathogen-associated-DNA |
59 |
1.10e-01 |
2.74e-01 |
0.11700 |
0.027000 |
1.13e-01 |
7.20e-01 |
1.32e-01 |
TCR-signaling |
94 |
6.13e-02 |
1.90e-01 |
0.11700 |
-0.110000 |
-3.76e-02 |
6.49e-02 |
5.29e-01 |
Detoxification-of-Reactive-Oxygen-Species |
33 |
6.14e-01 |
7.38e-01 |
0.11700 |
-0.065000 |
-9.67e-02 |
5.19e-01 |
3.36e-01 |
Transport-to-the-Golgi-and-subsequent-modification |
145 |
2.99e-06 |
5.79e-05 |
0.11600 |
0.110000 |
-3.79e-02 |
2.23e-02 |
4.32e-01 |
Cellular-responses-to-stress |
435 |
8.10e-03 |
4.37e-02 |
0.11600 |
-0.078600 |
-8.58e-02 |
5.16e-03 |
2.26e-03 |
Erythropoietin-activates-Phosphoinositide-3-kinase-(PI3K) |
11 |
6.55e-01 |
7.62e-01 |
0.11600 |
0.113000 |
2.50e-02 |
5.16e-01 |
8.86e-01 |
Antigen-processing:-Ubiquitination-&-Proteasome-degradation |
274 |
4.18e-02 |
1.48e-01 |
0.11600 |
-0.074600 |
-8.86e-02 |
3.41e-02 |
1.19e-02 |
Other-interleukin-signaling |
19 |
5.82e-01 |
7.24e-01 |
0.11600 |
0.038800 |
1.09e-01 |
7.70e-01 |
4.11e-01 |
HCMV-Infection |
80 |
2.50e-03 |
1.65e-02 |
0.11500 |
0.113000 |
-2.17e-02 |
8.02e-02 |
7.37e-01 |
IRE1alpha-activates-chaperones |
50 |
1.69e-02 |
7.37e-02 |
0.11500 |
0.111000 |
-3.08e-02 |
1.75e-01 |
7.06e-01 |
Acyl-chain-remodelling-of-PS |
14 |
7.03e-01 |
8.03e-01 |
0.11500 |
-0.043300 |
-1.07e-01 |
7.79e-01 |
4.90e-01 |
Formation-of-the-cornified-envelope |
17 |
2.31e-01 |
4.30e-01 |
0.11500 |
0.109000 |
-3.72e-02 |
4.37e-01 |
7.90e-01 |
Transcriptional-Regulation-by-VENTX |
34 |
3.07e-01 |
5.12e-01 |
0.11500 |
0.111000 |
2.90e-02 |
2.62e-01 |
7.70e-01 |
GPCR-ligand-binding |
157 |
4.65e-02 |
1.57e-01 |
0.11400 |
0.102000 |
5.13e-02 |
2.81e-02 |
2.68e-01 |
Asparagine-N-linked-glycosylation |
251 |
7.80e-09 |
2.56e-07 |
0.11400 |
0.111000 |
-2.45e-02 |
2.51e-03 |
5.05e-01 |
Retrograde-transport-at-the-Trans-Golgi-Network |
46 |
1.11e-02 |
5.52e-02 |
0.11300 |
0.064400 |
-9.32e-02 |
4.50e-01 |
2.75e-01 |
Negative-regulators-of-DDX58/IFIH1-signaling |
32 |
3.31e-01 |
5.31e-01 |
0.11300 |
0.027200 |
1.10e-01 |
7.90e-01 |
2.83e-01 |
Cellular-responses-to-external-stimuli |
438 |
1.01e-02 |
5.19e-02 |
0.11300 |
-0.075100 |
-8.40e-02 |
7.30e-03 |
2.70e-03 |
Regulation-of-Complement-cascade |
22 |
7.68e-01 |
8.41e-01 |
0.11200 |
-0.068400 |
-8.92e-02 |
5.79e-01 |
4.69e-01 |
Negative-regulation-of-the-PI3K/AKT-network |
87 |
3.36e-01 |
5.35e-01 |
0.11200 |
0.090800 |
6.58e-02 |
1.44e-01 |
2.89e-01 |
Inositol-phosphate-metabolism |
42 |
6.09e-01 |
7.37e-01 |
0.11200 |
0.068400 |
8.87e-02 |
4.43e-01 |
3.20e-01 |
Recruitment-of-NuMA-to-mitotic-centrosomes |
78 |
1.04e-01 |
2.64e-01 |
0.11200 |
0.107000 |
3.38e-02 |
1.03e-01 |
6.06e-01 |
Immune-System |
1477 |
5.03e-07 |
1.19e-05 |
0.11200 |
0.085000 |
7.26e-02 |
7.86e-08 |
4.51e-06 |
Butyrate-Response-Factor-1-(BRF1)-binds-and-destabilizes-mRNA |
16 |
7.38e-01 |
8.24e-01 |
0.11200 |
-0.099800 |
-5.03e-02 |
4.90e-01 |
7.28e-01 |
Regulation-of-TP53-Activity-through-Methylation |
17 |
2.93e-01 |
5.00e-01 |
0.11100 |
-0.109000 |
2.41e-02 |
4.38e-01 |
8.64e-01 |
Response-of-Mtb-to-phagocytosis |
21 |
6.71e-01 |
7.78e-01 |
0.11100 |
-0.049100 |
-9.92e-02 |
6.97e-01 |
4.31e-01 |
CTLA4-inhibitory-signaling |
19 |
6.32e-01 |
7.50e-01 |
0.11000 |
-0.103000 |
-3.96e-02 |
4.38e-01 |
7.65e-01 |
Frs2-mediated-activation |
11 |
5.37e-01 |
6.93e-01 |
0.11000 |
0.110000 |
-4.75e-03 |
5.27e-01 |
9.78e-01 |
COPII-mediated-vesicle-transport |
58 |
7.93e-03 |
4.31e-02 |
0.11000 |
0.043800 |
-1.01e-01 |
5.65e-01 |
1.85e-01 |
Myogenesis |
22 |
4.03e-01 |
5.94e-01 |
0.10900 |
0.109000 |
1.41e-02 |
3.78e-01 |
9.09e-01 |
Misspliced-GSK3beta-mutants-stabilize-beta-catenin |
15 |
6.41e-01 |
7.51e-01 |
0.10900 |
0.105000 |
2.98e-02 |
4.82e-01 |
8.41e-01 |
S33-mutants-of-beta-catenin-aren't-phosphorylated |
15 |
6.41e-01 |
7.51e-01 |
0.10900 |
0.105000 |
2.98e-02 |
4.82e-01 |
8.41e-01 |
S37-mutants-of-beta-catenin-aren't-phosphorylated |
15 |
6.41e-01 |
7.51e-01 |
0.10900 |
0.105000 |
2.98e-02 |
4.82e-01 |
8.41e-01 |
S45-mutants-of-beta-catenin-aren't-phosphorylated |
15 |
6.41e-01 |
7.51e-01 |
0.10900 |
0.105000 |
2.98e-02 |
4.82e-01 |
8.41e-01 |
T41-mutants-of-beta-catenin-aren't-phosphorylated |
15 |
6.41e-01 |
7.51e-01 |
0.10900 |
0.105000 |
2.98e-02 |
4.82e-01 |
8.41e-01 |
phosphorylation-site-mutants-of-CTNNB1-are-not-targeted-to-the-proteasome-by-the-destruction-complex |
15 |
6.41e-01 |
7.51e-01 |
0.10900 |
0.105000 |
2.98e-02 |
4.82e-01 |
8.41e-01 |
Interferon-Signaling |
141 |
9.06e-03 |
4.77e-02 |
0.10800 |
0.023500 |
1.06e-01 |
6.31e-01 |
3.03e-02 |
Extension-of-Telomeres |
28 |
4.85e-01 |
6.58e-01 |
0.10800 |
0.034600 |
1.02e-01 |
7.51e-01 |
3.48e-01 |
NoRC-negatively-regulates-rRNA-expression |
47 |
6.18e-01 |
7.41e-01 |
0.10800 |
-0.082800 |
-6.87e-02 |
3.27e-01 |
4.15e-01 |
Cooperation-of-Prefoldin-and-TriC/CCT--in-actin-and-tubulin-folding |
26 |
9.70e-02 |
2.50e-01 |
0.10700 |
-0.081600 |
6.93e-02 |
4.71e-01 |
5.41e-01 |
G-alpha-(12/13)-signalling-events |
70 |
3.78e-01 |
5.71e-01 |
0.10700 |
0.055400 |
9.12e-02 |
4.23e-01 |
1.87e-01 |
Signaling-by-EGFR-in-Cancer |
22 |
4.39e-01 |
6.25e-01 |
0.10700 |
0.105000 |
1.63e-02 |
3.92e-01 |
8.95e-01 |
PLC-beta-mediated-events |
45 |
3.51e-01 |
5.46e-01 |
0.10700 |
0.037100 |
1.00e-01 |
6.67e-01 |
2.46e-01 |
Transport-of-small-molecules |
492 |
7.64e-03 |
4.20e-02 |
0.10700 |
-0.067200 |
-8.26e-02 |
1.11e-02 |
1.80e-03 |
SUMOylation-of-ubiquitinylation-proteins |
37 |
5.02e-01 |
6.68e-01 |
0.10600 |
-0.044900 |
-9.63e-02 |
6.37e-01 |
3.11e-01 |
Physiological-factors |
11 |
8.00e-01 |
8.60e-01 |
0.10600 |
0.041900 |
9.76e-02 |
8.10e-01 |
5.75e-01 |
Regulation-of-TP53-Degradation |
34 |
7.13e-01 |
8.08e-01 |
0.10600 |
-0.081500 |
-6.78e-02 |
4.11e-01 |
4.94e-01 |
Transcription-of-E2F-targets-under-negative-control-by-DREAM-complex |
18 |
6.21e-01 |
7.44e-01 |
0.10600 |
0.101000 |
3.12e-02 |
4.58e-01 |
8.19e-01 |
SLC-mediated-transmembrane-transport |
150 |
1.18e-01 |
2.89e-01 |
0.10600 |
0.091400 |
5.33e-02 |
5.38e-02 |
2.61e-01 |
Cytochrome-P450---arranged-by-substrate-type |
27 |
7.31e-01 |
8.21e-01 |
0.10600 |
-0.060700 |
-8.65e-02 |
5.85e-01 |
4.36e-01 |
ADP-signalling-through-P2Y-purinoceptor-1 |
17 |
2.98e-01 |
5.06e-01 |
0.10500 |
0.100000 |
-3.25e-02 |
4.74e-01 |
8.17e-01 |
SUMOylation-of-chromatin-organization-proteins |
55 |
8.39e-02 |
2.32e-01 |
0.10500 |
-0.003940 |
-1.05e-01 |
9.60e-01 |
1.78e-01 |
Transferrin-endocytosis-and-recycling |
25 |
6.23e-01 |
7.45e-01 |
0.10500 |
0.095900 |
4.30e-02 |
4.07e-01 |
7.10e-01 |
Interleukin-17-signaling |
63 |
1.63e-01 |
3.56e-01 |
0.10500 |
-0.026700 |
-1.02e-01 |
7.14e-01 |
1.64e-01 |
Membrane-Trafficking |
530 |
1.50e-08 |
4.57e-07 |
0.10500 |
0.103000 |
1.75e-02 |
5.05e-05 |
4.93e-01 |
Gap-filling-DNA-repair-synthesis-and-ligation-in-TC-NER |
63 |
4.77e-01 |
6.53e-01 |
0.10500 |
-0.086600 |
-5.87e-02 |
2.35e-01 |
4.21e-01 |
Base-Excision-Repair,-AP-Site-Formation |
17 |
8.11e-01 |
8.65e-01 |
0.10500 |
0.057100 |
8.75e-02 |
6.83e-01 |
5.32e-01 |
ERCC6-(CSB)-and-EHMT2-(G9a)-positively-regulate-rRNA-expression |
16 |
3.05e-01 |
5.12e-01 |
0.10400 |
0.040100 |
-9.60e-02 |
7.81e-01 |
5.06e-01 |
Endogenous-sterols |
17 |
2.46e-01 |
4.44e-01 |
0.10400 |
0.085700 |
-5.88e-02 |
5.41e-01 |
6.75e-01 |
Metabolism-of-carbohydrates |
237 |
3.16e-04 |
3.13e-03 |
0.10400 |
0.102000 |
1.71e-02 |
6.78e-03 |
6.50e-01 |
Interactions-of-Rev-with-host-cellular-proteins |
34 |
6.01e-01 |
7.34e-01 |
0.10400 |
-0.049500 |
-9.11e-02 |
6.18e-01 |
3.58e-01 |
Formation-of-a-pool-of-free-40S-subunits |
70 |
1.94e-01 |
3.91e-01 |
0.10400 |
-0.033500 |
-9.80e-02 |
6.29e-01 |
1.57e-01 |
Signaling-by-ERBB2-KD-Mutants |
23 |
3.19e-01 |
5.22e-01 |
0.10300 |
0.103000 |
-4.67e-03 |
3.92e-01 |
9.69e-01 |
Vpr-mediated-nuclear-import-of-PICs |
31 |
4.43e-01 |
6.28e-01 |
0.10300 |
-0.028600 |
-9.91e-02 |
7.83e-01 |
3.40e-01 |
TP53-Regulates-Transcription-of-Cell-Cycle-Genes |
45 |
4.92e-01 |
6.61e-01 |
0.10300 |
0.091500 |
4.69e-02 |
2.88e-01 |
5.86e-01 |
SHC-mediated-cascade:FGFR2 |
14 |
5.82e-01 |
7.24e-01 |
0.10300 |
-0.009910 |
-1.02e-01 |
9.49e-01 |
5.08e-01 |
Neurotransmitter-receptors-and-postsynaptic-signal-transmission |
119 |
9.17e-02 |
2.42e-01 |
0.10300 |
0.095300 |
3.81e-02 |
7.30e-02 |
4.73e-01 |
Signaling-by-Interleukins |
331 |
5.30e-02 |
1.74e-01 |
0.10300 |
0.077400 |
6.73e-02 |
1.59e-02 |
3.60e-02 |
PKA-activation |
15 |
7.34e-01 |
8.22e-01 |
0.10200 |
-0.037200 |
-9.54e-02 |
8.03e-01 |
5.23e-01 |
Vesicle-mediated-transport |
560 |
1.04e-07 |
2.77e-06 |
0.10200 |
0.099800 |
2.24e-02 |
5.99e-05 |
3.68e-01 |
TCF-dependent-signaling-in-response-to-WNT |
151 |
2.75e-01 |
4.83e-01 |
0.10200 |
-0.070900 |
-7.32e-02 |
1.33e-01 |
1.21e-01 |
Activation-of-GABAB-receptors |
27 |
7.92e-01 |
8.55e-01 |
0.10200 |
0.070200 |
7.37e-02 |
5.28e-01 |
5.08e-01 |
GABA-B-receptor-activation |
27 |
7.92e-01 |
8.55e-01 |
0.10200 |
0.070200 |
7.37e-02 |
5.28e-01 |
5.08e-01 |
Dual-incision-in-TC-NER |
64 |
5.79e-01 |
7.22e-01 |
0.10200 |
-0.073400 |
-7.02e-02 |
3.11e-01 |
3.32e-01 |
TICAM1,-RIP1-mediated-IKK-complex-recruitment |
18 |
3.15e-01 |
5.19e-01 |
0.10100 |
0.028300 |
-9.74e-02 |
8.35e-01 |
4.75e-01 |
HCMV-Late-Events |
54 |
2.98e-02 |
1.14e-01 |
0.10100 |
0.096000 |
-3.10e-02 |
2.23e-01 |
6.94e-01 |
Ub-specific-processing-proteases |
151 |
1.46e-02 |
6.62e-02 |
0.10100 |
-0.098100 |
-2.31e-02 |
3.77e-02 |
6.25e-01 |
Cargo-recognition-for-clathrin-mediated-endocytosis |
85 |
6.34e-02 |
1.94e-01 |
0.10100 |
0.099400 |
1.65e-02 |
1.14e-01 |
7.93e-01 |
NS1-Mediated-Effects-on-Host-Pathways |
38 |
4.99e-01 |
6.65e-01 |
0.10000 |
-0.039100 |
-9.23e-02 |
6.77e-01 |
3.25e-01 |
MET-activates-RAS-signaling |
10 |
5.68e-01 |
7.15e-01 |
0.09950 |
0.097600 |
-1.95e-02 |
5.93e-01 |
9.15e-01 |
Insertion-of-tail-anchored-proteins-into-the-endoplasmic-reticulum-membrane |
19 |
8.38e-01 |
8.88e-01 |
0.09930 |
0.060800 |
7.85e-02 |
6.47e-01 |
5.53e-01 |
Initiation-of-Nuclear-Envelope-Reformation |
12 |
4.06e-01 |
5.94e-01 |
0.09890 |
0.080700 |
-5.72e-02 |
6.28e-01 |
7.32e-01 |
Nuclear-Envelope-Reassembly |
12 |
4.06e-01 |
5.94e-01 |
0.09890 |
0.080700 |
-5.72e-02 |
6.28e-01 |
7.32e-01 |
RIPK1-mediated-regulated-necrosis |
14 |
4.31e-01 |
6.15e-01 |
0.09870 |
0.095100 |
-2.65e-02 |
5.38e-01 |
8.64e-01 |
Regulated-Necrosis |
14 |
4.31e-01 |
6.15e-01 |
0.09870 |
0.095100 |
-2.65e-02 |
5.38e-01 |
8.64e-01 |
Organelle-biogenesis-and-maintenance |
264 |
3.42e-02 |
1.26e-01 |
0.09840 |
-0.048200 |
-8.58e-02 |
1.79e-01 |
1.67e-02 |
PI3K/AKT-Signaling-in-Cancer |
81 |
4.18e-01 |
6.04e-01 |
0.09830 |
0.082200 |
5.40e-02 |
2.01e-01 |
4.01e-01 |
Formation-of-RNA-Pol-II-elongation-complex |
56 |
6.12e-01 |
7.38e-01 |
0.09830 |
-0.076700 |
-6.16e-02 |
3.21e-01 |
4.25e-01 |
RNA-Polymerase-II-Transcription-Elongation |
56 |
6.12e-01 |
7.38e-01 |
0.09830 |
-0.076700 |
-6.16e-02 |
3.21e-01 |
4.25e-01 |
Plasma-lipoprotein-assembly,-remodeling,-and-clearance |
52 |
2.93e-01 |
5.00e-01 |
0.09800 |
-0.027400 |
-9.41e-02 |
7.33e-01 |
2.41e-01 |
GABA-receptor-activation |
32 |
7.72e-01 |
8.44e-01 |
0.09790 |
0.072600 |
6.57e-02 |
4.77e-01 |
5.21e-01 |
SRP-dependent-cotranslational-protein-targeting-to-membrane |
80 |
5.43e-02 |
1.77e-01 |
0.09780 |
-0.007340 |
-9.75e-02 |
9.10e-01 |
1.32e-01 |
Signaling-by-VEGF |
98 |
4.46e-01 |
6.30e-01 |
0.09750 |
0.063300 |
7.41e-02 |
2.79e-01 |
2.05e-01 |
Cyclin-D-associated-events-in-G1 |
43 |
2.22e-01 |
4.21e-01 |
0.09720 |
0.096800 |
8.87e-03 |
2.73e-01 |
9.20e-01 |
G1-Phase |
43 |
2.22e-01 |
4.21e-01 |
0.09720 |
0.096800 |
8.87e-03 |
2.73e-01 |
9.20e-01 |
RNA-Polymerase-III-Transcription-Initiation-From-Type-2-Promoter |
25 |
8.09e-01 |
8.65e-01 |
0.09690 |
-0.075300 |
-6.09e-02 |
5.15e-01 |
5.98e-01 |
Cell-Cycle-Checkpoints |
233 |
2.67e-02 |
1.05e-01 |
0.09680 |
0.040300 |
8.80e-02 |
2.90e-01 |
2.09e-02 |
Defective-TPR-may-confer-susceptibility-towards-thyroid-papillary-carcinoma-(TPC) |
30 |
5.05e-01 |
6.69e-01 |
0.09680 |
-0.027500 |
-9.28e-02 |
7.95e-01 |
3.79e-01 |
Regulation-of-Glucokinase-by-Glucokinase-Regulatory-Protein |
30 |
5.05e-01 |
6.69e-01 |
0.09680 |
-0.027500 |
-9.28e-02 |
7.95e-01 |
3.79e-01 |
Beta-catenin-phosphorylation-cascade |
17 |
3.41e-01 |
5.38e-01 |
0.09640 |
0.089300 |
-3.63e-02 |
5.24e-01 |
7.96e-01 |
Signaling-by-GPCR |
418 |
4.36e-02 |
1.52e-01 |
0.09580 |
0.065000 |
7.04e-02 |
2.32e-02 |
1.40e-02 |
IRS-related-events-triggered-by-IGF1R |
37 |
6.06e-01 |
7.35e-01 |
0.09580 |
0.085100 |
4.40e-02 |
3.71e-01 |
6.43e-01 |
Signaling-by-NTRKs |
91 |
2.16e-02 |
8.99e-02 |
0.09560 |
0.095600 |
-3.74e-03 |
1.15e-01 |
9.51e-01 |
Ras-activation-upon-Ca2+-influx-through-NMDA-receptor |
14 |
4.40e-01 |
6.25e-01 |
0.09560 |
0.091000 |
-2.94e-02 |
5.56e-01 |
8.49e-01 |
RUNX1-regulates-genes-involved-in-megakaryocyte-differentiation-and-platelet-function |
34 |
2.36e-01 |
4.35e-01 |
0.09540 |
-0.095300 |
4.40e-03 |
3.37e-01 |
9.65e-01 |
G2/M-Checkpoints |
125 |
1.43e-04 |
1.68e-03 |
0.09520 |
-0.065300 |
6.92e-02 |
2.08e-01 |
1.82e-01 |
MASTL-Facilitates-Mitotic-Progression |
10 |
8.08e-01 |
8.65e-01 |
0.09510 |
0.090800 |
2.82e-02 |
6.19e-01 |
8.77e-01 |
Signaling-by-NTRK1-(TRKA) |
73 |
4.63e-02 |
1.57e-01 |
0.09450 |
0.094300 |
-5.17e-03 |
1.64e-01 |
9.39e-01 |
Processing-of-DNA-double-strand-break-ends |
58 |
2.25e-01 |
4.23e-01 |
0.09430 |
0.019900 |
9.22e-02 |
7.93e-01 |
2.25e-01 |
Export-of-Viral-Ribonucleoproteins-from-Nucleus |
31 |
6.89e-01 |
7.92e-01 |
0.09400 |
-0.045600 |
-8.22e-02 |
6.60e-01 |
4.28e-01 |
Signaling-by-Hedgehog |
122 |
2.53e-01 |
4.52e-01 |
0.09390 |
0.047200 |
8.11e-02 |
3.68e-01 |
1.22e-01 |
Translesion-synthesis-by-Y-family-DNA-polymerases-bypasses-lesions-on-DNA-template |
37 |
1.93e-01 |
3.90e-01 |
0.09380 |
-0.009450 |
9.33e-02 |
9.21e-01 |
3.26e-01 |
RET-signaling |
36 |
4.64e-01 |
6.44e-01 |
0.09370 |
0.089800 |
2.67e-02 |
3.51e-01 |
7.82e-01 |
Metabolism-of-steroids |
104 |
1.57e-01 |
3.47e-01 |
0.09290 |
-0.031900 |
-8.72e-02 |
5.74e-01 |
1.25e-01 |
VEGFR2-mediated-cell-proliferation |
19 |
8.26e-01 |
8.78e-01 |
0.09240 |
0.049200 |
7.82e-02 |
7.11e-01 |
5.55e-01 |
SUMOylation-of-RNA-binding-proteins |
46 |
1.48e-01 |
3.35e-01 |
0.09230 |
0.007130 |
-9.20e-02 |
9.33e-01 |
2.81e-01 |
PKA-mediated-phosphorylation-of-CREB |
17 |
7.57e-01 |
8.35e-01 |
0.09210 |
-0.034100 |
-8.56e-02 |
8.08e-01 |
5.41e-01 |
Gamma-carboxylation,-hypusine-formation-and-arylsulfatase-activation |
27 |
7.67e-01 |
8.41e-01 |
0.09190 |
0.077600 |
4.93e-02 |
4.85e-01 |
6.57e-01 |
Uptake-and-function-of-anthrax-toxins |
10 |
8.41e-01 |
8.89e-01 |
0.09150 |
-0.031700 |
-8.58e-02 |
8.62e-01 |
6.38e-01 |
Oxidative-Stress-Induced-Senescence |
62 |
1.81e-01 |
3.75e-01 |
0.09150 |
-0.013800 |
-9.04e-02 |
8.51e-01 |
2.18e-01 |
TBC/RABGAPs |
42 |
2.15e-01 |
4.14e-01 |
0.09140 |
0.000542 |
-9.14e-02 |
9.95e-01 |
3.06e-01 |
Innate-Immune-System |
746 |
7.02e-03 |
3.91e-02 |
0.09130 |
0.067000 |
6.21e-02 |
2.01e-03 |
4.21e-03 |
PRC2-methylates-histones-and-DNA |
13 |
6.03e-01 |
7.34e-01 |
0.09110 |
0.004290 |
-9.10e-02 |
9.79e-01 |
5.70e-01 |
NRIF-signals-cell-death-from-the-nucleus |
16 |
8.26e-01 |
8.78e-01 |
0.09110 |
0.080500 |
4.26e-02 |
5.77e-01 |
7.68e-01 |
Inhibition-of-replication-initiation-of-damaged-DNA-by-RB1/E2F1 |
13 |
9.08e-01 |
9.35e-01 |
0.09090 |
0.057500 |
7.04e-02 |
7.20e-01 |
6.60e-01 |
Platelet-homeostasis |
64 |
6.47e-01 |
7.56e-01 |
0.09080 |
0.064200 |
6.42e-02 |
3.75e-01 |
3.75e-01 |
Termination-of-translesion-DNA-synthesis |
31 |
1.79e-01 |
3.72e-01 |
0.09070 |
-0.033300 |
8.44e-02 |
7.49e-01 |
4.16e-01 |
SHC-mediated-cascade:FGFR1 |
11 |
4.92e-01 |
6.61e-01 |
0.09050 |
0.062800 |
-6.52e-02 |
7.18e-01 |
7.08e-01 |
Adherens-junctions-interactions |
20 |
2.78e-01 |
4.84e-01 |
0.09050 |
0.058500 |
-6.90e-02 |
6.51e-01 |
5.93e-01 |
IRAK2-mediated-activation-of-TAK1-complex |
10 |
7.06e-01 |
8.03e-01 |
0.08960 |
-0.000215 |
-8.96e-02 |
9.99e-01 |
6.24e-01 |
PERK-regulates-gene-expression |
29 |
6.25e-01 |
7.46e-01 |
0.08960 |
-0.083800 |
-3.17e-02 |
4.35e-01 |
7.68e-01 |
Cell-Cycle,-Mitotic |
436 |
5.69e-02 |
1.83e-01 |
0.08960 |
0.066200 |
6.03e-02 |
1.83e-02 |
3.16e-02 |
Metabolic-disorders-of-biological-oxidation-enzymes |
17 |
3.51e-01 |
5.46e-01 |
0.08950 |
-0.051800 |
7.30e-02 |
7.12e-01 |
6.02e-01 |
Translesion-synthesis-by-REV1 |
16 |
6.40e-01 |
7.51e-01 |
0.08940 |
-0.088700 |
-1.10e-02 |
5.39e-01 |
9.40e-01 |
Signaling-by-Nuclear-Receptors |
200 |
5.01e-02 |
1.67e-01 |
0.08940 |
-0.033600 |
-8.28e-02 |
4.14e-01 |
4.39e-02 |
Response-of-EIF2AK4-(GCN2)-to-amino-acid-deficiency |
70 |
6.31e-01 |
7.50e-01 |
0.08920 |
-0.064000 |
-6.21e-02 |
3.55e-01 |
3.69e-01 |
Hedgehog-'on'-state |
77 |
1.07e-02 |
5.42e-02 |
0.08920 |
-0.045400 |
7.67e-02 |
4.91e-01 |
2.45e-01 |
Negative-regulation-of-FGFR2-signaling |
25 |
6.30e-01 |
7.49e-01 |
0.08890 |
-0.026600 |
-8.49e-02 |
8.18e-01 |
4.63e-01 |
Signaling-by-ERBB4 |
48 |
3.13e-01 |
5.18e-01 |
0.08830 |
0.086900 |
1.58e-02 |
2.98e-01 |
8.50e-01 |
RHO-GTPases-activate-IQGAPs |
10 |
8.93e-01 |
9.25e-01 |
0.08810 |
0.078100 |
4.07e-02 |
6.69e-01 |
8.24e-01 |
DCC-mediated-attractive-signaling |
13 |
7.48e-01 |
8.30e-01 |
0.08810 |
-0.086100 |
-1.88e-02 |
5.91e-01 |
9.07e-01 |
MAP3K8-(TPL2)-dependent-MAPK1/3-activation |
16 |
8.48e-01 |
8.96e-01 |
0.08790 |
0.076500 |
4.32e-02 |
5.96e-01 |
7.65e-01 |
Prolonged-ERK-activation-events |
13 |
5.32e-01 |
6.90e-01 |
0.08770 |
0.083900 |
-2.56e-02 |
6.01e-01 |
8.73e-01 |
Transport-of-bile-salts-and-organic-acids,-metal-ions-and-amine-compounds |
46 |
6.45e-01 |
7.54e-01 |
0.08740 |
0.075000 |
4.48e-02 |
3.79e-01 |
5.99e-01 |
Rev-mediated-nuclear-export-of-HIV-RNA |
33 |
7.05e-01 |
8.03e-01 |
0.08720 |
-0.041600 |
-7.66e-02 |
6.79e-01 |
4.47e-01 |
Early-Phase-of-HIV-Life-Cycle |
11 |
8.53e-01 |
8.98e-01 |
0.08700 |
-0.080700 |
-3.26e-02 |
6.43e-01 |
8.51e-01 |
Regulation-of-gene-expression-by-Hypoxia-inducible-Factor |
10 |
7.99e-01 |
8.59e-01 |
0.08700 |
-0.017300 |
-8.52e-02 |
9.24e-01 |
6.41e-01 |
Chromatin-modifying-enzymes |
194 |
1.00e-02 |
5.17e-02 |
0.08700 |
-0.014700 |
-8.57e-02 |
7.24e-01 |
4.00e-02 |
Chromatin-organization |
194 |
1.00e-02 |
5.17e-02 |
0.08700 |
-0.014700 |
-8.57e-02 |
7.24e-01 |
4.00e-02 |
Generation-of-second-messenger-molecules |
16 |
7.34e-01 |
8.22e-01 |
0.08690 |
0.083900 |
2.29e-02 |
5.62e-01 |
8.74e-01 |
TNFR2-non-canonical-NF-kB-pathway |
76 |
1.34e-02 |
6.31e-02 |
0.08670 |
-0.072700 |
4.73e-02 |
2.74e-01 |
4.77e-01 |
Antiviral-mechanism-by-IFN-stimulated-genes |
74 |
5.09e-01 |
6.73e-01 |
0.08650 |
-0.073900 |
-4.49e-02 |
2.72e-01 |
5.05e-01 |
Cell-Cycle |
519 |
4.15e-02 |
1.48e-01 |
0.08630 |
0.064500 |
5.73e-02 |
1.24e-02 |
2.64e-02 |
mRNA-decay-by-3'-to-5'-exoribonuclease |
15 |
6.39e-01 |
7.51e-01 |
0.08610 |
-0.086000 |
-3.96e-03 |
5.64e-01 |
9.79e-01 |
Signaling-by-WNT-in-cancer |
28 |
2.03e-01 |
4.02e-01 |
0.08560 |
0.067400 |
-5.28e-02 |
5.37e-01 |
6.29e-01 |
Cholesterol-biosynthesis |
23 |
8.60e-01 |
9.01e-01 |
0.08560 |
-0.054300 |
-6.61e-02 |
6.52e-01 |
5.83e-01 |
RNA-Polymerase-III-Transcription-Initiation-From-Type-1-Promoter |
26 |
8.52e-01 |
8.98e-01 |
0.08520 |
-0.063400 |
-5.69e-02 |
5.76e-01 |
6.16e-01 |
Pausing-and-recovery-of-Tat-mediated-HIV-elongation |
29 |
3.82e-01 |
5.73e-01 |
0.08470 |
-0.084600 |
3.43e-03 |
4.30e-01 |
9.74e-01 |
Tat-mediated-HIV-elongation-arrest-and-recovery |
29 |
3.82e-01 |
5.73e-01 |
0.08470 |
-0.084600 |
3.43e-03 |
4.30e-01 |
9.74e-01 |
TP53-Regulates-Transcription-of-Genes-Involved-in-G2-Cell-Cycle-Arrest |
17 |
9.01e-01 |
9.31e-01 |
0.08440 |
0.063700 |
5.53e-02 |
6.49e-01 |
6.93e-01 |
Synthesis-of-Leukotrienes-(LT)-and-Eoxins-(EX) |
12 |
6.14e-01 |
7.38e-01 |
0.08440 |
0.016500 |
-8.27e-02 |
9.21e-01 |
6.20e-01 |
Antigen-processing-Cross-presentation |
85 |
1.88e-02 |
8.03e-02 |
0.08430 |
-0.079300 |
2.87e-02 |
2.07e-01 |
6.48e-01 |
DNA-Damage/Telomere-Stress-Induced-Senescence |
25 |
8.55e-01 |
8.99e-01 |
0.08430 |
0.064700 |
5.41e-02 |
5.76e-01 |
6.40e-01 |
RHO-GTPases-Activate-NADPH-Oxidases |
19 |
3.51e-01 |
5.46e-01 |
0.08420 |
0.051800 |
-6.64e-02 |
6.96e-01 |
6.16e-01 |
Estrogen-dependent-nuclear-events-downstream-of-ESR-membrane-signaling |
22 |
8.10e-01 |
8.65e-01 |
0.08390 |
0.073300 |
4.07e-02 |
5.52e-01 |
7.41e-01 |
Ion-transport-by-P-type-ATPases |
38 |
3.14e-01 |
5.19e-01 |
0.08360 |
-0.000184 |
8.36e-02 |
9.98e-01 |
3.73e-01 |
Calnexin/calreticulin-cycle |
25 |
7.64e-01 |
8.40e-01 |
0.08230 |
0.074100 |
3.58e-02 |
5.21e-01 |
7.56e-01 |
COPI-mediated-anterograde-transport |
74 |
4.93e-02 |
1.65e-01 |
0.08200 |
0.079300 |
-2.08e-02 |
2.39e-01 |
7.58e-01 |
rRNA-modification-in-the-nucleus-and-cytosol |
54 |
3.51e-01 |
5.46e-01 |
0.08170 |
0.017200 |
7.99e-02 |
8.28e-01 |
3.10e-01 |
The-role-of-Nef-in-HIV-1-replication-and-disease-pathogenesis |
24 |
5.07e-01 |
6.71e-01 |
0.08170 |
0.081700 |
1.32e-03 |
4.88e-01 |
9.91e-01 |
Protein-folding |
84 |
5.32e-01 |
6.90e-01 |
0.08150 |
0.044300 |
6.84e-02 |
4.83e-01 |
2.79e-01 |
PCP/CE-pathway |
87 |
4.76e-01 |
6.53e-01 |
0.08120 |
-0.070300 |
-4.05e-02 |
2.57e-01 |
5.14e-01 |
E2F-mediated-regulation-of-DNA-replication |
22 |
8.21e-01 |
8.73e-01 |
0.08090 |
0.039100 |
7.09e-02 |
7.51e-01 |
5.65e-01 |
NOTCH3-Activation-and-Transmission-of-Signal-to-the-Nucleus |
25 |
5.21e-01 |
6.84e-01 |
0.08090 |
-0.004150 |
-8.08e-02 |
9.71e-01 |
4.85e-01 |
NF-kB-activation-through-FADD/RIP-1-pathway-mediated-by-caspase-8-and--10 |
10 |
5.98e-01 |
7.33e-01 |
0.08080 |
-0.056000 |
5.83e-02 |
7.59e-01 |
7.50e-01 |
ER-to-Golgi-Anterograde-Transport |
120 |
2.34e-03 |
1.60e-02 |
0.08030 |
0.055100 |
-5.85e-02 |
2.98e-01 |
2.69e-01 |
Late-Phase-of-HIV-Life-Cycle |
127 |
1.64e-01 |
3.56e-01 |
0.08010 |
-0.025400 |
-7.60e-02 |
6.22e-01 |
1.40e-01 |
B-WICH-complex-positively-regulates-rRNA-expression |
32 |
2.14e-01 |
4.14e-01 |
0.08010 |
-0.067900 |
4.25e-02 |
5.07e-01 |
6.78e-01 |
Homology-Directed-Repair |
95 |
3.04e-01 |
5.11e-01 |
0.08000 |
0.029100 |
7.46e-02 |
6.24e-01 |
2.10e-01 |
Neutrophil-degranulation |
356 |
9.72e-02 |
2.50e-01 |
0.07990 |
0.065600 |
4.56e-02 |
3.41e-02 |
1.41e-01 |
NOTCH3-Intracellular-Domain-Regulates-Transcription |
22 |
4.36e-01 |
6.22e-01 |
0.07990 |
0.077800 |
-1.82e-02 |
5.28e-01 |
8.82e-01 |
MyD88-cascade-initiated-on-plasma-membrane |
77 |
2.92e-01 |
4.99e-01 |
0.07950 |
-0.021200 |
-7.66e-02 |
7.48e-01 |
2.45e-01 |
Toll-Like-Receptor-10-(TLR10)-Cascade |
77 |
2.92e-01 |
4.99e-01 |
0.07950 |
-0.021200 |
-7.66e-02 |
7.48e-01 |
2.45e-01 |
Toll-Like-Receptor-5-(TLR5)-Cascade |
77 |
2.92e-01 |
4.99e-01 |
0.07950 |
-0.021200 |
-7.66e-02 |
7.48e-01 |
2.45e-01 |
Antigen-Presentation:-Folding,-assembly-and-peptide-loading-of-class-I-MHC |
16 |
8.60e-01 |
9.01e-01 |
0.07950 |
-0.036200 |
-7.08e-02 |
8.02e-01 |
6.24e-01 |
Regulation-of-IFNG-signaling |
13 |
9.30e-01 |
9.51e-01 |
0.07930 |
-0.051000 |
-6.08e-02 |
7.50e-01 |
7.04e-01 |
G-alpha-(z)-signalling-events |
37 |
6.88e-01 |
7.91e-01 |
0.07910 |
0.034000 |
7.14e-02 |
7.21e-01 |
4.52e-01 |
Interleukin-7-signaling |
20 |
6.77e-01 |
7.82e-01 |
0.07900 |
-0.014000 |
-7.78e-02 |
9.14e-01 |
5.47e-01 |
Binding-and-Uptake-of-Ligands-by-Scavenger-Receptors |
32 |
3.42e-01 |
5.38e-01 |
0.07860 |
-0.012200 |
7.77e-02 |
9.05e-01 |
4.47e-01 |
HIV-Life-Cycle |
138 |
2.06e-01 |
4.06e-01 |
0.07850 |
-0.029900 |
-7.26e-02 |
5.45e-01 |
1.41e-01 |
Signaling-by-FGFR1-in-disease |
32 |
4.52e-01 |
6.32e-01 |
0.07800 |
-0.002970 |
-7.79e-02 |
9.77e-01 |
4.46e-01 |
Transcriptional-regulation-by-RUNX1 |
158 |
1.32e-01 |
3.15e-01 |
0.07770 |
-0.073300 |
-2.59e-02 |
1.12e-01 |
5.75e-01 |
Axon-guidance |
432 |
8.63e-02 |
2.35e-01 |
0.07670 |
0.061900 |
4.54e-02 |
2.82e-02 |
1.08e-01 |
Synthesis-of-IP3-and-IP4-in-the-cytosol |
22 |
4.38e-01 |
6.24e-01 |
0.07650 |
-0.023400 |
7.28e-02 |
8.49e-01 |
5.54e-01 |
Nonhomologous-End-Joining-(NHEJ) |
32 |
6.51e-01 |
7.59e-01 |
0.07600 |
-0.072500 |
-2.29e-02 |
4.78e-01 |
8.23e-01 |
DNA-Damage-Bypass |
46 |
3.39e-01 |
5.36e-01 |
0.07530 |
0.002080 |
7.53e-02 |
9.81e-01 |
3.77e-01 |
Arachidonic-acid-metabolism |
36 |
3.28e-01 |
5.29e-01 |
0.07520 |
0.074200 |
-1.22e-02 |
4.41e-01 |
8.99e-01 |
Synthesis-of-DNA |
112 |
1.44e-02 |
6.58e-02 |
0.07510 |
-0.070000 |
2.74e-02 |
2.01e-01 |
6.17e-01 |
Notch-HLH-transcription-pathway |
27 |
3.56e-01 |
5.49e-01 |
0.07480 |
0.069200 |
-2.85e-02 |
5.34e-01 |
7.98e-01 |
GPCR-downstream-signalling |
380 |
9.94e-02 |
2.54e-01 |
0.07430 |
0.040500 |
6.22e-02 |
1.77e-01 |
3.80e-02 |
TAK1-activates-NFkB-by-phosphorylation-and-activation-of-IKKs-complex |
24 |
6.03e-01 |
7.34e-01 |
0.07410 |
0.005390 |
7.39e-02 |
9.64e-01 |
5.31e-01 |
Cooperation-of-PDCL-(PhLP1)-and-TRiC/CCT-in-G-protein-beta-folding |
31 |
8.61e-01 |
9.01e-01 |
0.07370 |
0.047000 |
5.68e-02 |
6.50e-01 |
5.85e-01 |
Interleukin-2-signaling |
10 |
7.25e-01 |
8.16e-01 |
0.07350 |
0.017400 |
-7.14e-02 |
9.24e-01 |
6.96e-01 |
Class-A/1-(Rhodopsin-like-receptors) |
108 |
2.46e-01 |
4.44e-01 |
0.07330 |
0.070300 |
2.09e-02 |
2.08e-01 |
7.08e-01 |
HSP90-chaperone-cycle-for-steroid-hormone-receptors-(SHR) |
31 |
4.92e-01 |
6.61e-01 |
0.07240 |
-0.072400 |
7.82e-05 |
4.85e-01 |
9.99e-01 |
Presynaptic-function-of-Kainate-receptors |
15 |
7.09e-01 |
8.05e-01 |
0.07240 |
0.072400 |
-1.79e-04 |
6.27e-01 |
9.99e-01 |
PCNA-Dependent-Long-Patch-Base-Excision-Repair |
20 |
5.92e-01 |
7.29e-01 |
0.07240 |
-0.006680 |
7.21e-02 |
9.59e-01 |
5.77e-01 |
G-alpha-(i)-signalling-events |
192 |
2.74e-01 |
4.81e-01 |
0.07230 |
0.036000 |
6.27e-02 |
3.90e-01 |
1.35e-01 |
Toll-like-Receptor-Cascades |
133 |
3.31e-01 |
5.31e-01 |
0.07170 |
0.064800 |
3.06e-02 |
1.97e-01 |
5.43e-01 |
Negative-epigenetic-regulation-of-rRNA-expression |
50 |
7.57e-01 |
8.35e-01 |
0.07160 |
-0.059400 |
-4.00e-02 |
4.68e-01 |
6.25e-01 |
Other-semaphorin-interactions |
19 |
4.90e-01 |
6.61e-01 |
0.07150 |
0.034700 |
-6.26e-02 |
7.94e-01 |
6.37e-01 |
RNA-Polymerase-III-Chain-Elongation |
16 |
9.13e-01 |
9.39e-01 |
0.07140 |
-0.059600 |
-3.93e-02 |
6.80e-01 |
7.85e-01 |
Fatty-acyl-CoA-biosynthesis |
28 |
8.78e-01 |
9.16e-01 |
0.07120 |
-0.044500 |
-5.56e-02 |
6.84e-01 |
6.11e-01 |
Host-Interactions-with-Influenza-Factors |
39 |
5.59e-01 |
7.09e-01 |
0.07090 |
-0.014200 |
-6.95e-02 |
8.78e-01 |
4.53e-01 |
Translesion-synthesis-by-POLK |
17 |
5.71e-01 |
7.17e-01 |
0.07070 |
-0.066500 |
2.40e-02 |
6.35e-01 |
8.64e-01 |
Prefoldin-mediated-transfer-of-substrate--to-CCT/TriC |
24 |
3.95e-01 |
5.86e-01 |
0.07040 |
-0.044600 |
5.45e-02 |
7.06e-01 |
6.44e-01 |
Unfolded-Protein-Response-(UPR) |
86 |
1.36e-01 |
3.21e-01 |
0.07010 |
0.070000 |
-3.89e-03 |
2.63e-01 |
9.50e-01 |
RNA-Polymerase-II-Transcription |
957 |
2.44e-03 |
1.64e-02 |
0.06990 |
-0.033700 |
-6.12e-02 |
8.07e-02 |
1.51e-03 |
Activation-of-G-protein-gated-Potassium-channels |
15 |
8.92e-01 |
9.25e-01 |
0.06980 |
-0.030700 |
-6.27e-02 |
8.37e-01 |
6.74e-01 |
G-protein-gated-Potassium-channels |
15 |
8.92e-01 |
9.25e-01 |
0.06980 |
-0.030700 |
-6.27e-02 |
8.37e-01 |
6.74e-01 |
Inhibition--of-voltage-gated-Ca2+-channels-via-Gbeta/gamma-subunits |
15 |
8.92e-01 |
9.25e-01 |
0.06980 |
-0.030700 |
-6.27e-02 |
8.37e-01 |
6.74e-01 |
Glutathione-synthesis-and-recycling |
10 |
8.53e-01 |
8.98e-01 |
0.06980 |
0.010900 |
6.89e-02 |
9.52e-01 |
7.06e-01 |
Nuclear-Envelope-Breakdown |
51 |
3.04e-01 |
5.11e-01 |
0.06970 |
0.069600 |
-4.56e-03 |
3.90e-01 |
9.55e-01 |
ATF4-activates-genes-in-response-to-endoplasmic-reticulum--stress |
24 |
4.03e-01 |
5.93e-01 |
0.06970 |
-0.053900 |
4.42e-02 |
6.48e-01 |
7.08e-01 |
Class-I-MHC-mediated-antigen-processing-&-presentation |
323 |
2.18e-01 |
4.18e-01 |
0.06950 |
-0.040900 |
-5.62e-02 |
2.08e-01 |
8.37e-02 |
Telomere-Maintenance |
34 |
6.06e-01 |
7.35e-01 |
0.06940 |
0.012900 |
6.82e-02 |
8.96e-01 |
4.92e-01 |
Processing-and-activation-of-SUMO |
10 |
8.40e-01 |
8.89e-01 |
0.06910 |
0.068700 |
6.97e-03 |
7.07e-01 |
9.70e-01 |
KSRP-(KHSRP)-binds-and-destabilizes-mRNA |
16 |
7.68e-01 |
8.41e-01 |
0.06860 |
-0.068100 |
-8.34e-03 |
6.37e-01 |
9.54e-01 |
Purine-salvage |
11 |
8.98e-01 |
9.29e-01 |
0.06860 |
-0.023600 |
-6.44e-02 |
8.92e-01 |
7.12e-01 |
DNA-Replication |
119 |
1.33e-02 |
6.29e-02 |
0.06840 |
-0.052900 |
4.34e-02 |
3.20e-01 |
4.14e-01 |
ERKs-are-inactivated |
12 |
8.90e-01 |
9.25e-01 |
0.06800 |
-0.023100 |
-6.40e-02 |
8.90e-01 |
7.01e-01 |
G-beta:gamma-signalling-through-PI3Kgamma |
19 |
5.12e-01 |
6.76e-01 |
0.06790 |
0.056100 |
-3.83e-02 |
6.72e-01 |
7.73e-01 |
MAPK6/MAPK4-signaling |
81 |
2.79e-01 |
4.84e-01 |
0.06790 |
-0.067300 |
-8.93e-03 |
2.95e-01 |
8.90e-01 |
NOTCH4-Intracellular-Domain-Regulates-Transcription |
18 |
9.32e-01 |
9.52e-01 |
0.06750 |
0.044500 |
5.08e-02 |
7.44e-01 |
7.09e-01 |
Regulation-of-TP53-Activity-through-Phosphorylation |
88 |
1.95e-01 |
3.91e-01 |
0.06740 |
0.002260 |
6.74e-02 |
9.71e-01 |
2.75e-01 |
FCERI-mediated-Ca+2-mobilization |
26 |
9.05e-01 |
9.34e-01 |
0.06720 |
0.044800 |
5.00e-02 |
6.92e-01 |
6.59e-01 |
HCMV-Early-Events |
57 |
1.34e-01 |
3.17e-01 |
0.06700 |
0.047200 |
-4.76e-02 |
5.38e-01 |
5.35e-01 |
Negative-regulation-of-MAPK-pathway |
38 |
8.69e-01 |
9.08e-01 |
0.06700 |
-0.047500 |
-4.72e-02 |
6.12e-01 |
6.15e-01 |
Signaling-by-FGFR1 |
38 |
3.43e-01 |
5.38e-01 |
0.06670 |
0.063800 |
-1.97e-02 |
4.97e-01 |
8.34e-01 |
G1/S-Transition |
126 |
1.72e-02 |
7.47e-02 |
0.06660 |
-0.058500 |
3.19e-02 |
2.57e-01 |
5.37e-01 |
Infectious-disease |
362 |
9.88e-02 |
2.53e-01 |
0.06640 |
-0.030400 |
-5.91e-02 |
3.22e-01 |
5.46e-02 |
Signaling-by-FGFR |
67 |
7.19e-01 |
8.13e-01 |
0.06620 |
-0.036200 |
-5.55e-02 |
6.09e-01 |
4.33e-01 |
Signaling-by-cytosolic-FGFR1-fusion-mutants |
18 |
5.37e-01 |
6.93e-01 |
0.06620 |
-0.045700 |
4.80e-02 |
7.37e-01 |
7.25e-01 |
Plasma-lipoprotein-assembly |
14 |
6.40e-01 |
7.51e-01 |
0.06610 |
0.031200 |
-5.83e-02 |
8.40e-01 |
7.06e-01 |
SUMOylation-of-transcription-factors |
15 |
6.24e-01 |
7.45e-01 |
0.06610 |
0.030000 |
-5.89e-02 |
8.41e-01 |
6.93e-01 |
TNF-signaling |
42 |
8.07e-01 |
8.65e-01 |
0.06610 |
0.055900 |
3.52e-02 |
5.31e-01 |
6.93e-01 |
PIP3-activates-AKT-signaling |
237 |
3.56e-01 |
5.49e-01 |
0.06600 |
-0.038400 |
-5.36e-02 |
3.10e-01 |
1.56e-01 |
Chaperone-Mediated-Autophagy |
14 |
9.06e-01 |
9.34e-01 |
0.06580 |
-0.059500 |
-2.81e-02 |
7.00e-01 |
8.56e-01 |
MAPK-family-signaling-cascades |
242 |
4.05e-01 |
5.94e-01 |
0.06560 |
0.042100 |
5.02e-02 |
2.61e-01 |
1.79e-01 |
Gene-expression-(Transcription) |
1076 |
2.07e-03 |
1.45e-02 |
0.06540 |
-0.030400 |
-5.78e-02 |
9.59e-02 |
1.55e-03 |
Gap-filling-DNA-repair-synthesis-and-ligation-in-GG-NER |
24 |
4.59e-01 |
6.38e-01 |
0.06460 |
-0.039900 |
5.08e-02 |
7.35e-01 |
6.67e-01 |
Regulation-of-necroptotic-cell-death |
12 |
7.54e-01 |
8.34e-01 |
0.06460 |
0.012000 |
-6.34e-02 |
9.43e-01 |
7.04e-01 |
Tristetraprolin-(TTP,-ZFP36)-binds-and-destabilizes-mRNA |
16 |
6.73e-01 |
7.78e-01 |
0.06450 |
-0.062600 |
1.52e-02 |
6.65e-01 |
9.16e-01 |
Negative-regulation-of-FGFR1-signaling |
22 |
6.24e-01 |
7.45e-01 |
0.06440 |
0.007490 |
-6.40e-02 |
9.52e-01 |
6.03e-01 |
Interleukin-1-family-signaling |
114 |
8.79e-02 |
2.37e-01 |
0.06430 |
-0.063800 |
7.72e-03 |
2.40e-01 |
8.87e-01 |
Regulation-of-beta-cell-development |
19 |
9.25e-01 |
9.47e-01 |
0.06420 |
0.051900 |
3.78e-02 |
6.95e-01 |
7.75e-01 |
TP53-regulates-transcription-of-additional-cell-cycle-genes-whose-exact-role-in-the-p53-pathway-remain-uncertain |
18 |
8.28e-01 |
8.79e-01 |
0.06390 |
-0.016700 |
-6.16e-02 |
9.02e-01 |
6.51e-01 |
CD28-dependent-PI3K/Akt-signaling |
21 |
5.34e-01 |
6.91e-01 |
0.06350 |
-0.031900 |
5.50e-02 |
8.00e-01 |
6.63e-01 |
Mitotic-Prophase |
80 |
1.05e-01 |
2.65e-01 |
0.06340 |
0.026600 |
-5.76e-02 |
6.82e-01 |
3.73e-01 |
Fanconi-Anemia-Pathway |
34 |
5.53e-01 |
7.03e-01 |
0.06320 |
-0.063200 |
1.27e-04 |
5.24e-01 |
9.99e-01 |
Phase-2---plateau-phase |
16 |
6.26e-01 |
7.46e-01 |
0.06300 |
-0.031200 |
5.47e-02 |
8.29e-01 |
7.05e-01 |
Regulation-of-TP53-Activity-through-Acetylation |
28 |
8.61e-01 |
9.01e-01 |
0.06290 |
-0.030600 |
-5.49e-02 |
7.79e-01 |
6.15e-01 |
SUMOylation-of-DNA-damage-response-and-repair-proteins |
73 |
5.39e-01 |
6.93e-01 |
0.06270 |
-0.020700 |
-5.92e-02 |
7.60e-01 |
3.82e-01 |
Post-translational-protein-modification |
1122 |
8.61e-07 |
1.93e-05 |
0.06270 |
0.062100 |
8.38e-03 |
5.27e-04 |
6.40e-01 |
Intracellular-signaling-by-second-messengers |
272 |
3.81e-01 |
5.73e-01 |
0.06260 |
-0.038900 |
-4.91e-02 |
2.71e-01 |
1.65e-01 |
Deubiquitination |
220 |
8.02e-03 |
4.35e-02 |
0.06250 |
-0.061300 |
1.21e-02 |
1.18e-01 |
7.58e-01 |
Cellular-Senescence |
118 |
3.67e-02 |
1.34e-01 |
0.06250 |
0.055400 |
-2.87e-02 |
2.99e-01 |
5.90e-01 |
Metabolism-of-proteins |
1577 |
1.20e-07 |
3.14e-06 |
0.06240 |
-0.013100 |
-6.10e-02 |
3.93e-01 |
7.33e-05 |
Meiosis |
45 |
4.69e-01 |
6.48e-01 |
0.06220 |
0.062200 |
-5.39e-05 |
4.71e-01 |
1.00e+00 |
AKT-phosphorylates-targets-in-the-cytosol |
14 |
8.71e-01 |
9.09e-01 |
0.06140 |
-0.015700 |
-5.94e-02 |
9.19e-01 |
7.01e-01 |
Nuclear-Pore-Complex-(NPC)-Disassembly |
35 |
3.57e-01 |
5.51e-01 |
0.06140 |
0.047300 |
-3.92e-02 |
6.29e-01 |
6.88e-01 |
Nicotinamide-salvaging |
16 |
6.69e-01 |
7.77e-01 |
0.06130 |
-0.021700 |
5.73e-02 |
8.80e-01 |
6.92e-01 |
Cleavage-of-the-damaged-pyrimidine |
15 |
9.49e-01 |
9.65e-01 |
0.06110 |
0.037500 |
4.82e-02 |
8.01e-01 |
7.47e-01 |
Depyrimidination |
15 |
9.49e-01 |
9.65e-01 |
0.06110 |
0.037500 |
4.82e-02 |
8.01e-01 |
7.47e-01 |
Recognition-and-association-of-DNA-glycosylase-with-site-containing-an-affected-pyrimidine |
15 |
9.49e-01 |
9.65e-01 |
0.06110 |
0.037500 |
4.82e-02 |
8.01e-01 |
7.47e-01 |
FCERI-mediated-MAPK-activation |
29 |
4.65e-01 |
6.45e-01 |
0.06000 |
0.029000 |
-5.25e-02 |
7.87e-01 |
6.25e-01 |
Transcriptional-regulation-by-RUNX2 |
109 |
1.04e-01 |
2.64e-01 |
0.05970 |
-0.013000 |
5.83e-02 |
8.15e-01 |
2.94e-01 |
DAG-and-IP3-signaling |
36 |
8.10e-01 |
8.65e-01 |
0.05910 |
-0.053700 |
-2.47e-02 |
5.77e-01 |
7.98e-01 |
Chaperonin-mediated-protein-folding |
78 |
4.52e-01 |
6.32e-01 |
0.05900 |
0.012100 |
5.78e-02 |
8.53e-01 |
3.78e-01 |
Mitotic-G1-phase-and-G1/S-transition |
143 |
3.90e-02 |
1.41e-01 |
0.05890 |
-0.019900 |
5.55e-02 |
6.82e-01 |
2.53e-01 |
tRNA-modification-in-the-nucleus-and-cytosol |
41 |
5.74e-01 |
7.19e-01 |
0.05810 |
-0.058100 |
-2.77e-03 |
5.20e-01 |
9.76e-01 |
Generic-Transcription-Pathway |
843 |
1.96e-02 |
8.23e-02 |
0.05800 |
-0.026700 |
-5.15e-02 |
1.92e-01 |
1.20e-02 |
Purine-catabolism |
16 |
7.47e-01 |
8.30e-01 |
0.05790 |
-0.008910 |
5.72e-02 |
9.51e-01 |
6.92e-01 |
PKA-activation-in-glucagon-signalling |
15 |
7.06e-01 |
8.03e-01 |
0.05740 |
0.052200 |
-2.40e-02 |
7.26e-01 |
8.72e-01 |
Toll-Like-Receptor-4-(TLR4)-Cascade |
113 |
5.30e-01 |
6.90e-01 |
0.05670 |
0.051900 |
2.27e-02 |
3.41e-01 |
6.77e-01 |
Downstream-signal-transduction |
28 |
9.15e-01 |
9.40e-01 |
0.05670 |
0.033500 |
4.57e-02 |
7.59e-01 |
6.76e-01 |
Meiotic-recombination |
23 |
8.16e-01 |
8.69e-01 |
0.05610 |
-0.012600 |
-5.47e-02 |
9.17e-01 |
6.50e-01 |
SUMOylation-of-transcription-cofactors |
42 |
7.15e-01 |
8.10e-01 |
0.05590 |
-0.014700 |
-5.39e-02 |
8.69e-01 |
5.46e-01 |
Muscle-contraction |
148 |
2.98e-02 |
1.14e-01 |
0.05550 |
-0.043800 |
3.41e-02 |
3.59e-01 |
4.74e-01 |
Disease |
881 |
8.96e-04 |
7.40e-03 |
0.05530 |
0.053800 |
1.28e-02 |
7.31e-03 |
5.24e-01 |
SLC-transporter-disorders |
65 |
2.24e-01 |
4.21e-01 |
0.05470 |
0.032400 |
-4.41e-02 |
6.51e-01 |
5.39e-01 |
Insulin-receptor-signalling-cascade |
39 |
5.65e-01 |
7.13e-01 |
0.05420 |
0.054000 |
-4.89e-03 |
5.60e-01 |
9.58e-01 |
Resolution-of-Abasic-Sites-(AP-sites) |
37 |
7.68e-01 |
8.41e-01 |
0.05350 |
0.014600 |
5.14e-02 |
8.78e-01 |
5.89e-01 |
Translesion-synthesis-by-POLI |
17 |
6.84e-01 |
7.90e-01 |
0.05320 |
-0.037400 |
3.79e-02 |
7.90e-01 |
7.87e-01 |
Signaling-by-Insulin-receptor |
58 |
4.87e-01 |
6.59e-01 |
0.05290 |
0.052900 |
-7.05e-04 |
4.86e-01 |
9.93e-01 |
Integration-of-energy-metabolism |
86 |
8.10e-01 |
8.65e-01 |
0.05220 |
-0.040500 |
-3.29e-02 |
5.16e-01 |
5.99e-01 |
Neuronal-System |
251 |
5.35e-01 |
6.92e-01 |
0.05180 |
0.031600 |
4.10e-02 |
3.90e-01 |
2.65e-01 |
PI3K-Cascade |
30 |
9.35e-01 |
9.54e-01 |
0.05160 |
0.038000 |
3.49e-02 |
7.19e-01 |
7.41e-01 |
RNA-Polymerase-III-Transcription-Termination |
21 |
6.85e-01 |
7.90e-01 |
0.05120 |
0.047200 |
-1.98e-02 |
7.08e-01 |
8.75e-01 |
Suppression-of-phagosomal-maturation |
13 |
7.68e-01 |
8.41e-01 |
0.05120 |
0.031100 |
-4.06e-02 |
8.46e-01 |
8.00e-01 |
Signaling-by-NOTCH1 |
69 |
3.62e-01 |
5.54e-01 |
0.05000 |
0.048600 |
-1.14e-02 |
4.85e-01 |
8.70e-01 |
Translocation-of-SLC2A4-(GLUT4)-to-the-plasma-membrane |
51 |
8.70e-01 |
9.09e-01 |
0.04950 |
-0.027200 |
-4.13e-02 |
7.37e-01 |
6.10e-01 |
Ca2+-pathway |
52 |
4.67e-01 |
6.46e-01 |
0.04920 |
0.047700 |
-1.23e-02 |
5.52e-01 |
8.78e-01 |
Activation-of-AMPK-downstream-of-NMDARs |
10 |
8.56e-01 |
9.00e-01 |
0.04910 |
0.015100 |
-4.68e-02 |
9.34e-01 |
7.98e-01 |
Signaling-by-WNT |
233 |
5.39e-01 |
6.93e-01 |
0.04910 |
-0.027000 |
-4.10e-02 |
4.79e-01 |
2.82e-01 |
Association-of-TriC/CCT-with-target-proteins-during-biosynthesis |
37 |
6.51e-01 |
7.60e-01 |
0.04910 |
-0.049000 |
3.23e-03 |
6.06e-01 |
9.73e-01 |
Signaling-by-NOTCH3 |
46 |
4.22e-01 |
6.06e-01 |
0.04900 |
0.031300 |
-3.78e-02 |
7.14e-01 |
6.58e-01 |
TRAF6-mediated-induction-of-NFkB-and-MAP-kinases-upon-TLR7/8-or-9-activation |
83 |
3.69e-01 |
5.64e-01 |
0.04890 |
0.004760 |
-4.87e-02 |
9.40e-01 |
4.44e-01 |
MyD88-independent-TLR4-cascade |
90 |
2.40e-01 |
4.38e-01 |
0.04890 |
0.045800 |
-1.71e-02 |
4.53e-01 |
7.79e-01 |
TRIF(TICAM1)-mediated-TLR4-signaling |
90 |
2.40e-01 |
4.38e-01 |
0.04890 |
0.045800 |
-1.71e-02 |
4.53e-01 |
7.79e-01 |
Synthesis-of-very-long-chain-fatty-acyl-CoAs |
18 |
9.48e-01 |
9.65e-01 |
0.04890 |
0.025000 |
4.20e-02 |
8.54e-01 |
7.58e-01 |
Intrinsic-Pathway-for-Apoptosis |
47 |
5.75e-01 |
7.19e-01 |
0.04850 |
0.048300 |
-4.57e-03 |
5.67e-01 |
9.57e-01 |
G-beta:gamma-signalling-through-PLC-beta |
14 |
8.07e-01 |
8.65e-01 |
0.04800 |
0.045000 |
-1.66e-02 |
7.71e-01 |
9.14e-01 |
Beta-catenin-independent-WNT-signaling |
131 |
7.48e-01 |
8.30e-01 |
0.04780 |
-0.038400 |
-2.85e-02 |
4.49e-01 |
5.73e-01 |
Toll-Like-Receptor-3-(TLR3)-Cascade |
87 |
2.23e-01 |
4.21e-01 |
0.04720 |
0.029600 |
-3.67e-02 |
6.34e-01 |
5.54e-01 |
Estrogen-dependent-gene-expression |
83 |
7.31e-01 |
8.21e-01 |
0.04710 |
-0.019400 |
-4.29e-02 |
7.60e-01 |
5.00e-01 |
Signalling-to-ERKs |
30 |
6.73e-01 |
7.78e-01 |
0.04710 |
0.045700 |
-1.11e-02 |
6.65e-01 |
9.16e-01 |
Constitutive-Signaling-by-NOTCH1-HD+PEST-Domain-Mutants |
57 |
4.79e-01 |
6.53e-01 |
0.04590 |
0.012100 |
-4.43e-02 |
8.74e-01 |
5.63e-01 |
Constitutive-Signaling-by-NOTCH1-PEST-Domain-Mutants |
57 |
4.79e-01 |
6.53e-01 |
0.04590 |
0.012100 |
-4.43e-02 |
8.74e-01 |
5.63e-01 |
Signaling-by-NOTCH1-HD+PEST-Domain-Mutants-in-Cancer |
57 |
4.79e-01 |
6.53e-01 |
0.04590 |
0.012100 |
-4.43e-02 |
8.74e-01 |
5.63e-01 |
Signaling-by-NOTCH1-PEST-Domain-Mutants-in-Cancer |
57 |
4.79e-01 |
6.53e-01 |
0.04590 |
0.012100 |
-4.43e-02 |
8.74e-01 |
5.63e-01 |
Signaling-by-NOTCH1-in-Cancer |
57 |
4.79e-01 |
6.53e-01 |
0.04590 |
0.012100 |
-4.43e-02 |
8.74e-01 |
5.63e-01 |
Oncogene-Induced-Senescence |
32 |
6.72e-01 |
7.78e-01 |
0.04520 |
0.043700 |
-1.15e-02 |
6.69e-01 |
9.10e-01 |
Costimulation-by-the-CD28-family |
52 |
5.46e-01 |
6.96e-01 |
0.04490 |
-0.009390 |
4.39e-02 |
9.07e-01 |
5.85e-01 |
Developmental-Biology |
654 |
1.38e-02 |
6.40e-02 |
0.04480 |
0.044400 |
6.05e-03 |
5.45e-02 |
7.93e-01 |
Hedgehog-'off'-state |
93 |
3.04e-01 |
5.11e-01 |
0.04480 |
-0.042600 |
1.38e-02 |
4.78e-01 |
8.18e-01 |
G-protein-beta:gamma-signalling |
26 |
7.88e-01 |
8.52e-01 |
0.04430 |
0.044300 |
-1.97e-03 |
6.96e-01 |
9.86e-01 |
Base-Excision-Repair |
44 |
7.81e-01 |
8.48e-01 |
0.04410 |
0.009330 |
4.31e-02 |
9.15e-01 |
6.21e-01 |
Signaling-by-ERBB2 |
47 |
7.95e-01 |
8.57e-01 |
0.04240 |
0.041200 |
1.02e-02 |
6.25e-01 |
9.04e-01 |
NOTCH1-Intracellular-Domain-Regulates-Transcription |
46 |
5.54e-01 |
7.03e-01 |
0.04190 |
0.036600 |
-2.03e-02 |
6.68e-01 |
8.11e-01 |
Infection-with-Mycobacterium-tuberculosis |
24 |
7.30e-01 |
8.21e-01 |
0.04170 |
0.022600 |
-3.50e-02 |
8.48e-01 |
7.67e-01 |
N-glycan-trimming-in-the-ER-and-Calnexin/Calreticulin-cycle |
34 |
6.41e-01 |
7.51e-01 |
0.04160 |
0.035100 |
-2.25e-02 |
7.24e-01 |
8.21e-01 |
Regulation-of-insulin-secretion |
59 |
7.56e-01 |
8.35e-01 |
0.04120 |
0.009280 |
4.01e-02 |
9.02e-01 |
5.95e-01 |
CD209-(DC-SIGN)-signaling |
18 |
9.56e-01 |
9.68e-01 |
0.04090 |
-0.018600 |
-3.64e-02 |
8.91e-01 |
7.89e-01 |
Insulin-receptor-recycling |
20 |
7.75e-01 |
8.45e-01 |
0.04090 |
0.033800 |
-2.30e-02 |
7.94e-01 |
8.58e-01 |
ROS-and-RNS-production-in-phagocytes |
28 |
6.97e-01 |
7.99e-01 |
0.04090 |
0.024500 |
-3.27e-02 |
8.23e-01 |
7.64e-01 |
Resolution-of-AP-sites-via-the-multiple-nucleotide-patch-replacement-pathway |
24 |
7.48e-01 |
8.30e-01 |
0.04070 |
-0.019400 |
3.57e-02 |
8.69e-01 |
7.62e-01 |
G-alpha-(q)-signalling-events |
118 |
8.50e-01 |
8.97e-01 |
0.04050 |
0.027200 |
3.00e-02 |
6.10e-01 |
5.74e-01 |
RNA-Polymerase-III-Transcription-Initiation |
34 |
9.55e-01 |
9.68e-01 |
0.03990 |
-0.026300 |
-3.00e-02 |
7.91e-01 |
7.63e-01 |
Transcriptional-regulation-by-RUNX3 |
92 |
3.60e-01 |
5.53e-01 |
0.03930 |
-0.018100 |
3.49e-02 |
7.65e-01 |
5.64e-01 |
Spry-regulation-of-FGF-signaling |
16 |
9.66e-01 |
9.75e-01 |
0.03920 |
-0.018500 |
-3.46e-02 |
8.98e-01 |
8.11e-01 |
IRS-mediated-signalling |
34 |
9.21e-01 |
9.46e-01 |
0.03910 |
0.035100 |
1.71e-02 |
7.23e-01 |
8.63e-01 |
Erythropoietin-activates-RAS |
13 |
8.69e-01 |
9.08e-01 |
0.03800 |
0.019500 |
-3.27e-02 |
9.03e-01 |
8.38e-01 |
M-Phase |
299 |
3.01e-01 |
5.09e-01 |
0.03780 |
0.036900 |
8.21e-03 |
2.74e-01 |
8.08e-01 |
MyD88-dependent-cascade-initiated-on-endosome |
84 |
5.40e-01 |
6.93e-01 |
0.03780 |
0.004450 |
-3.75e-02 |
9.44e-01 |
5.53e-01 |
Toll-Like-Receptor-7/8-(TLR7/8)-Cascade |
84 |
5.40e-01 |
6.93e-01 |
0.03780 |
0.004450 |
-3.75e-02 |
9.44e-01 |
5.53e-01 |
Toll-Like-Receptor-9-(TLR9)-Cascade |
88 |
4.09e-01 |
5.96e-01 |
0.03710 |
0.018600 |
-3.21e-02 |
7.64e-01 |
6.03e-01 |
Activated-NOTCH1-Transmits-Signal-to-the-Nucleus |
28 |
7.83e-01 |
8.49e-01 |
0.03590 |
0.013200 |
-3.34e-02 |
9.04e-01 |
7.60e-01 |
MAPK1/MAPK3-signaling |
207 |
4.71e-01 |
6.49e-01 |
0.03580 |
0.007670 |
3.50e-02 |
8.50e-01 |
3.87e-01 |
Nicotinate-metabolism |
27 |
7.91e-01 |
8.55e-01 |
0.03560 |
-0.032900 |
1.36e-02 |
7.67e-01 |
9.03e-01 |
Downregulation-of-ERBB2-signaling |
27 |
7.79e-01 |
8.47e-01 |
0.03460 |
0.027700 |
-2.08e-02 |
8.04e-01 |
8.52e-01 |
Regulation-of-TP53-Activity |
148 |
5.33e-01 |
6.91e-01 |
0.03420 |
-0.034100 |
-3.36e-03 |
4.75e-01 |
9.44e-01 |
RNA-Polymerase-III-Abortive-And-Retractive-Initiation |
39 |
7.06e-01 |
8.03e-01 |
0.03400 |
0.027000 |
-2.06e-02 |
7.71e-01 |
8.24e-01 |
RNA-Polymerase-III-Transcription |
39 |
7.06e-01 |
8.03e-01 |
0.03400 |
0.027000 |
-2.06e-02 |
7.71e-01 |
8.24e-01 |
SUMOylation |
159 |
4.60e-01 |
6.39e-01 |
0.03330 |
0.033300 |
-4.64e-04 |
4.70e-01 |
9.92e-01 |
Signaling-by-Erythropoietin |
24 |
8.20e-01 |
8.73e-01 |
0.03290 |
0.027100 |
-1.87e-02 |
8.18e-01 |
8.74e-01 |
Diseases-of-carbohydrate-metabolism |
29 |
9.74e-01 |
9.82e-01 |
0.03280 |
0.024000 |
2.24e-02 |
8.23e-01 |
8.35e-01 |
ESR-mediated-signaling |
142 |
3.31e-01 |
5.31e-01 |
0.03220 |
0.027100 |
-1.74e-02 |
5.77e-01 |
7.21e-01 |
Initial-triggering-of-complement |
11 |
9.59e-01 |
9.71e-01 |
0.03150 |
0.031400 |
2.45e-03 |
8.57e-01 |
9.89e-01 |
Ion-channel-transport |
110 |
8.09e-01 |
8.65e-01 |
0.03120 |
-0.029100 |
-1.12e-02 |
5.98e-01 |
8.40e-01 |
HuR-(ELAVL1)-binds-and-stabilizes-mRNA |
10 |
9.86e-01 |
9.89e-01 |
0.03100 |
-0.027300 |
-1.46e-02 |
8.81e-01 |
9.36e-01 |
RAF/MAP-kinase-cascade |
202 |
4.46e-01 |
6.30e-01 |
0.03090 |
0.000450 |
3.09e-02 |
9.91e-01 |
4.50e-01 |
Mitotic-G2-G2/M-phases |
175 |
5.02e-01 |
6.68e-01 |
0.03080 |
0.000669 |
3.08e-02 |
9.88e-01 |
4.84e-01 |
TP53-Regulates-Transcription-of-DNA-Repair-Genes |
59 |
6.62e-01 |
7.69e-01 |
0.02990 |
-0.021700 |
2.05e-02 |
7.73e-01 |
7.86e-01 |
MyD88:MAL(TIRAP)-cascade-initiated-on-plasma-membrane |
88 |
7.77e-01 |
8.45e-01 |
0.02950 |
-0.004340 |
-2.91e-02 |
9.44e-01 |
6.37e-01 |
Toll-Like-Receptor-2-(TLR2)-Cascade |
88 |
7.77e-01 |
8.45e-01 |
0.02950 |
-0.004340 |
-2.91e-02 |
9.44e-01 |
6.37e-01 |
Toll-Like-Receptor-TLR1:TLR2-Cascade |
88 |
7.77e-01 |
8.45e-01 |
0.02950 |
-0.004340 |
-2.91e-02 |
9.44e-01 |
6.37e-01 |
Toll-Like-Receptor-TLR6:TLR2-Cascade |
88 |
7.77e-01 |
8.45e-01 |
0.02950 |
-0.004340 |
-2.91e-02 |
9.44e-01 |
6.37e-01 |
SUMO-E3-ligases-SUMOylate-target-proteins |
153 |
4.41e-01 |
6.26e-01 |
0.02830 |
0.026400 |
-1.02e-02 |
5.73e-01 |
8.28e-01 |
S-Phase |
152 |
4.25e-01 |
6.08e-01 |
0.02750 |
-0.023400 |
1.45e-02 |
6.19e-01 |
7.58e-01 |
Diseases-of-signal-transduction |
331 |
7.58e-01 |
8.35e-01 |
0.02730 |
0.023000 |
1.47e-02 |
4.75e-01 |
6.47e-01 |
Formation-of-the-beta-catenin:TCF-transactivating-complex |
31 |
9.77e-01 |
9.82e-01 |
0.02670 |
0.021900 |
1.52e-02 |
8.33e-01 |
8.83e-01 |
Recognition-of-DNA-damage-by-PCNA-containing-replication-complex |
29 |
8.82e-01 |
9.19e-01 |
0.02650 |
-0.025600 |
7.04e-03 |
8.12e-01 |
9.48e-01 |
Mitotic-Metaphase-and-Anaphase |
165 |
8.98e-01 |
9.29e-01 |
0.02610 |
0.020900 |
1.56e-02 |
6.44e-01 |
7.30e-01 |
Positive-epigenetic-regulation-of-rRNA-expression |
46 |
9.24e-01 |
9.47e-01 |
0.02580 |
-0.024900 |
-6.71e-03 |
7.70e-01 |
9.37e-01 |
Signaling-by-NOTCH |
164 |
8.98e-01 |
9.29e-01 |
0.02560 |
-0.020800 |
-1.50e-02 |
6.46e-01 |
7.41e-01 |
DNA-Repair |
271 |
6.31e-01 |
7.50e-01 |
0.02550 |
-0.024700 |
-6.29e-03 |
4.86e-01 |
8.59e-01 |
Epigenetic-regulation-of-gene-expression |
87 |
7.52e-01 |
8.33e-01 |
0.02520 |
0.025000 |
-3.03e-03 |
6.88e-01 |
9.61e-01 |
RNA-Polymerase-III-Transcription-Initiation-From-Type-3-Promoter |
26 |
8.83e-01 |
9.19e-01 |
0.02500 |
-0.014300 |
2.05e-02 |
9.00e-01 |
8.57e-01 |
p38MAPK-events |
12 |
9.50e-01 |
9.65e-01 |
0.02460 |
0.010500 |
-2.23e-02 |
9.50e-01 |
8.94e-01 |
MECP2-regulates-neuronal-receptors-and-channels |
12 |
9.78e-01 |
9.82e-01 |
0.02400 |
0.023700 |
3.68e-03 |
8.87e-01 |
9.82e-01 |
Netrin-1-signaling |
39 |
9.05e-01 |
9.34e-01 |
0.02360 |
-0.023600 |
8.40e-04 |
7.99e-01 |
9.93e-01 |
Mitotic-Anaphase |
164 |
9.14e-01 |
9.39e-01 |
0.02340 |
0.019000 |
1.36e-02 |
6.75e-01 |
7.65e-01 |
G2/M-Transition |
173 |
5.61e-01 |
7.10e-01 |
0.02260 |
-0.007700 |
2.12e-02 |
8.62e-01 |
6.30e-01 |
FLT3-Signaling |
220 |
5.31e-01 |
6.90e-01 |
0.02240 |
-0.004790 |
2.19e-02 |
9.03e-01 |
5.77e-01 |
SUMOylation-of-DNA-replication-proteins |
45 |
8.60e-01 |
9.01e-01 |
0.02240 |
0.020900 |
-8.05e-03 |
8.09e-01 |
9.26e-01 |
PKMTs-methylate-histone-lysines |
42 |
9.81e-01 |
9.85e-01 |
0.02100 |
-0.017300 |
-1.21e-02 |
8.47e-01 |
8.92e-01 |
Separation-of-Sister-Chromatids |
154 |
9.23e-01 |
9.46e-01 |
0.02040 |
0.010400 |
1.76e-02 |
8.24e-01 |
7.07e-01 |
Ca-dependent-events |
32 |
9.35e-01 |
9.54e-01 |
0.02010 |
0.019900 |
-2.53e-03 |
8.45e-01 |
9.80e-01 |
rRNA-processing-in-the-nucleus-and-cytosol |
156 |
9.28e-01 |
9.50e-01 |
0.01920 |
0.009540 |
1.66e-02 |
8.37e-01 |
7.20e-01 |
NOTCH2-Activation-and-Transmission-of-Signal-to-the-Nucleus |
21 |
9.75e-01 |
9.82e-01 |
0.01900 |
0.018900 |
2.71e-03 |
8.81e-01 |
9.83e-01 |
DNA-Double-Strand-Break-Repair |
123 |
7.36e-01 |
8.23e-01 |
0.01800 |
-0.011000 |
1.42e-02 |
8.33e-01 |
7.86e-01 |
Adaptive-Immune-System |
558 |
5.24e-01 |
6.87e-01 |
0.01720 |
0.017100 |
6.61e-04 |
4.91e-01 |
9.79e-01 |
FGFR1-mutant-receptor-activation |
25 |
9.76e-01 |
9.82e-01 |
0.01630 |
-0.001540 |
-1.63e-02 |
9.89e-01 |
8.88e-01 |
Apoptosis |
152 |
8.29e-01 |
8.80e-01 |
0.01420 |
-0.013700 |
3.72e-03 |
7.70e-01 |
9.37e-01 |
Major-pathway-of-rRNA-processing-in-the-nucleolus-and-cytosol |
147 |
9.54e-01 |
9.68e-01 |
0.01350 |
0.005440 |
1.24e-02 |
9.09e-01 |
7.96e-01 |
Inactivation,-recovery-and-regulation-of-the-phototransduction-cascade |
17 |
9.97e-01 |
9.97e-01 |
0.01260 |
-0.010400 |
-7.04e-03 |
9.41e-01 |
9.60e-01 |
The-phototransduction-cascade |
17 |
9.97e-01 |
9.97e-01 |
0.01260 |
-0.010400 |
-7.04e-03 |
9.41e-01 |
9.60e-01 |
CaM-pathway |
30 |
9.64e-01 |
9.73e-01 |
0.01250 |
0.008680 |
-9.04e-03 |
9.34e-01 |
9.32e-01 |
Calmodulin-induced-events |
30 |
9.64e-01 |
9.73e-01 |
0.01250 |
0.008680 |
-9.04e-03 |
9.34e-01 |
9.32e-01 |
Glucagon-like-Peptide-1-(GLP1)-regulates-insulin-secretion |
31 |
9.87e-01 |
9.89e-01 |
0.01040 |
0.000508 |
1.04e-02 |
9.96e-01 |
9.20e-01 |
Opioid-Signalling |
72 |
9.68e-01 |
9.76e-01 |
0.00783 |
0.003990 |
-6.74e-03 |
9.53e-01 |
9.21e-01 |
Programmed-Cell-Death |
155 |
9.53e-01 |
9.68e-01 |
0.00777 |
-0.000879 |
7.72e-03 |
9.85e-01 |
8.69e-01 |
NOD1/2-Signaling-Pathway |
28 |
9.91e-01 |
9.93e-01 |
0.00721 |
0.001710 |
-7.00e-03 |
9.87e-01 |
9.49e-01 |